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General introduction
Ageing is frequently characterized by age-related adverse cerebral outcomes such as 
dementia, late-life depression and stroke.1 The burden of these diseases is high and is 
likely to increase in future decades as a result of the ageing of the general population.1 
Identifying possible factors contributing to these diseases is needed for future prevention 
and treatment. One important factor may be the functional and structural deterioration 
of the microvasculature (i.e., microvascular dysfunction).
The microvasculature facilitates, among other things, oxygen and nutrient delivery to 
the brain,2 and microvascular dysfunction may thus be implicated in the development of 
adverse cerebral outcome. Microvascular dysfunction has been associated with various 
cardiovascular risk factors,3 and emerging evidence indicates that it may be implicated in 
the pathways between these risk factors and adverse cerebral outcome.2-5 To elucidate the 
role of microvascular dysfunction in adverse cerebral outcome, this thesis aims to identify 
possible causes of microvascular dysfunction and to investigate whether microvascular 
dysfunction is associated with dementia, late-life depression and stroke. In addition, 
this thesis aims to evaluate whether microvascular dysfunction mediates the pathways 
between several cardiovascular risk factors and dementia, late-life depression and stroke.
Microvasculature – structure and function
The microvasculature is, in terms of surface area, the largest component of the vascular 
system (98%) and includes all blood vessels with a diameter below 150-200 μm.2 This 
network of blood vessels facilitates local blood perfusion, blood-tissue diffusion and 
haemostatic balance,6 which is needed for nutrient distribution and waste product 
collection in tissues. In addition, the microvasculature regulates blood pressure via 
vascular resistance.7 The microvasculature consists of three types of small vessels: 
arterioles, capillaries and venules. Arterioles regulate blood flow according to local 
metabolic demand using vasomotion. The capillaries consist of only a single endothelial 
layer, which helps facilitate exchange of substances with the interstitium, both via passive 
diffusion and active transcellular transport. The latter is especially important in brain tissue, 
because the uninterrupted endothelial lining making up the blood-brain barrier allows 
passive diffusion of only small molecules such as water and ions, as well as lipid-soluble 
molecules, whereas exchange of molecules such as glucose relies on active transcellular 
transport.8, 9 Small venules collect capillary blood, regulate capillary pressure, and support 
recruitment of inflammatory cells (e.g., leukocytes) from blood into tissue.2, 10
Microvascular dysfunction – potential causes
Microvascular dysfunction has been associated with cardiovascular risk factors such as 
arterial stiffening11 and type 2 diabetes.12, 13 Arterial elasticity dampens cardiac pulsatile 
energy, which protects the microvasculature from high pulsatile damage. Arterial 
stiffening increases the pulsatile intensity flowing into the microvasculature, which 
induces a microvascular remodelling response and may cause microvascular damage 
directly. The remodelling response initially serves to limit the penetration of the pulsatile 
load into the microvasculature by raising vascular resistance, but may ultimately lead 
to maladaptive proliferation of the arteriolar wall.14 Type 2 diabetes may also induce 
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microvascular dysfunction via various mechanisms, including hyperglycaemia, arterial 
stiffening, impaired insulin-dependent dilation, production of advanced glycation end 
products, increased oxidative stress and epigenetic changes.13 In addition to arterial 
stiffness and type 2 diabetes, other determinants of microvascular dysfunction, such as 
inflammatory processes, oxidative stress, hypertension, ageing and obesity, have been 
identified and may share these pathophysiological mechanisms.2 
Microvascular dysfunction – consequences: focus on the brain
Prolonged injury to the microvasculature may result in structural and functional 
microvascular changes, including capillary rarefaction, glycocalyx degeneration, impaired 
capillary flow regulation, impaired arteriolar and venular dilation response, blood-brain 
barrier dysfunction, increased inflammatory response and procoagulant activation.5, 
6, 15 These changes may lead to inefficient nutrient and oxygen extraction from the 
microcirculation6 and may thus threaten tissue function by lack of nutrients and hypoxia. 
The effects of microvascular dysfunction could be particularly detrimental to cerebral 
tissue due to its high microvascular blood flow and metabolic needs. The cerebral 
microvasculature is involved in the regulation of many processes that are important 
for cognitive function and mood regulation (i.e., cerebral perfusion, neurogenesis, 
neurovascular coupling, blood-brain barrier permeability and cerebral autoregulation).15 
Impairment of these processes may lead to neuronal dysfunction and ischaemia, which 
could ultimately lead to lower cognitive performance and depression.11, 15-18 In addition, 
acute and prolonged cerebral hypoperfusion and impaired haemostatic regulation may 
predispose to stroke. 
Microvascular dysfunction - markers
Only a few organs can be used to measure microvascular function noninvasively. These 
measures include brain measures (magnetic resonance imaging features of cerebral small 
vessel disease);4 eye measures (flicker light-induced retinal arteriolar and venular dilation 
response);19 kidney measures (albuminuria);20 plasma biomarkers of microvascular 
dysfunction21 and skin measures (heat-induced skin hyperaemia).19 Cerebral small vessel 
disease features are closely linked to brain microvascular structure and evidence indicates 
that these features originate from cerebral microvascular dysfunction.3, 4, 6 To the extent 
that microvascular dysfunction is a generalised phenomenon, measures of microvascular 
dysfunction in other vascular beds such as the retina, kidney and skin, or plasma biomarkers 
of microvascular dysfunction may also reflect brain microvascular dysfunction.5, 12
Contribution of this thesis to current knowledge
It has been hypothesised that cerebral small vessel disease is an important contributor 
to adverse cerebral outcome (i.e., dementia, depression and stroke) and increased 
mortality risk.3 However, systematic research on these possible consequences of cerebral 
small vessel disease is limited. Seven meta-analyses22-28 have examined the association 
of certain features of cerebral small vessel disease (i.e., white matter hyperintensities 
and cerebral microbleeds) and these outcomes. However, no meta-analysis on incident 
dementia, depression or stroke, or all-cause mortality has thus far been conducted for 
other features of cerebral small vessel disease (i.e., lacunes, perivascular spaces and total 
cerebral atrophy). Furthermore, no meta-analysis has evaluated the prognostic value of 
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the presence of combined cerebral small vessel disease features. It is, however, important 
to investigate the effects of individual and combined cerebral small vessel disease 
features on incident dementia, depression and stroke, and all-cause mortality, because 
cerebral small vessel disease is highly prevalent in the general population,29 and timely 
intervention may help prevent or reduce progression of cerebral small vessel disease and 
these clinical outcomes.
In addition, cerebral small vessel disease is thought to mediate the association between 
type 2 diabetes and incident depression.17 In view of the increased risk of depression in 
type 2 diabetes, identifying factors that mediate this relation might help to prevent or 
treat type 2 diabetes-related depression.13, 30 However, no previous study has investigated 
whether the association between type 2 diabetes and depressive symptoms is mediated 
by cerebral small vessel disease. 
It has been hypothesised that cerebral small vessel disease reflects microvascular 
dysfunction, and that microvascular dysfunction contributes to cognitive decline and 
dementia.3 However, it is unknown whether other measures of microvascular dysfunction 
in various vascular beds, such as the retina, kidney and skin, or plasma biomarkers of 
microvascular dysfunction, contribute similarly.5, 12 Multiple measures of generalised 
microvascular dysfunction may, however, better determine cognitive function than a 
microvascular dysfunction measure in a single vascular bed, such as cerebral small vessel 
disease.
In this respect, generalised microvascular dysfunction may also mediate the association 
between greater arterial stiffness and worse cognitive function. Previous studies have 
shown an association between arterial stiffness and cognitive function.11, 16, 31-44 However, 
whether any association between aortic or carotid stiffness and worse cognitive 
performance is explained, or mediated, by microvascular dysfunction is unknown.
Finally, it has been hypothesised that greater blood pressure variability (i.e., greater 
fluctuations of blood pressure over time) may lead to microvascular dysfunction45, 46 
via increases in pulsatile pressure45 and sudden falls in blood pressure.46 Vascular beds 
of organs with low vascular impedance (i.e., the microvasculature of the brain, eyes and 
kidneys) may be particularly vulnerable, because pulsatile energy may penetrate deeply 
into these microvascular beds.45 However, no studies have investigated the association 
between blood pressure variability and measures of microvascular dysfunction in multiple 
vascular beds.47-49
Cohort studies used in this thesis
In this thesis, data of two cohort studies are used: The Age, Gene/Environment Susceptibility 
(AGES)-Reykjavik Study and The Maastricht Study. The AGES-Reykjavik Study is an 
observational population-based cohort study originating from the Reykjavik Study.50 The 
present thesis includes longitudinal data from 3,316 participants of the AGES-Reykjavik 
Study, who were examined from 2002 to 2006 and re-examined five years later, from 
2007 to 2011. The Maastricht Study is an ongoing observational population-based cohort 
study that focuses on the aaetiology, pathophysiology, complications and comorbidities 
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of type 2 diabetes and is characterized by an extensive phenotyping approach.51 The 
present thesis includes cross-sectional data from the 3,451 participants who completed 
the baseline survey between November 2010 and September 2013. 
Outline of this thesis
Figure 1.1 summarizes the investigated associations in this thesis (see below).
In chapter two, we conducted a systematic review and meta-analysis on the association 
between various cerebral small vessel disease features and incident stroke, dementia and 
depression, and all-cause mortality. Additionally, we investigated the effect of presence of 
two or more individual cerebral small vessel disease features on these outcomes. 
In chapter three, we investigated, in the AGES-Reykjavik study, the longitudinal association 
between baseline type 2 diabetes and change in depressive symptoms over time. In 
addition, we investigated whether any such association was mediated by cerebral small 
vessel disease.
In chapter four, we investigated, in The Maastricht Study, whether a composite score 
of various microvascular dysfunction measures was associated with worse cognitive 
performance.
In chapter five, we investigated, in The Maastricht Study, the associations between arterial 
stiffness and worse cognitive performance. In addition we investigated whether any 
such association is mediated by a composite score of various microvascular dysfunction 
measures.
In chapter six, we investigated, in The Maastricht Study, whether very short- to mid-
term blood pressure variability was associated with various microvascular dysfunction 
measures.
Finally, in chapter seven, we discussed the key findings of this thesis, their clinical 
implications and recommendations for future research. In addition, we addressed relevant 
methodological considerations.
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Figure 1.1. Schematic representation of the investigated associations in the present thesis. Numbers indicate 
corresponding chapters.
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Abstract
MRI features of cerebral small vessel disease, i.e. white matter hyperintensities, lacunes, 
microbleeds, perivascular spaces, and cerebral atrophy, may be associated with 
clinical events, but the strength of these associations remains unclear. We conducted 
a systematic review and meta-analysis on the association between these features and 
incident ischaemic and haemorrhagic stroke, all-cause dementia and depression, and all-
cause mortality. For the association with stroke, 36 studies were identified (number of 
individuals/events [n]=38,432/4,136), for dementia 28 (n=16,458/1,709), for depression 
nine (n=9,538/1,746), and for mortality 28 (n=23,031/2,558). Only two studies evaluated 
perivascular spaces; these results were not pooled. Pooled analyses showed that all other 
features were associated with all outcomes (hazard ratios ranged 1.22-2.72). Combinations 
of two features were more strongly associated with stroke than any individual feature. 
Individual features and combinations of CSVD features are strongly associated with 
incident ischaemic and haemorrhagic stroke, all-cause dementia and depression, and 
all-cause mortality. If these associations are causal, the strength of these associations 
suggests that a substantial burden of disease is attributable to CSVD. 
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Introduction
Cerebral small vessel disease (CSVD) features include white matter hyperintensities (WMHs) 
and lacunes of presumed vascular origin, cerebral microbleeds (CMBs), perivascular 
spaces, and total cerebral atrophy.1 These features are related to ageing and vascular 
risk factors,2 and are highly prevalent.1 CSVD has been suggested to be an important 
source of morbidity associated with ischaemic and haemorrhagic stroke, dementia, and 
depression,2 and CSVD may increase mortality risk.2 
However, systematic evidence for the importance of MRI CSVD features is limited. For 
instance, no meta-analysis for incident stroke, dementia, depression, or mortality has been 
conducted for lacunes, perivascular spaces, or total cerebral atrophy. Two meta-analyses3, 
4 have examined the association of only WMHs3 or microbleeds 4 and incident stroke and 
dementia, and mortality. Of two meta-analyses5, 6 on WMHs and incident depression, only 
one6 found an association. Three other meta-analyses7-9 have examined the association 
between CMBs and incident stroke. However, these studies included only individuals with 
prior stroke,7-9 and evaluated only haemorrhagic stroke.7, 9 Finally, no meta-analysis has 
evaluated the predictive value of presence of combined CSVD features. 
We did a systematic review and meta-analysis on the association between CSVD features, 
including WMHs, lacunes, CMBs, perivascular spaces, and total cerebral atrophy, and 
incident ischaemic and haemorrhagic stroke, all-cause dementia and depression, and all-
cause mortality. Additionally, we investigated the effect of two or more individual CSVD 
features combined on any of these outcomes. 
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Methods
This review was prepared according to the meta-analyses of observational studies in 
epidemiology (MOOSE) checklist (Appendix A).10 This protocol was published in PROSPERO 
(CRD42016038521) (Appendix B).11
Evaluation procedure
Two independent investigators (SR and TVS) selected all relevant studies based on title 
and abstract, retrieved selected full texts, performed eligibility assessments, extracted 
data, and assessed risk of bias. Disagreement between the reviewers was resolved by 
consensus. A third independent reviewer (CS) solved any persisting disagreements.
Information sources and search
We identified relevant studies through a search of MEDLINE and Embase, from inception 
to March 2017 (for search terms see Tables S1.1-S1.4). We applied no language restrictions. 
We hand-searched reference lists of eligible studies and related meta-analyses to identify 
further relevant studies. 
Eligibility criteria and study selection
We included prospective cohort studies in adults (with and without a history of stroke 
or depression) that evaluated the association between baseline MRI features of CSVD 
and incident ischaemic or haemorrhagic stroke, dementia or depression, or all-cause 
mortality. For CSVD, we included WMHs and lacunes of presumed vascular origin, CMBs, 
perivascular spaces, and total cerebral atrophy.1 Studies were also included when they 
did not specifically assess lacunes but did assess subcortical infarcts (infarcts in the 
deep brain region not extending into the cortex) and silent infarcts (infarcts detected 
in individuals without prior stroke), which include lacunes.1 We excluded studies with a 
sample size ≤50, a mean follow-up <12 months, or including only CSVD occurring in long-
term inflammatory or neurodegenerative conditions (e.g. multiple sclerosis or Parkinson’s 
disease). In the case of multiple publications from the same cohort, we included the most 
up-to-date or comprehensive information. 
Data collection process
We used a predesigned extraction form to collect information on the following items: 
study size; follow-up duration; age; sex; prior stroke; baseline cognitive performance; prior 
depression; MRI characteristics; definitions of CSVD features; outcome definitions; number 
of events; statistical analysis used; reported risk estimates; and variables adjusted for in the 
analyses. Any relevant missing information was requested from corresponding authors. 
Risk of bias assessment
We evaluated risk of bias with the Newcastle-Ottawa scale (NOS) (Appendix C). 
Variable definition
We used definitions of CSVD features and outcomes as reported in the original published 
papers. Incident stroke included fatal and non-fatal cerebral infarction and intracerebral 
haemorrhage. Incident dementia included Alzheimer’s disease, presumed vascular 
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dementia and dementia not further specified. Incident depression subtype was not 
specified by any of the included studies. For stroke and depression, we included both first 
and recurrent events.
Statistical analysis
We pooled results for each CSVD feature when ≥three studies were available with the same 
outcome. We pooled hazard ratios (HRs) using the random effects inverse variance method. 
We included the fully adjusted HR (but without adjustments for other CSVD features) (if 
available). HRs were reported by 49 studies, whereas fifteen studies reported results as odds 
ratios or relative risks (Table S3); these were treated as HRs. 
For WMHs, we separately pooled dichotomous and continuous measures. For dichotomous 
measures, we compared the HR for a higher vs. a lower category. When ≥two categories for 
WMHs were present, we selected the two categories with the highest number of participants 
and events. For total cerebral atrophy, we pooled only studies using a continuous scale (as 
percentage total intracranial volume or raw volume), as there were few data with atrophy 
measured dichotomously. We standardized continuous measures per standard deviation. 
For studies that reported only deep or periventricular WMHs instead of total WMHs, we 
included the results for periventricular WMHs in the main analysis, because periventricular 
WMHs more closely represent total WMHs.12 Similarly, for studies that reported only deep 
or lobar CMBs instead of total CMBs, we included the results for deep CMBs in the main 
analysis, because deep CMBs more closely represent total CMBs8 and are more strongly 
related to hypertension.1 For analyses with combined presence of ≥two individual CSVD 
features as the determinant, we pooled HRs for any combination of individual features.
We evaluated the level of statistical heterogeneity across pooled studies per CSVD feature 
using the I2 test.13 High statistical heterogeneity was defined as I2 >60%. We assessed potential 
publication bias using funnel plots and, when ≥ten studies were included in the analysis, by 
Egger’s test. We corrected for the potential effect of significant funnel plot asymmetry using 
the trim and fill approach.14 
We did several pre-specified sensitivity analyses. We repeated analyses by subtype of 
disease (ischaemic or haemorrhagic stroke, and Alzheimer’s disease or presumed vascular 
dementia); using only population-based cohort studies; using only studies with high-risk 
populations (e.g. individuals with prior stroke or other cardiovascular disease, mild cognitive 
impairment, prior depression, or chronic kidney disease); including only high-quality studies 
(defined as NOS score >four); using only studies that measured WMHs on an observer-
rated semi-quantitative scale; using only studies that measured WMHs on an automated 
quantitative scale; replacing the results for periventricular WMHs with those for deep 
WMHs; replacing the risk estimates for deep CMBs with those for lobar CMBs; and replacing 
adjusted risk estimates with unadjusted risk estimates. In addition, we did several post hoc 
analyses, including repeating the analyses using only studies that included individuals with 
prior stroke. Other post hoc analyses are described in the supplemental material (Table S2).
Analyses were done with Review Manager 5.3 and R 3.2.3.  
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Results
Selection process and study characteristics
Figure 1 shows the selection process of included studies. In the systematic review, we 
included 36 studies for ischaemic or haemorrhagic stroke (n=38,432/4,136 individuals/
events), 28 for all-cause dementia (n=16,458/1,709), nine for depression (n=9,538/1,746), 
and 28 for all-cause mortality (n=23,031/2,558). Table S3 shows the number of included 
studies in the pooled analyses and per CSVD feature. Only two studies evaluated perivascular 
spaces; these results were not pooled (Table S3). Full study characteristics and NOS scores 
are provided as supplemental material (Tables S4.1-S4.4 and S5.1-S5.4, respectively). 
Stroke
All CSVD features were statistically significantly associated with incident ischaemic or 
haemorrhagic stroke, with moderate to substantial heterogeneity across studies pooled 
per CSVD feature (Figure 2, Figures S1.1a-S1.1e). Of all included studies, 95% found a 
positive association between any feature and stroke (Figures S1.1a-S1.1e). One study in the 
systematic review could not be included in the pooled analysis because no risk estimates 
were presented (Table S3). This study reported a statistically significant association 
between WMHs and stroke. 
For analyses with stroke subtype as the outcome (ischaemic or haemorrhagic), sufficient 
studies were available for WMHs on a dichotomous scale (14 studies) and CMBs (10 
studies) (Table S3). For WMHs, the HRs were qualitatively similar for the risk of ischaemic 
and haemorrhagic stroke (Figure S2.1). For CMBs, the risk of haemorrhagic stroke was 
higher than that of ischaemic stroke (Figure S2.4). 
Dementia
All features, except CMBs, were statistically significantly associated with incident all-
cause dementia, with moderate to substantial heterogeneity across studies pooled 
per CSVD feature (Figure 2, Figures S1.2a-S1.2e). Of all included studies, 80% found a 
positive association between any feature and dementia (Figures S1.2a-S1.2e). 12 studies 
were excluded from the pooled analysis (Table S3), of which six (four on WMHs, one on 
perivascular spaces and one on total cerebral atrophy) found a statistically significant 
association with dementia. 
For analyses with dementia subtype as the outcome (Alzheimer’s disease or presumed 
vascular dementia), sufficient studies were available for WMHs on a dichotomous scale 
(9 studies) (Table S3). For WMHs, the risk of presumed vascular dementia was higher than 
that of Alzheimer’s disease (Figure S2.1). 
Depression
WMHs on a dichotomous scale and total cerebral atrophy were statistically significantly 
associated with incident depression, with low to substantial heterogeneity across studies 
pooled per CSVD feature (Figure 2, Figures S1.3a-S1.3c). Of all included studies, 94% 
found a positive association between any feature and depression (Figures S1.3a-S1.3c). 
Four studies were excluded from the pooled analysis (Table S3), of which one, on lacunes, 
found a statistically significant association with depression. 
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Figure 1. A & B
All-cause mortality
WMHs, lacunes and CMBs were statistically significantly associated with all-cause 
mortality, with low to moderate heterogeneity across studies pooled per CSVD feature 
(Figure 2, Figures S1.4a-S1.4d). Of all included studies, 94% found a positive association 
between any feature and all-cause mortality (Figures S1.4a-S1.4d). All four studies that 
were excluded from the pooled analysis (Table S3) showed a statistically significant 
association with all-cause mortality.





Figure 1. C & D
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Combinations of CSVD features
For incident stroke, two studies examined the combined effect of WMHs and lacunes and 
one of WMHs and CMBs (Table S3). No study examined the combined effect of ≥three 
individual features, or examined the association between multiple individual features 
combined and any of the other outcomes. The combination of two CSVD features was 
statistically significantly associated with incident ischaemic and haemorrhagic stroke 
(Figure 2, Figure S1.1f ). This risk was higher than the risk of any individual CSVD feature 
(Figure 2).
Sources of heterogeneity
Substantial heterogeneity (I2>60%) was present in four of the 17 main analyses (Figure 2). 
Exploration of heterogeneity showed that more concordance was present in analyses with 
only high-quality studies and with only studies that measured WMHs on an automated 
quantitative scale (Tables S6.1-S6.4). Results of these analyses were qualitatively similar to 
the results of the main analyses. 
Potential publication bias
Significant funnel plot asymmetry was found for analyses with stroke (for WMHs 
on a dichotomous scale, lacunes and CMBs) and all-cause mortality (for WMHs on a 
dichotomous scale) (Table S7, Figure S3). We used the trim and fill approach to adjust the 
estimates for funnel plot asymmetry. The adjusted estimates were qualitatively similar to 
those in the main analyses (Table S8).
Sensitivity analyses
Results were quantitatively similar when analyses were repeated using only population-
based cohort studies; using only high-quality studies; replacing the risk estimates for 
periventricular WMHs with those for deep WMHs; replacing the risk estimates for deep 
CMBs with those for lobar CMBs; and replacing adjusted risk estimates with unadjusted 
risk estimates (Figures S2.1-S2.5). In high-risk populations, the associations between 
WMHs and lacunes and all-cause dementia were weaker and not statistically significant 
(Figures S2.1, S2.3). For all studied outcomes, except for depression, the strength of the 
association was higher for WMHs measured on an automated quantitative scale than for 
WMHs measured on an observer rated semi-quantitative scale (Figure S2.1). Finally, in the 
post hoc analyses of studies with only stroke cases, WMHs, lacunes and microbleeds were 
associated with incident recurrent stroke, and WMHs and microbleeds, but not lacunes, 
were associated with higher mortality (Figure S2.1-2.5). The results of the other post hoc 
analyses are provided in the supplemental material (Figures S2.1-S2.5). 
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Figure 2. Pooled hazard ratios (95% confi dence intervals) for the association between MRI features of cerebral 
small vessel disease (CSVD) and incident ischaemic and haemorrhagic stroke, all-cause dementia and depression, 
and all-cause mortality. *Higher vs. lower as defi ned by the individual studies. †Heterogeneity, I2 < 30%, ‡I2 = 
30–60%, #I2 > 60%. For the forest plots of each pooled analysis, see supplemental material, Figures S1.1-S1.4.
Abbreviations: WMHs = white matter hyperintensities; SD = standard deviation
Discussion
Main fi ndings
This systematic review and meta-analysis shows that various individual CSVD features 
are consistently and strongly associated with a higher incidence of ischaemic and 
haemorrhagic stroke, all-cause dementia and depression, and all-cause mortality. In 
addition, the combination of two CSVD features is more strongly associated with incident 
stroke than individual features alone. The combined eff ect of multiple CSVD features 
could not be investigated for all-cause dementia or depression, or all-cause mortality. This 
indicates that, if these associations are causal, the strength of these associations suggests 
that a substantial burden of disease is attributable to CSVD. 
Our fi ndings agree with and extend previous meta-analyses3-9 on CSVD. These studies 
evaluated only WMHs,3, 5, 6 or only CMBs,4, 7-9 and found an association with incident stroke, 
dementia, depression or mortality. The pres ent meta-analysis is the fi rst to evaluate 
the eff ect of various CSVD features in diff erent study populations on multiple clinical 
outcomes. 
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Methodologic considerations
Some methodological issues warrant consideration. First, the associations with all 
outcomes were consistent across the different MRI features. Our analyses suggest 
individual MRI features of CSVD may not carry a differential risk for a specific clinical event, 
but may reflect disease severity, consistent with the hypothesis that these features are 
manifestations of the same disease.1 For instance, cerebral microbleeds were associated 
not only with incident intracerebral haemorrhage, but also with ischaemic stroke. In 
accordance, a recent study among individuals with CADASIL 15 found that presence of 
cerebral microbleeds was associated with ischaemic stroke. Second, there was substantial 
quantitative heterogeneity in four of the 17 main analyses. More concordance was present 
among high-quality studies and among studies that measured WMHs on an automated 
quantitative scale. Third, potential publication bias was present in four of the 17 main 
analyses. However, additional analyses suggested that this bias may have led to only a 
slight overestimation of true effect estimates (adjusted estimates calculated using the 
trim and fill approach were qualitatively similar to the results of the main analysis). Fourth, 
only two studies evaluated perivascular spaces, and only three studies evaluated the 
effect of combinations of CSVD features. Evidence for associations between perivascular 
spaces or combined CSVD features and the outcomes studied is, therefore, weak, and this 
requires further study. Fifth, effect estimates for stroke were higher than for dementia 
and depression, and mortality. The assessment of dementia and depression may have 
a larger measurement error than the assessment of stroke or death. Furthermore, other 
non-vascular factors may lead to dementia, depression, or greater mortality. Sixth, the 
association between CMBs and incident dementia was not statistically significant. 
This needs to be interpreted cautiously, because only four studies with relatively small 
samples were included in this analysis. Finally, results of most sensitivity analyses were 
consistent with our main analyses, with few exceptions. For CMBs, risk of haemorrhagic 
stroke was higher than for ischaemic stroke, which is in accordance with a previous meta-
analysis.8 This may be due to direct enlargement of CMBs transforming to intracranial 
haemorrhage.16 In addition, in high-risk populations, the associations between WMHs 
and lacunes and all-cause dementia were weaker than those in the population based 
studies. Similarly, in stroke populations, the associations between MWHs, lacunes and 
microbleeds and (recurrent) stroke and mortality were weaker. This may be due to the 
lower quality and smaller sample size of studies done in high-risk populations (only three 
of these 12 studies had a NOS score >four and their mean sample size was 209) and stroke 
populations (four of these 21 studies had a NOS score >four and their mean sample size 
was 861) as compared to population-based studies (11 of these 12 studies had a NOS 
score >four and their mean sample size was 1,484).
Underlying mechanisms
CSVD may lead to stroke, dementia, depression, and mortality through multiple 
mechanisms. First, CSVD may be a direct cause of stroke, dementia, and depression. 
Notably, MRI features of CSVD may reflect poor cerebral blood flow regulation, 
predisposing to ischemia (e.g. due to chronic cerebral hypoperfusion), which may lead to 
stroke.17 Furthermore, interruption of prefrontal subcortical structures or loops involved 
in cognitive function or mood regulation may directly lead to cognitive decline and 
depression.1, 18 Second, CSVD may indirectly lead to cognitive decline and depression 
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through incident stroke. Similarly, CSVD may increase mortality risk through incident 
stroke, dementia, and depression. Third, CSVD has been suggested19 to lead to cognitive 
decline through interaction with Alzheimer’s disease pathology. In accordance, the present 
study showed that CSVD increased the risk not only of presumed vascular dementia, but 
also of Alzheimer’s disease. Fourth, CSVD reflecting an individual’s poor health or social 
economic status might also explain our findings, particularly the association between 
CSVD and all-cause mortality. Although studies that adjusted for measures of frailty (e.g. 
walking speed) or education found similar results, we cannot exclude the possibility of 
residual confounding. 
Implications
This review has several clinical and research implications. It shows that individuals 
with CSVD features are at high risk of ischaemic and haemorrhagic stroke, all-cause 
dementia, depression and mortality; a risk similar to that of individuals with diabetes20-23 
or hypertension.24-28 An incidental finding of CSVD should be recognized as implying 
a substantial risk of stroke, dementia, depression, and mortality, and should prompt 
work-up and treatment of relevant risk factors. Prevention of CSVD itself could be an 
important therapeutic goal, although evidence for effective interventions is lacking. Trials 
are therefore needed that target suspected mechanisms of CSVD, including blood-brain 
barrier dysfunction, capillary flow pattern dysregulation, and blood pressure variability.17 
In addition, CSVD may be a surrogate marker of risk of stroke, dementia and depression. 
CSVD features can be quantified reliably29 and their change over time may be more sensitive 
than change of cognition.30 However, only one previous study31 found that reduction of 
progression of CSVD correlated with reduced occurrence of clinical endpoints, while 
others32, 33 did not. This requires further study. Finally, the present study showed that the 
combination of two CSVD features is most strongly associated with incident stroke. This 
suggests that imaging scales that integrate many CSVD features, such as the scale recently 
developed by Huijts et al.,34 are most suitable to assess CSVD and most likely to enable 
improved risk prediction of clinical outcomes beyond established risk factors. 
Limitations
This review has some limitations. We only evaluated baseline measurements of CSVD. 
Baseline measurements may, however, not accurately reflect the exposure to new lesions 
during follow-up. We also did not evaluate the location of CSVD features, although their 
clinical consequences may depend upon location, so our estimates are an average over 
possibly different associations per region. In addition, the pooled estimates for WMHs 
on a dichotomous scale should be interpreted with caution. Different definitions of this 
measure were used across studies which hampers its interpretation. 
Conclusion
The present systematic review and meta-analysis shows that various CSVD features 
are strongly and consistently associated with a higher incidence of ischaemic and 
haemorrhagic stroke, all-cause dementia and depression, and greater all-cause mortality.
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Supplemental material
Supplemental methods section
Appendix A. MOOSE Statement - Reporting Checklist for Authors, Editors, and Reviewers 
of Meta-analyses of Observational Studies
Reporting Criteria Reported (Yes/No)
Reporting of Background
   Problem definition Yes
   Hypothesis statement Yes
   Description of Study Outcome(s) Yes
   Type of exposure or intervention used Yes
   Type of study design used Yes
   Study population Yes
Reporting of Search Strategy
Qualifications of searchers (e.g. librarians and investigators) Yes
   Search strategy, including time period
   included in the synthesis and keywords
Yes (Supplemental material, 
Tables S1.1 to S1.4)
   Effort to include all available studies, 
   including contact with authors
Yes
   Databases and registries searched Yes
   Search software used, name and 
   version, including special features used 
   (eg, explosion)
Yes
   Use of hand searching (eg, reference 
   lists of obtained articles)
Yes
   List of citations located and those 
   excluded, including justification
Yes (Figure 1, Table S3)
   Method for addressing articles 
   published in languages other than 
   English
Yes
   Method of handling abstracts and 
   unpublished studies
Yes
   Description of any contact with authors Yes
Reporting of Methods
   Description of relevance or 
   appropriateness of studies assembled for 
   assessing the hypothesis to be tested
Yes
   Rationale for the selection and coding of 
   data (e.g. sound clinical principles or 
   convenience)
Yes
   Documentation of how data were 
   classified and coded (e.g. multiple raters, 
   blinding, and interrater reliability)
Yes
   Assessment of confounding (e.g. 
   comparability of cases and controls in 
   studies where appropriate
Yes
   Assessment of study quality, including 
   blinding of quality assessors; 
   stratification or regression on possible 
   predictors of study results
Yes (Supplemental material, Appendix C)
   Assessment of heterogeneity Yes (Supplemental material, Table S2)
2
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Reporting Criteria Reported (Yes/No)
   Description of statistical methods (e.g. 
   complete description of fixed or random 
   effects models, justification of whether    
   the chosen models account for predictors 
   of study results, dose-response models, 
   or cumulative meta-analysis) in sufficient 
   detail to be replicated
Yes
   Provision of appropriate tables and 
   graphics
Yes (Figure 1, Supplemental material)
Reporting of Results
   Table giving descriptive information for 
   each study included
Yes (Supplemental material, Tables S4.1 to 
S4.4, Tables S5.1 to S5.4)
   Results of sensitivity testing (e.g. 
   subgroup analysis)
Yes (Supplemental material, Figures S2.1 to 
S2.4, Tables S6.1 to S6.4)
   Indication of statistical uncertainty of 
   findings
Yes
Reporting of Discussion
   Quantitative assessment of bias (e.g. 
   publication bias)
Yes (Supplemental material, Figure S3, 
Table S7 and S8)
   Justification for exclusion (e.g. exclusion 
   of non–English-language citations)
No
   Assessment of quality of included studies Yes (Supplemental material, Tables S5.1 
to S5.4)
Reporting of Conclusions
   Consideration of alternative explanations 
   for observed results
Yes
   Generalization of the conclusions (i.e. 
   appropriate for the data presented and 
   within the domain of the literature review)
Yes
   Guidelines for future research Yes
   Disclosure of funding source Yes
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Appendix B. PROSPERO protocol
2
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Appendix C. Adjusted Newcastle-Ottawa Scale
For the present study, items 2 and 3 (selection category) of the original Newcastle-Ottawa 
Scale (NOS) for cohort studies were combined (for the individual items, see below). The 
original items evaluated the quality of the assessment of the exposed and non-exposed 
cohorts, respectively. In the present study, however, the total study was “exposed” to 
the risk factor under study (i.e. cerebral small vessel disease). A study can be awarded 
a maximum of one star for each numbered item within the selection and outcome 
categories. A maximum of two stars can be given for comparability. 
The individual items of the scale are described below. 
Selection
1) Representativeness of the cohort
a) truly representative of the general population *
b) somewhat representative of the general population *
c) high risk populations (e.g. individuals with: prior stroke, mild cognitive impairment, 
cardiovascular disease, prior depression (for the association with incident depression), 
or individuals receiving dialysis)
d) no description or other cohorts
2) Ascertainment of determinant (cerebral small vessel disease)
a) use of an MRI scanner with a field strength of 1.5 Tesla or higher and the following 
(minimal) sequences: for white matter hyperintensities: T2-weighted and fluid-
attenuated inversion recovery (FLAIR); for lacunes: T1- and(or) T2-weighted; for 
cerebral microbleeds: T2*-weighted gradient echo sequence; for perivascular spaces: 
T2-weighted; and for total cerebral atrophy: T1/FLAIR *
b) not a method described above
c) no description




1) Comparability of cohorts based on of the design or analysis
a) study controls for cardiovascular risk factors; smoking habits, type 2 diabetes, and 
systolic blood pressure, and/or use of antihypertensive medication. * 
b) study controls for age, sex, and (for studies evaluating incident dementia) education *
c) other
42   |   Chapter 2
Outcome
1) Assessment of outcome
a) objective measurements and/or record linkage and/or expert opinion * 
For depression: validated criteria, ICD codes  
For dementia: validated cognitive tests, ICD codes
For stroke: clinical diagnosis
For mortality: population or hospital register 
b) self- and/or peer-report
c) no description/other
2) Was follow-up long enough for outcomes to occur
a) yes (median/mean follow-up duration >4 year) *
b) no
3) Adequacy of follow-up of cohorts
a) complete follow-up and/or all subjects accounted for *
b) subjects lost to follow-up unlikely to introduce bias, small number lost (>80 % 
follow-up), or description provided of those lost *
c) follow up rate <80% and no description of those lost to follow-up
d) no statement
2
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Supplemental results section
Table S1.1 –Search strategy for incident ischaemic and haemorrhagic stroke
PubMed
(((“White matter” AND (hyperintens* OR lesion* OR disease* OR change*)) OR (“leukoaraiosis” OR 
“Leukoaraiosis”[Mesh] OR “Leukoaraiosis/pathology”[Mesh]) OR ((“cerebral small vessel” OR “cerebral small-
vessel”) AND disease*) OR “Cerebral Small Vessel Diseases”[Mesh]) OR (((“lacunar” OR “deep” OR “subcortical” 
OR “silent” OR “small vessel”) AND (infarc* OR Stroke*)) OR “Stroke, Lacunar”[Mesh] OR ((microinfarct* OR 
microscopic infarct*) AND (“brain” OR cerebral* OR cerebrum*))) OR ((“brain” OR cerebral* OR cerebrum*) AND 
((microhemorrhag* OR microbleed* OR microhaemorrhag*) OR (“dot-like” AND (suscept* OR hemosid*)))) 
OR ((“brain” OR cerebral* OR cerebrum*) AND (Virchow-Robin* OR Virchow Robin* OR “etat crible”  OR 
(perivascular space*))) OR ((“brain” OR cerebral* OR cerebrum*) AND (“Atrophy” OR volum* OR “volume loss”))) 
AND (“Magnetic Resonance Imaging”[Mesh] OR “MRI” OR “magnetic resonance imaging”) AND ((“Stroke” or 
((“brain” OR cerebral* OR cerebrum*) AND (Infarction* OR hemorrhag* OR haemorrhag*)) or “Stroke”[Mesh] 
or “Stroke/epidemiology”[Mesh] or “Cerebral Hemorrhage”[Mesh] OR “Cerebral Infarction”[Mesh])) AND 
(“Longitudinal study” OR “Cohort study” OR “Prospective study” OR “Longitudinal Studies”[Mesh] or “Cohort 
Studies”[Mesh] OR “Prospective Studies”[Mesh])
Embase
(((exp white matter/ AND (hyperintensity.mp. OR lesion.mp. OR disease.mp. OR exp diseases/)) OR exp white 
matter lesion/ OR leukoaraiosis.mp. OR cerebral small vessel disease.mp. OR exp cerebrovascular disease/) 
OR (exp lacunar stroke/ OR ((lacunar.mp. OR deep.mp. OR subcortical.mp. OR silent.mp. OR small vessel.mp.) 
AND (exp infarction/ OR exp stroke/)) OR ((microinfarct.mp. OR microscopic infarct.mp.) AND (cerebral.mp. OR 
exp brain/ OR cerebrum.mp.))) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (microhaemorrhage.
mp. OR microhemorrhage.mp. OR microbleed.mp.)) OR (dot-like.mp. AND (susceptible.mp. OR hemosiderin.
mp.))) OR ((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (virchow-robin.mp. OR Virchow robin.mp. 
OR etat crible.mp. OR perivascular space.mp.)) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp. OR exp 
brain size/) AND (exp atrophy/ OR volume loss.mp.)) OR exp brain atrophy/)) AND (((cerebral.mp. OR exp 
brain/ OR cerebrum.mp.) AND (exp infarction/ OR exp stroke/ OR exp bleeding/ OR microhaemorrhage.
mp. OR microhemorrhage.mp.)) OR Exp brain infarction/ OR exp cerebrovascular accident/) AND (MRI.mp. 
OR magnetic resonance imaging.mp. OR exp nuclear magnetic resonance imaging/) AND (exp longitudinal 
study/ OR exp cohort analysis/ OR exp prospective study/)
44   |   Chapter 2
Table S1.2 –Search strategy for incident all-cause dementia
PubMed
(((((((“White matter” AND (hyperintens* OR lesion* OR disease* OR change*)) OR (“leukoaraiosis” OR 
“Leukoaraiosis”[Mesh] OR “Leukoaraiosis/pathology”[Mesh]) OR ((“cerebral small vessel” OR “cerebral small-
vessel”) AND disease*) OR “Cerebral Small Vessel Diseases”[Mesh]) OR (((“lacunar” OR “deep” OR “subcortical” 
OR “silent” OR “small vessel”) AND (infarc* OR Stroke*)) OR “Stroke, Lacunar”[Mesh] OR ((microinfarct* OR 
microscopic infarct*) AND (“brain” OR cerebral* OR cerebrum*))) OR ((“brain” OR cerebral* OR cerebrum*) AND 
((microhemorrhag* OR microbleed* OR microhaemorrhag*) OR (“dot-like” AND (suscept* OR hemosid*)))) 
OR ((“brain” OR cerebral* OR cerebrum*) AND (Virchow-Robin* OR Virchow Robin* OR “etat crible” OR 
(perivascular space*))) OR ((“brain” OR cerebral* OR cerebrum*) AND (“Atrophy” OR volum* OR “volume loss”))) 
AND (“Magnetic Resonance Imaging”[Mesh] OR “MRI” OR “magnetic resonance imaging”))) AND ((“Dementia” 
OR “Alzheimer disease” OR “Vascular dementia” OR “Dementia”[Mesh] OR “Dementia/epidemiology”[Mesh] 
OR “Alzheimer Disease”[Mesh] OR “Dementia, Multi-Infarct”[Mesh] OR “Dementia, Vascular”[Mesh] OR 
“Mild Cognitive Impairment”[Mesh] OR “cognitive impairment”)))) AND ((“Longitudinal study” OR “Cohort 
study” OR “Prospective study” OR “Longitudinal Studies”[Mesh] OR “Cohort Studies”[Mesh] OR “Prospective 
Studies”[Mesh]))
Embase
(((exp white matter/ AND (hyperintensity.mp. OR lesion.mp. OR disease.mp. OR exp diseases/)) OR exp white 
matter lesion/ OR leukoaraiosis.mp. OR cerebral small vessel disease.mp. OR exp cerebrovascular disease/) OR 
(exp lacunar stroke/ OR ((lacunar.mp. OR deep.mp. OR subcortical.mp. OR silent.mp. OR small vessel.mp.) AND 
(exp infarction/ OR exp stroke/)) OR ((microinfarct.mp. OR microscopic infarct.mp.) AND (cerebral.mp. OR exp 
brain/ OR cerebrum.mp.))) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (microhaemorrhage.mp. 
OR microhemorrhage.mp. OR microbleed.mp.)) OR (dot-like.mp. AND (susceptible.mp. OR hemosiderin.mp.))) 
OR ((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (virchow-robin.mp. OR Virchow robin.mp. OR etat 
crible.mp. OR perivascular space.mp.)) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp. OR exp brain size/) 
AND (exp atrophy/ OR volume loss.mp.)) OR exp brain atrophy/)) AND (exp dementia/ OR exp Alzheimer 
disease/ OR exp multinfarct dementia/ OR vascular dementia.mp. OR exp cognitive defect/ OR cognitive 
impairment.mp.) AND (MRI.mp. OR magnetic resonance imaging.mp. OR exp nuclear magnetic resonance 
imaging/) AND (exp longitudinal study/ OR exp cohort analysis/ OR exp prospective study/) 
Table S1.3 –Search strategy for incident depression
PubMed
(((“White matter” AND (hyperintens* OR lesion* OR disease* OR change*)) OR (“leukoaraiosis” OR 
“Leukoaraiosis”[Mesh] OR “Leukoaraiosis/pathology”[Mesh]) OR ((“cerebral small vessel” OR “cerebral small-
vessel”) AND disease*) OR “Cerebral Small Vessel Diseases”[Mesh]) OR (((“lacunar” OR “deep” OR “subcortical” 
OR “silent” OR “small vessel”) AND (infarc* OR Stroke*)) OR “Stroke, Lacunar”[Mesh] OR ((microinfarct* OR 
microscopic infarct*) AND (“brain” OR cerebral* OR cerebrum*))) OR ((“brain” OR cerebral* OR cerebrum*) AND 
((microhemorrhag* OR microbleed* OR microhaemorrhag*) OR (“dot-like” AND (suscept* OR hemosid*)))) 
OR ((“brain” OR cerebral* OR cerebrum*) AND (Virchow-Robin* OR Virchow Robin* OR “etat crible”  OR 
(perivascular space*))) OR ((“brain” OR cerebral* OR cerebrum*) AND (“Atrophy” OR volum* OR “volume loss”))) 
AND (“Magnetic Resonance Imaging”[Mesh] OR “MRI” OR “magnetic resonance imaging”) AND (“Depression” 
OR “Depression”[Mesh] OR “Depressive Disorder, Major”[Mesh] OR “Suicide” OR “Suicide”[Mesh]) AND 
(“Longitudinal study” OR “Cohort study” OR “Prospective study” OR “Longitudinal Studies”[Mesh] or “Cohort 
Studies”[Mesh] OR “Prospective Studies”[Mesh])
 Embase
(((exp white matter/ AND (hyperintensity.mp. OR lesion.mp. OR disease.mp. OR exp diseases/)) OR exp white 
matter lesion/ OR leukoaraiosis.mp. OR cerebral small vessel disease.mp. OR exp cerebrovascular disease/) 
OR (exp lacunar stroke/ OR ((lacunar.mp. OR deep.mp. OR subcortical.mp. OR silent.mp. OR small vessel.mp.) 
AND (exp infarction/ OR exp stroke/)) OR ((microinfarct.mp. OR microscopic infarct.mp.) AND (cerebral.mp. OR 
exp brain/ OR cerebrum.mp.))) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (microhaemorrhage.
mp. OR microhemorrhage.mp. OR microbleed.mp.)) OR (dot-like.mp. AND (susceptible.mp. OR hemosiderin.
mp.))) OR ((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (virchow-robin.mp. OR Virchow robin.mp. OR 
etat crible.mp. OR perivascular space.mp.)) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp. OR exp brain 
size/) AND (exp atrophy/ OR volume loss.mp.)) OR exp brain atrophy/)) AND (exp depression/ OR exp major 
depression/ OR exp suicide/ OR exp suicide attempt/) AND (MRI.mp. OR magnetic resonance imaging.mp. 
OR exp nuclear magnetic resonance imaging/) AND (exp longitudinal study/ OR exp cohort analysis/ OR exp 
prospective study/) 
2
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Table S1.4 –Search strategy for all-cause mortality
PubMed
(((“White matter” AND (hyperintens* OR lesion* OR disease* OR change*)) OR (“leukoaraiosis” OR 
“Leukoaraiosis”[Mesh] OR “Leukoaraiosis/pathology”[Mesh]) OR ((“cerebral small vessel” OR “cerebral small-
vessel”) AND disease*) OR “Cerebral Small Vessel Diseases”[Mesh]) OR (((“lacunar” OR “deep” OR “subcortical” 
OR “silent” OR “small vessel”) AND (infarc* OR Stroke*)) OR “Stroke, Lacunar”[Mesh] OR ((microinfarct* OR 
microscopic infarct*) AND (“brain” OR cerebral* OR cerebrum*))) OR ((“brain” OR cerebral* OR cerebrum*) AND 
((microhemorrhag* OR microbleed* OR microhaemorrhag*) OR (“dot-like” AND (suscept* OR hemosid*)))) 
OR ((“brain” OR cerebral* OR cerebrum*) AND (Virchow-Robin* OR Virchow Robin* OR “etat crible”  OR 
(perivascular space*))) OR ((“brain” OR cerebral* OR cerebrum*) AND (“Atrophy” OR volum* OR “volume loss”))) 
AND (“Magnetic Resonance Imaging”[Mesh] OR “MRI” OR “magnetic resonance imaging”) AND (“Death” OR 
“Mortality” OR “Death”[Mesh] OR “all-cause mortality” OR “Mortality”[Mesh] OR “survival analysis”[Mesh] OR 
“survival analysis”) AND (“Longitudinal study” OR “Cohort study” OR “Prospective study” OR “Longitudinal 
Studies”[Mesh] or “Cohort Studies”[Mesh] OR “Prospective Studies”[Mesh])
Embase
(((exp white matter/ AND (hyperintensity.mp. OR lesion.mp. OR disease.mp. OR exp diseases/)) OR exp white 
matter lesion/ OR leukoaraiosis.mp. OR cerebral small vessel disease.mp. OR exp cerebrovascular disease/) 
OR (exp lacunar stroke/ OR ((lacunar.mp. OR deep.mp. OR subcortical.mp. OR silent.mp. OR small vessel.mp.) 
AND (exp infarction/ OR exp stroke/)) OR ((microinfarct.mp. OR microscopic infarct.mp.) AND (cerebral.mp. OR 
exp brain/ OR cerebrum.mp.))) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (microhaemorrhage.
mp. OR microhemorrhage.mp. OR microbleed.mp.)) OR (dot-like.mp. AND (susceptible.mp. OR hemosiderin.
mp.))) OR ((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (virchow-robin.mp. OR Virchow robin.mp. OR 
etat crible.mp. OR perivascular space.mp.)) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp. OR exp brain 
size/) AND (exp atrophy/ OR volume loss.mp.)) OR exp brain atrophy/)) AND (exp death/ OR exp mortality/ 
OR exp survival/ OR survival analysis.mp.) AND (MRI.mp. OR magnetic resonance imaging.mp. OR exp nuclear 
magnetic resonance imaging/) AND (exp longitudinal study/ OR exp cohort analysis/ OR exp prospective 
study/) 
Table S2 – Description of post hoc analyses
Post hoc analyses
Post hoc analyses were done when at least 3 studies were available per outcome. Results were pooled using 
only studies with a first episode of ischaemic of haemorrhagic stroke or depression; using only studies with 
stroke patients; using only hazard ratios (i.e. excluding studies that reported odds ratios or relative risks); 
using risk estimates comparing highest vs. lowest categories of white matter hyperintensities (irrespective of 
the number of participants per category), instead of risk estimates comparing higher and lower categories 
with the highest number of participants and events; using only risk estimates for silent cerebral infarcts; 
excluding studies that reported risk estimates for silent cerebral infarcts only; using only studies with 
Newcastle-Ottawa Scale (NOS) score >3; using only studies with NOS score >5; using only risk estimates of 
periventricular white matter hyperintensities; using only risk estimates of deep white matter hyperintensities; 
using only risk estimates for deep cerebral microbleeds; and using only risk estimates for lobar cerebral 
microbleeds.
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Table S5.1 – Newcastle-Ottawa Scale scores for studies on the association between cerebral small vessel disease 
and incident ischaemic and haemorrhagic stroke
Study S1 S2 S3 C1 O1 O2 O3 Total score
Akoudad et al., 20115 1 1 0 2 1 1 1 7
Andersen et al., 20162 0 1 0 1 1 0 1 4
Andersen et al., 20173 0 1 0 0 1 1 1 4
Appelros et al., 20054 0 0 0 0 1 0 1 2
Benedictus et al., 20155 0 0 0 1 1 0 1 3
Bernick et al., 20016 1 1 1 1 0 1 0 5
Bokura et al., 20117 1 0 1 1 0 0 1 4
Bokura et al., 20068 1 0 0 2 1 1 0 5
Boulanger et al., 20069 0 1 0 0 0 0 1 2
Buyck et al., 200910 1 1 1 2 1 1 1 8
Conijn et al., 201111 0 1 0 2 1 1 1 6
Debette et al., 201012 1 0 1 2 1 1 0 6
Fan et al., 200313 0 1 0 0 0 0 1 2
Fu et al., 200514 0 1 0 0 0 0 1 2
Gerdes et al., 200615 0 1 0 0 0 0 0 1
Gioia et al., 201216 0 1 0 2 0 0 0 3
Haji et al., 201517 0 0 0 0 0 0 0 0
Imaizumi et al., 201518 0 1 0 0 0 0 1 2
Inzitari et al., 200919 0 0 0 0 1 0 0 1
Ishikawa et al., 200720 1 1 1 0 0 0 0 3
Kaffashian et al., 2016a21 1 1 1 2 1 1 1 8
Kaffashian et al., 2016b22 1 1 1 2 1 1 1 8
Kario et al., 200123 0 1 1 1 1 0 1 5
Kobayashi et al., 199724 1 0 1 0 0 0 1 3
Kuller et al., 200425 1 0 1 1 1 0 0 4
Kumral et al., 201526 0 0 0 0 0 1 1 2
Kwa et al., 201227 0 0 0 1 0 0 1 2
Melkas et al., 201228 0 0 0 1 1 1 0 3
Mok et al., 200929 0 1 0 0 0 1 1 3
Naganuma et al., 201330 0 1 1 0 0 0 1 3
Naganuma et al., 201531 0 1 1 2 0 1 1 6
Naka et al., 200632 0 0 0 2 1 0 1 4
Nishikawa et al., 200933 1 1 1 1 1 0 0 5
Ntaios et al., 201534 0 0 0 0 1 0 0 1
Poels et al., 201235 1 1 1 2 1 1 1 8
Putaala et al., 201136 0 0 0 1 0 1 1 3
Smith et al., 200437 0 0 0 0 0 0 0 0
Soo et al., 200838 0 1 0 0 1 0 1 3
Thijs et al., 201039 0 0 0 1 1 0 1 3
van der Veen et al., 201440 0 1 0 2 1 1 0 5
Weber et al., 201241 0 0 0 0 0 0 0 0
Weinstein et al., 201342 1 0 1 2 1 1 0 6
Windham et al., 201543 1 1 1 2 1 1 1 8
Yamauchi et al., 200244 0 0 0 2 1 1 0 4
Newcastle-Ottawa Scale score (NOS) for studies on the association between cerebral small vessel disease and 
incident haemorrhagic and ischaemic stroke. For an explanation of the individual items, see the provided 
adjusted NOS (Appendix C). Maximal NOS score is 8. Articles indicated in bold are of high methodologic quality 
(NOS score >4). S1= Representativeness of the cohort; S2 = ascertainment of determinant; S3= presence of 
outcome of interest at start of study; C1= Comparability of cohorts: use of adjustments; O1= assessment of 
outcome; O2= follow up duration; O3= adequacy of follow up.
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Table S5.2 – Newcastle-Ottawa Scale scores for studies on the association between cerebral small vessel disease 
and incident all-cause dementia 
Study S1 S2 S3 C1 O1 O2 O3 Total score
Akoudad et al., 201564 1 1 1 2 1 0 1 7
Bombois et al., 200846 0 1 1 2 1 0 1 6
Debette et al., 201012 1 1 1 1 1 1 1 7
DeCarli et al., 200447 0 0 0 0 0 0 1 1
Firbank et al., 201248 0 1 1 0 1 0 0 3
Geroldi et al., 200649 0 0 1 0 1 0 0 2
Godin et al., 201050 1 1 1 2 0 1 1 7
Gomar et al., 201151 0 0 1 0 1 0 0 2
Ikram et al., 201052 1 1 1 2 1 1 1 8
Kaffashian et al., 2016a21 1 1 1 2 1 1 1 8
Kaffashian et al., 016b22 1 1 1 2 1 1 1 8
Kantarci et al., 200953 0 1 1 1 1 0 1 5
Kim et al., 201554 0 1 1 1 1 0 1 5
Kitagawa et al., 201555 1 1 1 2 1 1 0 7
Korf et al., 200456 0 1 1 0 1 0 0 3
Kuller, 200357 1 1 1 1 0 1 0 5
Lopez et al., 201458 1 1 1 1 1 0 1 6
Meguro et al., 200759 0 1 1 0 1 1 0 4
Miwa et al., 201460 0 1 1 1 1 1 0 5
Prasad et al., 201161 0 0 1 0 1 0 0 2
Prins et al., 200462 1 1 1 0 1 1 1 6
Prins et al., 201363 0 1 1 0 0 0 1 3
Rosano et al., 200764 1 1 1 1 1 1 0 6
Sluimer et al., 200865 0 0 1 0 1 0 0 2
Smith et al., 200866 0 1 1 0 1 1 0 4
Staekenborg et al., 200967 0 0 1 0 1 0 0 2
Steffens et al., 200268 0 0 1 0 1 0 0 2
Steffens et al., 200769 0 0 1 0 1 1 0 3
Stephan et al., 201570 1 1 1 2 1 1 1 8
Stoub et al., 201471 1 1 1 0 1 1 0 5
Tapiola et al., 200872 0 1 1 0 1 0 0 3
van Straaten et al., 200873 0 1 1 0 1 0 0 3
van Uden et al., 201574 0 1 1 1 1 1 1 6
Verdelho et al., 201075 0 1 1 0 1 0 0 3
Vermeer et al., 200376 1 1 1 1 1 0 1 6
Weinstein et al., 201342 1 1 1 2 1 1 0 7
Yamamoto et al., 200277 0 1 1 0 1 1 0 4
Zhu et al., 201078 1 1 1 0 1 0 1 5
Newcastle-Ottawa Scale score (NOS) for studies on the association between cerebral small vessel disease and 
incident dementia. For an explanation of the individual items, see the provided adjusted NOS (Appendix C). 
Maximal NOS score is 8. Articles indicated with bold are of high methodologic quality (NOS score >4). S1= 
Representativeness of the cohort; S2 = ascertainment of determinant; S3= presence of outcome of interest at 
start of study; C1= Comparability of cohorts: use of adjustments; O1= assessment of outcome; O2= follow up 
duration; O3= adequacy of follow up. 
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Table S5.3 – Newcastle-Ottawa Scale scores for studies on the association between cerebral small vessel disease 
and  incident depression
Study S1 S2 S3 C1 O1 O2 O3 Total score
Godin et al., 200987 1 1 1 1 1 1 0 6
Ikram et al., 200980 1 1 1 1 1 1 1 7
Kim et al., 201681 0 1 1 0 1 0 0 3
Park et al., 201582 1 1 1 1 1 0 0 5
Perez, 201383 1 1 1 1 1 0 1 6
Qiu et al., 201684 1 0 1 1 1 1 0 5
Steffens et al., 200285 1 0 1 1 1 1 0 5
Teodorczuk et al., 200786 0 1 1 0 1 0 1 4
Teodorczuk et al., 201087 0 1 1 0 1 0 1 4
van Sloten et al., 201588 1 1 1 1 1 1 1 7
Versluis et al., 200689 1 1 1 1 1 0 1 6
Newcastle-Ottawa Scale score (NOS) for studies on the association between cerebral small vessel disease and 
incident depression. For an explanation of the individual items, see the provided adjusted NOS (Appendix C). 
Maximal NOS score is 8. Articles indicated with bold are of high methodologic quality (NOS score >4). S1= 
Representativeness of the cohort; S2 = ascertainment of determinant; S3= presence of outcome of interest at 
start of study; C1= Comparability of cohorts: use of adjustments; O1= assessment of outcome; O2= follow up 
duration; O3= adequacy of follow up.
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Table S5.4 – Newcastle-Ottawa Scale scores for studies on the association between cerebral small vessel disease 
and incident all-cause mortality
Study S1 S2 S3 C1 O1 O2 O3 Total score
Akoudad et al., 20151 1 1 1 2 1 1 1 8
Altmann-Schneider et al., 201190 0 1 1 2 1 1 1 7
Andersen et al., 20162 0 1 1 1 0 0 1 4
Andersen et al., 20173 0 1 1 0 1 1 1 5
Appelros et al., 20054 0 0 1 0 1 1 0 3
Benedictus et al., 20155 0 0 1 1 1 0 1 4
Bokura et al., 20068 1 0 1 2 0 1 0 5
Boulanger et al., 20069 0 1 1 0 0 0 1 3
Conijn et al., 201111 0 1 1 2 1 1 1 7
Debette et al., 201012 1 0 1 2 1 1 0 6
Fan et al., 200313 0 1 1 0 0 0 1 3
Firbank et al., 201248 0 1 1 0 0 0 0 2
Fu et al., 200514 0 1 1 0 0 0 1 3
Haji et al., 201517 0 0 1 0 1 0 0 2
Henneman et al., 200991 0 1 1 1 1 0 0 4
Ikram et al., 200980 1 1 1 1 1 1 1 7
Inzitari et al., 200919 0 0 1 0 0 0 0 1
Kerber et al., 200692 1 1 1 0 1 1 1 6
Kuller et al., 200793 1 0 1 2 1 1 1 7
Kwa et al., 201227 0 0 1 1 0 0 1 3
Lavretsky et al., 201094 0 1 1 0 0 1 0 3
Levy et al., 200395 0 1 1 1 1 1 0 5
Mok et al., 200929 0 1 1 0 0 1 1 4
Oksala et al., 200996 0 0 1 1 2 1 1 6
Putaala et al., 201136 0 0 1 1 1 1 1 5
Staff et al., 201097 1 0 1 0 1 1 0 4
van der Holst et al., 201698 1 1 1 2 1 1 1 8
van der Veen et al., 201440 0 1 1 2 1 1 0 6
Weber et al., 201241 0 0 1 0 0 0 0 1
Windham et al., 201543 1 1 1 2 1 1 1 8
Yamauchi et al., 200244 0 0 1 0 1 1 0 3
Newcastle-Ottawa Scale score (NOS) for studies on the association between cerebral small vessel disease and 
all-cause mortality. For an explanation of the individual items, see the provided adjusted NOS (Appendix C). 
Maximal NOS score is 8. Articles indicated with bold are of high methodologic quality (NOS score >4). S1= 
Representativeness of the cohort; S2 = ascertainment of determinant; S3= presence of outcome of interest at 
start of study; C1= Comparability of cohorts: use of adjustments; O1= assessment of outcome; O2= follow up 
duration; O3= adequacy of follow up.
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Table S6.1 – Heterogeneity for analyses with incident ischaemic and haemorrhagic stroke
 
Heterogeneity (I2) in the main and sensitivity analyses for the association of cerebral small vessel disease with 
incident ischaemic and haemorrhagic stroke. For a description of the sensitivity analyses, see Figures S2.1 to S2.5. 
Abbreviations: CMBs: cerebral microbleeds; DWMHs: deep white matter hyperintensities; HRs: hazard ratios; 
ICH: intracerebral haemorrhage; NOS: Newcastle-Ottawa scale score; pop: population; PVHs: periventricular 
hyperintensities; WMHs: white matter hyperintensities.
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S6.2 – Heterogeneity for analyses with incident all-cause dementia
Heterogeneity (I2) in the main and sensitivity analyses for the association of cerebral small vessel disease with 
incident all-cause dementia. For a description of the sensitivity analyses, see Figures S2.1 to S2.5. Abbreviations: 
CMBs: cerebral microbleeds; DWMHs: deep white matter hyperintensities; HRs: hazard ratios; ICH: intracerebral 
haemorrhage; NOS: Newcastle-Ottawa scale score; pop: population; PVHs: periventricular hyperintensities; 
WMHs: white matter hyperintensities.
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Table S6.3 – Heterogeneity for analysis with incident depression
Heterogeneity (I2) in the main and sensitivity analyses for the association of cerebral small vessel disease 
with incident depression. For a description of the sensitivity analyses, see Figures S2.1 to S2.5. Abbreviations: 
CMBs: cerebral microbleeds; DWMHs: deep white matter hyperintensities; HRs: hazard ratios; ICH: intracerebral 
haemorrhage; NOS: Newcastle-Ottawa scale score; pop: population; PVHs: periventricular hyperintensities; 
WMHs: white matter hyperintensities.
86   |   Chapter 2
Table S6.4 – Heterogeneity for analysis with all-cause mortality
Heterogeneity (I2) in the main and sensitivity analyses for the association of cerebral small vessel disease 
with all-cause mortality. For a description of the sensitivity analyses, see Figures S2.1 to S2.5. Abbreviations: 
CMBs: cerebral microbleeds; DWMHs: deep white matter hyperintensities; HRs: hazard ratios; ICH: intracerebral 
haemorrhage; NOS: Newcastle-Ottawa scale score; pop: population; PVHs: periventricular hyperintensities; 
WMHs: white matter hyperintensities.
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Table S7 –Egger’s Tests to detect significant funnel plot asymmetry
Association T-value df p-value
WMHs on a dichotomous scale with ischaemic or 
haemorrhagic stroke
4.70 21 0.0001
Lacunes with ischaemic or haemorrhagic stroke 2.55 13 0.02
CMBs with ischaemic or haemorrhagic stroke 3.01 13 0.01
WMHs on a dichotomous scale with all-cause 
dementia
0.22 13 0.83
Lacunes with all-cause dementia 2.00 8 0.08
WMHs on a dichotomous scale with all-cause 
mortality
2.33 14 0.04
Lacunes with all-cause mortality -0.33 9 0.75
CMBs with all-cause mortality -0.56 8 0.59
Tests were done when more than 10 studies were available per analysis. Abbreviations: CMBs: cerebral 
microbleeds; df: degrees of freedom; WMHs: white matter hyperintensities.
Table S8- Trim and fill test for analyses with significant funnel plot asymmetry
Association Estimated 
hazard ratio
Estimated 95% CI interval Estimated number of 
missing studies
Lower limit Upper limit
WMHs on a dichotomous scale 
with stroke
1.94 1.54 2.45 7
Lacunes with stroke 2.36 1.84 3.02 4
CMBs with stroke 1.62 1.23 2.13 4
WMHs on a dichotomous scale 
with mortality
1.68 1.48 1.90 4
Abbreviations: CI: confidence interval; CMBs: cerebral microbleeds; WMHs: white matter hyperintensities.
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Figure S1.1a, Forest plot for the association between white matter hyperintensities on a dichotomous scale and 
incident ischaemic and haemorrhagic stroke
 
*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham 
Offspring study.
Figure S1.1b, Forest plot for the association between white matter hyperintensities on a continuous scale and 
incident ischaemic and haemorrhagic stroke
 
*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham 
Offspring study.
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Figure S1.1c, Forest plot for the association between lacunes and incident ischaemic and haemorrhagic stroke
 
Figure S1.1d, Forest plot for the association between cerebral microbleeds and incident ischaemic and 
haemorrhagic stroke
 
Figure S1.1e, Forest plot for the association between total cerebral atrophy and incident ischaemic and 
haemorrhagic stroke
 
*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham 
Offspring study.
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Figure S1.1f, Forest plot for the association between combinations of cerebral small vessel disease features and 
incident ischaemic and haemorrhagic stroke
 
Figure S1.2a, Forest plot for the association between white matter hyperintensities on a dichotomous scale and 
incident all-cause dementia
 
*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham 
Offspring study.
Figure S1.2b, Forest plot for the association between white matter hyperintensities on a continuous scale and 
incident all-cause dementia
 
*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham 
Offspring study.
2
Cerebral small vessel disease and risk of incident stroke, dementia and depression |   91 
Figure S1.2c, Forest plot for the association between lacunes and incident all-cause dementia
 
Figure S1.2d, Forest plot for the association between cerebral microbleeds and incident all-cause dementia
 
Figure S1.2e, Forest plot for the association between total cerebral atrophy and incident all-cause dementia
 
*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham 
Offspring study.
Figure S1.3a, Forest plot for the association between white matter hyperintensities on a dichotomous scale and 
incident depression
 
92   |   Chapter 2
Figure S1.3b, Forest plot for the association between white matter hyperintensities on a continuous scale and 
incident depression
 
Figure S1.3c, Forest plot for the association between total cerebral atrophy and incident depression
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Figure S1.4b, Forest plot for the association between white matter hyperintensities on a continuous scale and 
all-cause mortality
 
Figure S1.4c, Forest plot for the association between lacunes and all-cause mortality
 
Figure S1.4d, Forest plot for the association between cerebral microbleeds and all-cause mortality
 
Figures S1.1 to S1.4. Forest plots for the associations between features of cerebral small vessel disease and 
incident ischaemic and haemorrhagic stroke, all-cause dementia and depression, and all-cause mortality. 
Abbreviations: CI: confidence interval; df: degrees of freedom; IV: inverse variance; SE: standard error; 
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Figure S2.1 – Pooled hazard ratios for sensitivity analyses for white matter hyperintensities on a dichotomous 
scale (High vs. low)*
 
Figures S2.1. Pooled hazard ratios (HRs) (95% confidence intervals) for the association between features of 
white matter hyperintensities on a dichotomous scale and incident ischaemic and haemorrhagic stroke, all-
cause dementia, depression, and all-cause mortality. *High vs. low as defined by the individual studies. Results 
were pooled when at least 3 studies were available. The following pre-specified analyses were done: analyses 
were repeated using only subtypes of stroke (ischaemic and haemorrhage) or dementia (Alzheimer’s disease and 
presumed vascular dementia) as the outcome; using only population-based cohort studies; using only studies 
with high-risk populations; using only high-quality studies (defined as Newcastle-Ottawa Scale (NOS) score >4); 
using only studies that measured white matter hyperintensities (WMHs) on an observer-rated semi-quantitative 
scale; using only studies that measured WMHs on an automated quantitative scale; replacing the risk estimates 
for periventricular WMHs with those for deep WMHs; and replacing adjusted risk estimates with unadjusted risk 
estimates. The following post hoc analyses were done: analyses were repeated using only studies with a first 
episode of stroke or depression; using only studies with stroke patients; using only hazard ratios (i.e. excluding 
studies that reported odds ratios or relative risks); using risk estimates comparing highest vs. lowest categories 
of WMHs (irrespective of the number of participants per category) (indicated in the figures as “extreme groups”), 
instead of risk estimates comparing higher and lower categories with the highest number of participants and 
events; using only studies with NOS score >3; using only studies with NOS score >5; using only risk estimates 
of periventricular white matter hyperintensities (PVHs); and using only risk estimates of deep white matter 
hyperintensities (DWMHs). Abbreviations: AD: Alzheimer’s disease; CMBs: cerebral microbleeds; DWMHs: deep 
white matter hyperintensities; HRs: hazard ratios; ICH: intracerebral haemorrhage; IS: ischaemic stroke; NOS: 
Newcastle-Ottawa scale score; pop: population; PVHs: periventricular hyperintensities; VaD: presumed vascular 
dementia; WMHs: white matter hyperintensities.
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Figure S2.2 – Pooled hazard ratios for sensitivity analyses for white matter hyperintensities on a continuous 
scale (per 1 SD increase)
 
Figures S2.2. Pooled hazard ratios (HRs) (95% confidence intervals) for the association between white matter 
hyperintensities on a continuous scale and incident ischaemic and haemorrhagic stroke, all-cause dementia, 
depression, and all-cause mortality. Results were pooled when at least 3 studies were available. The following 
pre-specified analyses were done: analyses were repeated using only subtypes of stroke (ischaemic and 
haemorrhage) or dementia (Alzheimer’s disease and presumed vascular dementia) as the outcome; using only 
population-based cohort studies; using only studies with high-risk populations; using only high-quality studies 
(defined as Newcastle-Ottawa Scale (NOS) score >4); replacing the risk estimates for periventricular WMHs with 
those for deep WMHs; and replacing adjusted risk estimates with unadjusted risk estimates. The following post 
hoc analyses were done: analyses were repeated using only studies with a first episode of stroke or depression; 
using only studies with stroke patients; using only hazard ratios (i.e. excluding studies that reported odds 
ratios or relative risks); using only studies with NOS score >3; using only studies with NOS score >5; using only 
risk estimates of periventricular white matter hyperintensities (PVHs); and using only risk estimates of deep 
white matter hyperintensities (DWMHs). Abbreviations: AD: Alzheimer’s disease; DWMHs: deep white matter 
hyperintensities; HRs: hazard ratios; ICH: intracerebral haemorrhage; IS: ischaemic stroke; NOS: Newcastle-
Ottawa scale score; pop: population; PVHs: periventricular hyperintensities; SD: standard deviation; VaD: 
presumed vascular dementia; WMHs: white matter hyperintensities.
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Figure S2.3 – Pooled hazard ratios for sensitivity analyses for lacunes (absence vs. presence)
 
Figures S2.3. Pooled hazard ratios (HRs) (95% confidence intervals) for the association between lacunes and 
incident ischaemic and haemorrhagic stroke, all-cause dementia, depression, and all-cause mortality. Results 
were pooled when at least 3 studies were available. The following pre-specified analyses were done: analyses 
were repeated using only subtypes of stroke (ischaemic and haemorrhage) or dementia (Alzheimer’s disease and 
presumed vascular dementia) as the outcome; using only population-based cohort studies; using only studies 
with high-risk populations; using only high-quality studies (defined as Newcastle-Ottawa Scale (NOS) score 
>4); and replacing adjusted risk estimates with unadjusted risk estimates. The following post hoc analyses were 
done: analyses were repeated using only studies with a first episode of stroke or depression; using only studies 
with stroke patients; using only hazard ratios (i.e. excluding studies that reported odds ratios or relative risks); 
using only risk estimates for silent infarcts; excluding studies that reported risk estimates for silent infarcts only; 
using only studies with NOS score >3; and using only studies with NOS score >5. Abbreviations: AD: Alzheimer’s 
disease; HRs: hazard ratios; ICH: intracerebral haemorrhage; IS: ischaemic stroke; NOS: Newcastle-Ottawa scale 
score; pop: population; VaD: presumed vascular dementia.
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Figure S2.4 – Pooled hazard ratios for sensitivity analyses for cerebral microbleeds (absence vs. presence)
 
Figures S2.4. Pooled hazard ratios (HRs) (95% confidence intervals) for the association between cerebral 
microbleeds and incident ischaemic and haemorrhagic stroke, all-cause dementia, depression, and all-cause 
mortality. Results were pooled when at least 3 studies were available. The following pre-specified analyses 
were done: analyses were repeated using only subtypes of stroke (ischaemic and haemorrhage) or dementia 
(Alzheimer’s disease and presumed vascular dementia) as the outcome; using only population-based cohort 
studies; using only studies with high-risk populations; using only high-quality studies (defined as Newcastle-
Ottawa Scale (NOS) score >4); replacing the risk estimates for deep cerebral microbleeds (CMBs) with those for 
lobar CMBs; and replacing adjusted risk estimates with unadjusted risk estimates. The following post hoc analyses 
were done: analyses were repeated using only studies with a first episode of stroke or depression; using only 
studies with stroke patients; using only hazard ratios (i.e. excluding studies that reported odds ratios or relative 
risks); using only studies with NOS score >3; using only studies with NOS score >5; using only risk estimates for 
deep CMBs; and using only risk estimates for lobar CMBs. Abbreviations: AD: Alzheimer’s disease; CMBs: cerebral 
microbleeds; HRs: hazard ratios; ICH: intracerebral haemorrhage; IS: ischaemic stroke; NOS: Newcastle-Ottawa 
scale score; pop: population; VaD: presumed vascular dementia.
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Figure S2.5 – Pooled hazard ratios for sensitivity analyses for total cerebral atrophy (per 1 SD decrease)
 
Figures S2.5. Pooled hazard ratios (HRs) (95% confidence intervals) for the association between cerebral atrophy 
and incident ischaemic and haemorrhagic stroke, all-cause dementia, depression, and all-cause mortality.  Results 
were pooled when at least 3 studies were available. The following pre-specified analyses were done: analyses 
were repeated using only subtypes of stroke (ischaemic and haemorrhage) or dementia (Alzheimer’s disease and 
presumed vascular dementia) as the outcome; using only population-based cohort studies; using only studies 
with high-risk populations; using only high-quality studies (defined as Newcastle-Ottawa Scale (NOS) score 
>4); and replacing adjusted risk estimates with unadjusted risk estimates. The following post hoc analyses were 
done: analyses were repeated using only studies with a first episode of stroke or depression; using only studies 
with stroke patients; using only hazard ratios (i.e. excluding studies that reported odds ratios or relative risks); 
using only studies with NOS score >3; and using only studies with NOS score >5. Abbreviations: AD: Alzheimer’s 
disease; HRs: hazard ratios; ICH: intracerebral haemorrhage; IS: ischaemic stroke; NOS: Newcastle-Ottawa scale 
score; pop: population; SD: standard deviation; VaD: presumed vascular dementia.
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Log hazard ratio 
C D 
Log hazard ratio Log hazard ratio 
Funnel plot for the association between white matter hyperintensities on a dichotomous scale and incident 
haemorrhagic and ischaemic stroke (A), lacunes and incident haemorrhagic and ischaemic stroke (B), cerebral 
microbleeds and incident haemorrhagic and ischaemic stroke (C), and white matter hyperintensities on a 
dichotomous scale and all-cause mortality (D). Filled dots correspond to the observed risk estimates, blank 
dots represent missed studies imputed using the trim and fill test. Diagonal lines indicate the expected 95% 
confidence intervals around the summary estimate. Hazard ratios are plotted on a natural log scale.
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Abstract
Importance: The association between type 2 diabetes and depression has been 
frequently reported. However, the pathophysiologic mechanisms for this association are 
not well known. Cerebral small vessel disease is a consequence of type 2 diabetes and 
may mediate this association. 
Objective: To evaluate whether cerebral small vessel disease explains, or mediates, the 
association between type 2 diabetes and risk of depressive symptoms.
Design, setting and participants: Longitudinal cohort study in a Iceland general 
community (Age, Gene/Environment Susceptibility-Reykjavik Study) with examinations 
from 2002/2006 (baseline) and five years later.
Exposures: Type 2 diabetes defined as self-reported history of type 2 diabetes, use of 
blood glucose-lowering drugs, or fasting blood glucose level ≥7.0 mmol/L, and cerebral 
small vessel disease load that was quantified with a scale reflecting MRI features of high 
white matter hyperintensity volume, low total brain parenchyma volume and presence of 
subcortical infarcts, cerebral microbleeds and large perivascular spaces. 
Main Outcome: Change in 15-item Geriatric Depression Scale score between baseline 
and follow-up.
Results: The study population included 2,135 individuals free of dementia and baseline 
depression (mean age [SD 4.6] at baseline 74.5 years, 1,245 [58.3%]  women and 197 
[9.2%] with type 2 diabetes). On average, the GDS-15 score increased 0.4 points (SD 1.6) 
over time. Baseline type 2 diabetes was associated with a greater increase in depressive 
symptoms score over time (β 0.316; 95%CI 0.074, 0.558), adjusted for age, sex, education 
and cardiovascular risk factors. Baseline cerebral small vessel disease features and change 
of cerebral small vessel disease features over time statistically significantly explained, or 
mediated, a part of this association. 
Conclusions and Relevance: Type 2 diabetes is associated with a greater increase in 
depressive symptoms score over time, and cerebral small vessel disease in part explains 
this association.
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Introduction
Depression is an important health concern in type 2 diabetes. It is twice as common in 
individuals with type 2 diabetes as in the general population and is associated with a higher 
risk of diabetes-related complications and mortality.1 The factors that mediate the relation 
between type 2 diabetes and depression are, however, incompletely understood. Cerebral 
microvascular dysfunction and damage may be such a mediator. Cerebral microvascular 
dysfunction may disrupt deep and frontal brain structures involved in mood regulation, 
leading to depressive symptoms.2, 3
Cerebral small vessel disease (CSVD), a marker of cerebral microvascular dysfunction and 
damage,4 can be measured on brain magnetic resonance imaging (MRI) as higher white 
matter hyperintensity (WMH) volume, lower total brain parenchyma volume, subcortical 
infarcts, cerebral microbleeds, and large perivascular spaces.4 These MRI features are more 
prevalent in individuals with type 2 diabetes than in those without.5 In addition, CSVD 
is associated with a higher incidence of depressive symptoms.6 However, no previous 
study has investigated whether the association between type 2 diabetes and depressive 
symptoms is explained, or mediated, by CSVD.
In view of the above, we investigated in a large population-based cohort the association 
between baseline type 2 diabetes and change in depressive symptoms over time. In 
addition, we evaluated whether this association was explained by MRI features of CSVD, 
i.e. higher WMH volume, lower total brain parenchyma volume, subcortical infarcts, 
cerebral microbleeds, and large perivascular spaces.
Methods
Participants
Participants were from the population-based Age, Gene/Environment Susceptibility 
(AGES)-Reykjavik Study cohort originating from the Reykjavik Study, described previously.7 
Briefly, from 2002-2006, 5,764 surviving participants of the Reykjavik Study were 
examined and 3,316 (57.5%) were re-examined five years later, from 2007–2011. Reasons 
for not attending the follow-up examination included: death (n=1,039); refusal (n=1,198); 
and lost to follow-up (n=211). The AGES-Reykjavik Study was approved by the National 
Bioethics Committee in Iceland (approval number=VSN-00-063), and by the Institutional 
Review Board overseeing the National Institute on Aging and the National Insititutes of 
Health. After complete description of the study to the subject, written informed consent 
was obtained.
Type 2 diabetes mellitus
Baseline type 2 diabetes was defined as self-reported history of type 2 diabetes, use of 
blood glucose-lowering drugs, or a fasting blood glucose level ≥7.0 mmol/L.8
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Depressive symptoms
Depressive symptoms were assessed with use of the 15-item Geriatric Depression Scale 
(GDS-15; score range 0-15) at baseline and at follow-up five years later.9, 10 We calculated 
the change in GDS-15 score over time by subtracting the GDS-15 score at baseline from 
the GDS-15 score at follow-up. In addition, we distinguished an apathy subscale including 
all three apathy items of the GDS-15 (GDS-3A, range 0-3) and a subscale including the 
remaining depression items (GDS-12D, range 0-12), as described previously.11 Additionally, 
use of antidepressant medication (tricyclics, selective serotonin reuptake inhibitors, other 
nontricyclics and monoamine oxidase inhibitors) was assessed from medication bottles 
brought to the clinic at baseline and at follow-up. 
Brain MRI measures
Image acquisition
All eligible participants were offered high-resolution 1.5T brain MRI (Signa Twinspeed, 
General Electric Medical Systems). A standardized imaging protocol, described 
previously,12, 13 was used both at baseline and follow-up and included the following 
sequences: 3D spoiled-gradient recalled T1-weighted, proton density/T2-weighted fast 
spin-echo, fluid-attenuated inversion recovery (FLAIR) and T2*-weighted gradient-echo 
type echoplanar image (GRE-EPI). All images were acquired to give full brain coverage 
with slices angled parallel to the anterior commissure–posterior commissure line to give 
reproducible image views in the oblique-axial plane.
Image analysis
Five features of CSVD were evaluated: WMH volume, total brain parenchyma volume, 
subcortical infarcts, cerebral microbleeds and large perivascular spaces. WMH volume 
and total brain parenchyma volume were computed automatically with a previously 
described image analysis pipeline,14 and were expressed as the percentage of total 
intracranial volume. Subcortical infarcts were defined as subcortical brain parenchyma 
defects as described previously,13 with a diameter of ≥4 mm and a signal intensity similar 
to cerebrospinal fluid on all pulse sequences (T2-weighted, proton density-weighted 
and FLAIR), surrounded by an area of high signal intensity on FLAIR images, and without 
evidence of hemosiderin on T2*-weighted GRE-EPI sequence. Cerebral microbleeds were 
defined as focal areas of signal void visible on T2*-weighted GRE-EPI sequence.12 Large 
perivascular spaces were defined as defects in the subcortical area without a rim or area 
of high signal intensity on FLAIR and without evidence of hemosiderin on T2*-weighted 
GRE-EPI sequence.15
Confounding variables
Selection of confounding and co-varying measures was based on previous studies16, 17 
showing their association with type 2 diabetes or depressive symptoms. The following 
variables were assessed by questionnaire: education level (primary, secondary and 
college/university education), alcohol use (high [above median] vs. low [below median], 
stratified by sex), and smoking history (never, former, current). Body mass index (BMI) 
was calculated as measured weight in kg divided by height in cm squared. Hypertension 
was defined as systolic pressure ≥140 mmHg, diastolic pressure ≥90 mmHg or use of 
anti-hypertensive medication. Total/HDL cholesterol ratio, baseline coronary artery 
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disease and stroke, and incident stroke during follow-up were determined as described 
previously.7 Dementia was diagnosed according to international guidelines18 by a panel 
that included a geriatrician, a neurologist, a neuropsychologist and a neuroradiologist as 
described previously.7
Analytic sample
Of the 3,316 participants who attended the follow-up examination, 207 were excluded 
because of a diagnosis of dementia at baseline (n=47) or at follow-up (n=160). In addition, 
participants were excluded if they had missing data on brain MRI (n=701), GDS-15 score at 
baseline or at follow-up (n=149), or confounders (n=18). Finally, we excluded participants 
with baseline clinically relevant depressive symptoms defined as a GDS-15 score ≥6 
(n=106). In the main analysis, we did not exclude participants using antidepressant 
medication, because these medications are also prescribed for indications other than 
depression (e.g. diabetic polyneuropathy). The final study sample for the main analysis 
consisted of 2,135 participants. 
Statistical analysis
We summarized the baseline CSVD features and the change in CSVD features over time 
into a composite score of baseline CSVD and a composite score of CSVD change over time 
because we hypothesize that each CSVD feature may mediate the association between 
type 2 diabetes and depressive symptoms according to similar mechanisms. A composite 
score reduces the influence of the biological variability of its components19 and requires 
fewer statistical tests. We calculated a composite score of baseline CSVD as described 
previously;3 one point per CSVD feature at baseline was assigned based on the following 
cut-offs: for high WMH volume quartile 4 vs. quartiles 1 to 3; for low total brain parenchyma 
volume quartile 1 vs. quartiles 2 to 4; and for subcortical infarcts, cerebral microbleeds 
and large perivascular spaces presence vs. absence. The points for each feature were 
summed up to compute the composite score of baseline CSVD (range 0-5). Subsequently, 
we calculated a composite score of CSVD change over time between the baseline and 
follow-up examination by assigning one point per change in each CSVD feature over time 
based on the following cut-offs: for high increase in WMH volume quartile 4 vs. quartiles 1 
to 3; for high decrease in total brain parenchyma quartile 4 vs. quartiles 1 to 3; and for new 
subcortical infarcts, cerebral microbleeds and large perivascular spaces ≥1 new lesion(s) 
vs. no new lesions. 
The statistical analysis proceeded in two stages. First, multivariable linear regression 
analyses were used to estimate the associations between type 2 diabetes at baseline, the 
composite score of baseline CSVD, the composite score of CSVD change over time, and the 
change in the GDS-15 score over time. Analyses were adjusted for age, sex, education level 
(model 1), and additionally for alcohol use, smoking history, BMI and total/HDL cholesterol 
ratio (model 2). Second, we performed a mediation analysis20 to test the hypothesis that 
CSVD features explain the association between type 2 diabetes at baseline and change in 
the GDS-15 score over time. The mediation model quantifies the degree to which a variable 
statistically explains the association between a determinant and an outcome variable. We 
tested the potential explained associations of the composite score of baseline CSVD and 
the composite score of CSVD change over time separately. We used bootstrapping (10,000 
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samples) to calculate bias-corrected 95% confidence intervals (95% CIs) of the explained 
associations using the PROCESS statistical package for PASW statistics.20 
We did several additional analyses. First, we repeated the analysis with adjustment for each 
individual CSVD feature in the model separately. Second, we repeated the analysis with the 
GDS-15 score at follow-up as the outcome instead of the change in GDS-15 score over time, 
and with additional adjustment for the GDS-15 score at baseline. Third, we repeated the 
analysis after excluding participants using antidepressant medication at baseline. Fourth, 
it has been suggested that CSVD features may be most strongly associated with apathy-
related symptoms of depression.11 Therefore, we repeated the analysis with the change 
in GDS3-A and GDS12-D score over time as the outcome, respectively. Fifth, we repeated 
the analysis additionally adjusting for baseline coronary artery disease. Adjustment for 
coronary artery disease was not done in the main analysis, because data on coronary 
artery disease were missing in a relatively large number of participants (n=220). Sixth, we 
repeated the analysis additionally adjusting for hypertension, baseline stroke or incident 
stroke during follow-up. Adjustments for hypertension and stroke were not done in the 
main analysis, because of the risk of overadjustment bias: hypertension and stroke may 
be confounders, but may also mediate the associations between type 2 diabetes, CSVD 
features and change in depressive symptoms over time.21, 22
All analyses were done with PASW Statistics (version 23). A P value of <.05 was considered 
statistically significant.
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Results
The mean age of the participants at baseline was 74.5 (SD 4.6) years, 58.3% were women 
and 9.2% had type 2 diabetes. On average, the GDS-15 score increased 0.4 points (SD 1.6) 
over time. In participants with type 2 diabetes, the GDS-15 score increased 0.7 (SD 1.9) and 
in participants without type 2 diabetes 0.3 (SD 1.6). The mean time between baseline and 
follow-up was 5.2 (SD 0.2) years. Characteristics of the total study population according to 
presence of type 2 diabetes are given in Table 1. Characteristics of the individuals excluded 
from the analyses are provided in the Supplementary Material (eTable 1).
Participants with type 2 diabetes as compared to those without had a greater increase in 
GDS-15 score over time between the baseline and follow-up examination after adjustment 
for age, sex, education, alcohol use, smoking history, BMI, and total/HDL cholesterol ratio 
(Table 2). In addition, participants with type 2 diabetes had a higher composite score 
of baseline CSVD and a higher composite score of CSVD change over time after full 
adjustment (Table 2). A higher composite score of baseline CSVD and a higher composite 
score of CSVD change over time were associated with greater increase in GDS-15 score 
over time after full adjustment (Table 2).
Mediation analysis showed that the composite scores of baseline CSVD and CSVD change 
over time each statistically significantly explained part of the total association between 
type 2 diabetes and greater increase in GDS-15 score over time (Figure 1, panels A and B). 
Additional analyses
Most individual CSVD features attenuated the association between baseline type 2 
diabetes and greater increase in GDS-15 score over time (eFigures 1 and 2). Results 
were similar when we used the GDS-15 score at follow-up as the outcome, instead of 
the change in GDS-15 score over time, and with additional adjustment for the GDS-15 
score at baseline (eTable 2). The association between type 2 diabetes and change in GDS-
15 score over time was qualitatively similar when we excluded participants that used 
antidepressant medication at baseline (eTable 3). Type 2 diabetes was associated with 
a greater increase in the GDS3-A score over time, but not with change in the GDS12-D 
score over time (eTable 4). In addition, the composite score of CSVD change over time 
explained part of the total association of type 2 diabetes and a greater increase in GDS3-A 
score over time (eFigures 3 and 4). The results of the main analysis were comparable when 
we additionally adjusted for baseline coronary artery disease, hypertension, or baseline 
stroke and incident stroke during follow-up (eTable 5).
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Discussion
In this study, type 2 diabetes was independently associated with a greater increase in 
depressive symptoms over time, and CSVD features explained, or mediated, part of this 
association. 
The study findings are in accordance with the vascular depression hypothesis,2 and 
suggest that cerebral microvascular damage may contribute to the development of 
depressive symptoms, in individuals with type 2 diabetes. A previous meta-analysis found 
that CSVD features are associated with a higher risk of incident depressive symptoms.6 
In addition, a previous systematic review found that type 2 diabetes is associated with 
presence of CSVD features.5 This study extends these previous studies by showing that the 
association between type 2 diabetes and greater increase in depressive symptoms over 
time is partially explained by CSVD features. 
Type 2 diabetes may lead to CSVD via various mechanisms including impaired insulin-
dependent arteriolar dilation, advanced glycation, excessive oxidative stress and 
epigenetic changes.23, 24 The cerebral microvasculature, in turn, is involved in the regulation 
of many cerebral processes, including cerebral perfusion, neurovascular coupling, blood-
brain barrier permeability and neurogenesis.24 Impairment of these processes may lead 
to neuronal dysfunction, ischemia and cell death, which may ultimately contribute to 
depressive symptoms via damage in deep and frontal brain structures involved in mood 
regulation.24
Other mechanisms may, however, explain the observed associations. First, CSVD may 
indirectly lead to depression through incident stroke. However, adjusting for stroke at 
baseline or incident stroke during follow-up did not change our results. Second, CSVD 
may indirectly lead to depression through cognitive impairment. For the present study, 
however, we excluded individuals with dementia at baseline or at follow-up. Third, other 
confounding factors may explain the association between type 2 diabetes, CSVD features 
and change in depressive symptoms over time, such as lower socio-economic status 
and cardiovascular factors. However, the associations between type 2 diabetes, CSVD 
and depressive symptoms were independent of education level and cardiovascular risk 
factors.25, 26 Nevertheless, we cannot exclude the possibility of residual confounding.
Some part of the association between type 2 diabetes and higher depressive symptoms 
over time remained unexplained after taking into account the effect of CSVD features. 
This remaining association may be due to microvascular dysfunction that is not directly 
captured in the MRI scans in the present study (e.g. microinfarctions, increased blood-
brain permeability and lower cerebral vasoreactivity). In addition, it is possible that only a 
subset of individuals with type 2 diabetes develop depressive symptoms that are related 
to CSVD. Depressive symptoms in type 2 diabetes may be related to other mediators such 
as psychosocial factors,1 diabetes-related comorbidities1 and glucose neurotoxicity.27
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Strengths of the present study are the large population-based sample of older participants, 
the comprehensive brain MRI assessment of various CSVD features at baseline and follow-
up five years later and the extensive adjustment for a series of potential confounders.
Our study has certain limitations. First, the construction of a composite score of CSVD 
assumes that all its components are of equal importance in the association between type 
2 diabetes and higher depressive symptoms over time, which may not be necessarily true. 
However, we found that most individual CSVD features contributed to the effect of CSVD 
on the association between type 2 diabetes and higher depressive symptoms over time. 
Second, unavoidable survival bias may change the associations if among the persons who 
died, associations among type 2 diabetes, CVSD features and depressive symptoms differ 
from those in the sample. Third, we lacked power to investigate the association of baseline 
type 2 diabetes to incident depressive symptoms (GDS-15 score ≥6). Fourth, because we 
study associations of change in depressive symptoms with change in CSVD features, we 
cannot investigate the temporality of the association. However, it is likely that only many 
repeated measures made at short intervals will resolve temporal relations. 
In view of the increased risk of depression in type 2 diabetes, efforts to favorably influence 
cerebral microvascular function through lifestyle and pharmacological therapy might help 
to prevent or treat microvascular dysfunction-related depression.24, 28 Evidence suggests 
that weight loss and exercise may improve microvascular function and symptoms of 
depression.24 In addition, drugs, such as renin-angiotensin-aldosterone system inhibitors 
and antihyperglycemic agents (i.e. metformin and glucagon-like peptide 1 receptor (GLP-
1R) agonists), may improve microvascular function, possibly beyond their blood pressure- 
or glucose-lowering effects.24
In conclusion, the present study found that type 2 diabetes is independently associated 
with greater increase depressive symptoms over time, and that this association is in part 
explained by MRI features of CSVD. 
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type 2 diabetes 
(n=197; 9.2%)
Participants without 
type 2 diabetes 
(n=1,938; 90.8%)
Age
Baseline 74.5 (4.6) 74.6 (4.3) 74.5 (4.6)
Follow-up 79.7 (4.6) 79.7 (4.3) 79.7 (4.6)
Women 1,245 (58.3) 94 (47.7) 1,151 (59.4)
Education level
Primary 410 (19.2) 33 (16.8) 377 (19.5)
Secondary 1,106 (51.8) 103 (52.3) 1,003 (51.8)
College/university 619 (29.0) 61 (31.0) 558 (28.8)
Smoking history
Former smoker 985 (46.1) 101 (51.3 884 (45.6)
Current smoker 220 (10.3) 18 (9.1) 202 (10.4)
High alcohol use1 881 (41.3) 78 (39.6) 803 (41.4)
Body mass index (kg/m2) 27.2 (4.0) 28.9 (4.0) 27.1 (4.0)
Baseline coronary artery disease2 488 (26.2) 62 (31.5) 426 (22.0)
Stroke
Baseline 94 (4.4) 9 (4.6) 85 (4.4)
Incident 24 (1.1) 4 (2.0) 20 (1.0)
Incident depressive symptoms (GDS-15 
score ≥6)
92 (4.3) 13 (6.6) 79 (4.1)
Hypertension 1,651 (77.3) 179 (90.9) 1,472 (76.0)
Total/HDL cholesterol ratio 3.7 (1.1) 3.9 (1.2) 3.7 (1.1)
GDS-15 score
Baseline, median (IQR) 1 (0-3) 1 (1-2.5) 1 (1-3)
Change over time +0.4 (1.6) +0.7 (1.9) +0.3 (1.6)
Follow-up 2 (1-3) 2 (1-3) 2 (1-3)
Use of antidepressant medication
Baseline 215 (10.1) 19 (9.6) 196 (10.1)
Follow-up 287 (13.4) 23 (11.7) 264 (13.6)
Composite scores of cerebral small vessel disease features
Baseline 0.8 (0.9) 1.0 (1.0) 0.7 (0.9)
Change over time +0.6 (0.8) +0.8 (0.9) +0.6 (0.8)
Follow-up 0.9 (1.0) 1.3 (1.2) 0.9 (1.0)
Total brain parenchyma volume, ml
Baseline 1,097.0 (102.4) 1,089.1 (112.7) 1,097.9 (101.3)
Change over time -31.7 (17.1) -35.6 (18.8) -31.3 (16.9)
Follow-up 1,065.4 (99.4) 1,053.4 (110.5) 1,066.6 (98.1)
White matter hyperintensity volume, ml
Baseline, median (IQR) 11.2 (6.4-20.7) 13.2 (7.3-22.2) 11.1 (6.3-20.5)
Change over time +5.6 (7.4) +6.0 (8.2) +5.6 (7.3)
Follow-up 15.0 (8.1-28.9) 17.2 (9.9-31.9) 14.8 (7.9-28.7)
Subcortical infarcts
Baseline 154 (7.2) 31 (15.7) 123 (6.3)
Incident 87 (4.1) 13 (6.6) 74 (3.8)
Follow-up 212 (9.9) 37 (18.8) 175 (9.0)
3





type 2 diabetes 
(n=197; 9.2%)
Participants without 
type 2 diabetes 
(n=1,938; 90.8%)
Cerebral microbleeds
Baseline 355 (16.6) 38 (19.3) 317 (16.4)
Incident 377 (17.7) 45 (22.8) 332 (17.1)
Follow-up 630 (29.5) 74 (37.6) 556 (28.7)
Large perivascular spaces
Baseline 341 (16.0) 39 (19.8) 302 (15.6)
Incident 60 (2.8) 10 (5.1) 50 (2.6)
Follow-up 373 (17.5) 45 (22.8) 328 (16.9)
Numbers indicate mean (SD) or number of participants, unless otherwise stated. 1High alcohol use was defined 
as alcohol use above median, stratified by sex; 2Data missing in n=220. Abbreviations: GDS-15: 15-item Geriatric 
Depression Scale; IQR: interquartile range.
Table 2. Associations between type 2 diabetes at baseline, composite score of baseline cerebral small vessel 
disease, composite score of cerebral small vessel disease change over time, and change in GDS-15 score over 
time
Change in 15-item 
Geriatric Depression 
Scale score over 
time
Composite score of 
baseline cerebral 
small vessel disease
Composite score of 
cerebral small vessel 
disease change over 
time
Model β (95%CI) β (95%CI) β (95%CI)
Type 2 diabetes vs. no 
diabetes at baseline
1 0.339 (0.099; 0.579) 0.219 (0.093; 0.345) 0.205 (0.094; 0.316)
2 0.316 (0.074; 0.558) 0.244 (0.117; 0.371) 0.226 (0.114; 0.338)
Composite score of 
baseline cerebral small 
vessel disease
1 0.102 (0.014; 0.176) - -
2 0.095 (0.021; 0.183) - -
Composite score of 
cerebral small vessel 
disease change over time
1 0.207 (0.116; 0.298) - -
2 0.202 (0.111; 0.294) - -
Model 1: adjusted for age, sex, and education level; model 2: model 1 + alcohol use, smoking history, body mass 
index, and total/HDL cholesterol ratio.
Abbreviations: CI: confidence interval.
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Figure 1. Association between type 2 diabetes at baseline and higher 15-item Geriatric Depression Scale score 
over time between baseline and follow-up examination, and the proportion explained by the composite score 
of baseline cerebral small vessel disease (panel A), and the composite score of cerebral small vessel disease 
change over time (panel B). Solid lines indicate associations that are statistically significant; dashed lines 
indicate associations that are not statistically significant. Associations are given as regression coefficients (β) and 
corresponding 95% confidence intervals. All associations are adjusted for age, sex, education level, alcohol use, 
smoking history, body mass index and total/HDL cholesterol ratio. Abbreviations: CI: confidence interval; CSVD: 
cerebral small vessel disease; GDS-15: 15-item Geriatric Depression Scale.
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Table S2. Association between type 2 diabetes at baseline and 15-item Geriatric Depression Scale score at 





Model β 95%CI 95%CI
Type 2 diabetes vs. no 
diabetes
1 0.299 0.043 0.554
2 0.219 -0.037 0.475
3 0.276 0.047 0.505
Model 1: adjusted for age, sex, and education level; model 2: model 1 + alcohol use, smoking history, body mass 
index, and total/HDL cholesterol ratio; model 3: model 2 + Geriatric Depression Scale score at baseline.
Number of participants (n) available: 2,135.
Abbreviations: CI: confidence interval.
Table S3. Association between type 2 diabetes at baseline and change in 15-item Geriatric Depression Scale 





Model β 95%CI 95%CI
Type 2 diabetes vs. no 
diabetes
1 0.239 -0.003 0.481
2 0.226 0.004 0.493
Model 1: adjusted for age, sex, and education level; model 2: model 1 + alcohol use, smoking history, body mass 
index, and total/HDL cholesterol ratio.
Number of participants (n) available: 1,920.
Abbreviations: CI: confidence interval.
Table S4. Associations between type 2 diabetes at baseline and change in the apathy and remaining depression 
items of the 15-item Geriatric Depression Scale score over time
Change in GDS-3A score 
over time, excluding 
participants with apathy 
(GDS-3A≥2) at baseline 
(n=922)1
Change in GDS-12D score over 
time, excluding participants with 
remaining depression items (GDS-
12D≥2) at baseline (n=298)2




1 0.214 0.043 0.386 0.172 0.007 0.337
2 0.191 0.019 0.363 0.160 -0.007 0.326
Model 1: adjusted for age, sex, and education level; model 2: model 1 + alcohol use, smoking history, body mass 
index, total/HDL cholesterol ratio
1Number of participants (n) available: 1,301; 2Number of participants (n) available: 1,898.
Abbreviations: CI: confidence interval; GDS-3A: apathy items of the 15-item Geriatric Depression Scale; GDS-12D: 
remaining depression items of the 15-item Geriatric Depression Scale. 
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Figure S1. Explained proportion by combined and individual cerebral small vessel disease features at baseline 
on the association between type 2 diabetes at baseline and higher 15-item Geriatric Depression Scale score 
over time. Cerebral small vessel disease features explained 6.7% of the association between type 2 diabetes 
and higher 15-item Geriatric Depression Scale score over time. The proportion of the association explained by 
individual cerebral small vessel disease features were: for baseline total brain parenchyma volume 3.3%; for 
baseline white matter hyperintensity volume 6.7%; for baseline subcortical infarcts 53.3%; for baseline large 
perivascular spaces 36.7%. Baseline cerebral microbleeds did not explain the association between type 2 
diabetes and higher 15-item Geriatric Depression Scale score over time. 
 Figure S2. Explained proportion by combined and individual cerebral small vessel disease features change over 
time on the association between type 2 diabetes at baseline and higher 15-item Geriatric Depression Scale score 
over time. Cerebral small vessel disease features explained 13.6% of the association between type 2 diabetes 
and higher 15-item Geriatric Depression Scale score over time. The proportion of the association explained by 
individual cerebral small vessel disease features were: for decrease in total brain parenchyma volume over time 
19.3%; for increase in white matter hyperintensity volume over time 9.7%; for incident subcortical infarcts 14.5%; 
for incident cerebral microbleeds 8.1%; and for incident large perivascular spaces 48.4%. Baseline cerebral 
microbleeds did not explain the association between type 2 diabetes and higher 15-item Geriatric Depression 
Scale score over time.
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Figure S3. Association between type 2 diabetes at baseline and higher apathy items of the 15-item Geriatric 
Depression Scale score over time, and the proportion explained by the composite score of baseline cerebral 
small vessel disease (panel A), and the composite score of cerebral small vessel disease change over time 
(panel B). Solid lines indicate associations that are statistically significant; dashed lines indicate associations 
that are not statistically significant. Associations are given as regression coefficients (β) and corresponding 
95% confidence intervals. All associations are adjusted for: age, sex, education level, alcohol use, smoking 
history, body mass index, and total/HDL cholesterol ratio. Number of participants (n) available: 1,301. 
Abbreviations: CI: confidence interval; CSVD: cerebral small vessel disease; GDS-3A: apathy items of the 15-item 
Geriatric Depression Scale.
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Figure S4. Association between type 2 diabetes at baseline and higher remaining items of the 15-item Geriatric 
Depression Scale score over time, and the proportion explained by the composite score of baseline cerebral 
small vessel disease (panel A), and the composite score of cerebral small vessel disease change over time 
(panel B). Solid lines indicate associations that are statistically significant; dashed lines indicate associations 
that are not statistically significant. Associations are given as regression coefficients (β) and corresponding 
95% confidence intervals. All associations are adjusted for: age, sex, education level, alcohol use, smoking 
history, body mass index, and total/HDL cholesterol ratio. Number of participants (n) available: 1,898. 
Abbreviations: CI: confidence interval; CSVD: cerebral small vessel disease; GDS-12D: remaining items of the 15-
item Geriatric Depression Scale. 
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Abstract
Microvascular dysfunction may be associated with worse cognitive performance. Most 
previous studies did not adjust for important confounders, evaluated only individual 
measures of microvascular dysfunction, and showed inconsistent results. We evaluated 
the association between a comprehensive set of measures of microvascular dysfunction 
and cognitive performance in the population-based Maastricht Study.
We used cross-sectional data including 3011 participants (age 59.5±8.2; 48.9% women; 
26.5% type 2 diabetes [oversampled by design]). Measures of microvascular dysfunction 
included MRI features of cerebral small vessel disease, plasma biomarkers of microvascular 
dysfunction, albuminuria, flicker light-induced retinal arteriolar and venular dilation 
response and heat-induced skin hyperaemia. These measures were summarized into a 
microvascular dysfunction composite score. Cognitive domains assessed were memory, 
processing speed and executive function. A cognitive function score was calculated as the 
sum of the scores on these three cognitive domains. 
The microvascular dysfunction score was associated with a worse cognitive function 
score (standardized β,-0.087;95%CI -0.127; -0.047), independent of age, education level, 
sex, type 2 diabetes, smoking, alcohol use, hypertension, total/HDL cholesterol ratio, 
triglycerides, lipid-modifying medication, prior cardiovascular disease, depression and 
plasma biomarkers of low-grade inflammation. The fully adjusted beta-coefficient of the 
association between the microvascular dysfunction score and the cognitive function 
score was equivalent to two (range: one to three) years of aging for each standard 
deviation higher microvascular dysfunction score. The microvascular dysfunction score 
was associated with worse memory and processing speed, but not with worse executive 
function. 
The present study shows that microvascular dysfunction is associated with worse cognitive 
performance. 
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Introduction
Cognitive impairment and dementia are major health problems and their prevalence rises 
with the aging of the population1. The mechanisms underlying cognitive impairment 
remain, however, incompletely understood, and may include microvascular dysfunction 
and damage (“microvascular dysfunction”, MVD)2. 
The microvasculature is involved in the regulation of many cerebral processes, notably 
neurovascular coupling, cerebral autoregulation, blood-brain barrier permeability and 
neurogenesis2. Impairment of these processes may lead to neuronal dysfunction, ischemia 
and cell death, which may contribute to cognitive impairment2.
Microvascular function can be measured noninvasively in various organs. Indirect 
measures include magnetic resonance imaging (MRI) features of cerebral small vessel 
disease (CSVD, e.g. total brain parenchyma volume, white matter hyperintensity volume, 
and presence of lacunar infarcts and cerebral microbleeds)3; plasma biomarkers of MVD 
(e.g. soluble intercellular adhesion molecule-1 [sICAM-1], soluble vascular adhesion 
molecule-1 [sVCAM-1], soluble E-selectin [sE-selectin] and von Willebrand factor [vWF])4; 
and albuminuria (“urinary albumin excretion”, UAE)5. In addition, direct measures include 
flicker light-induced retinal arteriolar and venular dilation response6 and heat-induced 
skin hyperaemia6. CSVD features are closely linked to brain microvasculature structure and 
evidence indicates that these features originate from cerebral microvascular dysfunction3, 
7, 8; retinal arteriolar and venular dilation response are also closely linked to the brain 
microvasculature9; in addition, to the extent that MVD is a generalised phenomenon, 
plasma biomarkers of MVD, UAE, and skin hyperaemia may also reflect brain MVD10. 
These various measures of MVD (i.e. features of CSVD, plasma biomarkers of MVD, UAE, 
retinal arteriolar and venular dilation response and skin hyperaemia) may therefore be 
summarized into a total MVD composite score. A composite score reduces the influence 
of the biological variability of its components, as we assume substantial overlap 
among mechanisms underlying the associations between the MVD measures and 
cognitive performance. Furthermore, it reduces the chance of a type 1 error. However, 
no study evaluated the association between such a MVD composite score and cognitive 
performance. 
Some individual MVD measures, i.e. CSVD features, plasma biomarkers of MVD and UAE, 
have been associated with worse cognitive performance11-19, although not all measures 
consistently so15, 20, 21. In the Maastricht Study, we previously found a cross-sectional 
association between higher UAE and worse cognitive performance22. Previous studies, 
but not all, were relatively small (n<200)11, 20, used selected populations11, 20, 21, and may 
have been affected by residual confounding due to incomplete adjustment for education 
level and cardiovascular risk factors11, 12, 14. Furthermore, most studies did not adjust for 
depression or low-grade inflammation, although both factors are linked to MVD and 
worse cognitive performance14, 23, 24. Moreover, the associations between retinal arteriolar 
and venular dilation response and skin hyperaemia, and cognitive performance have not 
been investigated. 
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We therefore investigated, in a large population-based cohort with participants aged 
40-75 years, whether a composite score of MVD measures, including CSVD features, 
plasma biomarkers of MVD, UAE, retinal arteriolar and venular dilation response and skin 
hyperaemia, is associated with worse cognitive performance. We additionally evaluated 
whether any such association was independent of age, education level, sex, lifestyle 
factors, cardiovascular risk factors, current depression and low-grade inflammation.
Methods
Study population
We used data from The Maastricht Study, an observational population-based cohort study. 
The rationale and methodology have been described previously25. In brief, the study 
focuses on the aetiology, pathophysiology, complications, and comorbidities of diabetes 
mellitus type 2 (T2D) and is characterized by an extensive phenotyping approach. Eligible 
for participation were all individuals aged 40-75 years and living in the southern part 
of the Netherlands. Participants were recruited through mass media campaigns, the 
municipal registries, and the regional Diabetes Patient Registry via mailings. Recruitment 
was stratified according to known T2D status, with an oversampling of individuals with 
T2D, for reasons of efficiency. The present study includes cross-sectional data from 
3451 participants who completed the baseline survey between November 2010 and 
September 2013. The examinations of each participant were performed within a time 
window of three months. The study has been approved by the institutional medical 
ethical committee (NL31329.068.10) and the Ministry of Health, Welfare, and Sports of the 
Netherlands (Permit 131088-105234-PG). All participants gave written informed consent. 
Data are available from The Maastricht Study for any researcher who meets the criteria for 
access to confidential data, and the corresponding author may be contacted to request 
data.
Microvascular dysfunction
For all MVD measures, participants were asked to refrain from smoking and drinking 
caffeine-containing beverages three hours before the measurement. A light meal was 
allowed until ≥90 minutes prior to the examination.  For retinal measurements, pupils 
were dilated with 0.5% tropicamide and 2.5% phenylephrine at least 15 minutes before 
the start of the examination. Skin blood flow measurements were performed in a climate-
controlled room at 24°C.
Cerebral small vessel disease
Brain MRI measurements were implemented from December 2013 onwards and were 
available in 2313 of 3451 participants (67%). Brain MRI was performed on a 3T MRI scanner 
(Siemens Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany). We evaluated four 
CSVD features, i.e. total brain parenchyma volume, white matter hyperintensity volume, 
and presence of lacunar infarcts and cerebral microbleeds3. A detailed description of the 
MRI protocol and the definitions of the CSVD features is provided in Item S1 (Supplementary 
Material). The MRI protocol consisted of a 3D T1-weighted sequence, a fluid-attenuated 
inversion recovery sequence, a combined proton density and T2-weighted turbo spin echo 
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sequence and a susceptibility-weighted imaging sequence26. Volumes were determined 
semi-automatically, and lacunar infarcts and cerebral microbleeds were scored manually.
Plasma biomarkers of microvascular dysfunction
We measured four plasma biomarkers of MVD: sICAM-1, sVCAM-1, sE-selectin and 
vWF4. sICAM-1, sVCAM-1 and sE-selectin were measured in EDTA plasma samples with 
commercially available 4-plex sandwich immunoassay kits with different standards 
and antibodies (Meso Scale Discovery, Rockville, Maryland, United States of America). 
For this technique in this study, the intra- and inter-assay coefficients of variation were 
10.3 and 8.4% for sICAM-1, 5.0 and 4.7% for sVCAM-1, and 2.9 and 7.4% for sE-selectin, 
respectively. Von Willebrand Factor (vWF) was quantified in citrate plasma using ELISA 
(Dako, Glostrup, Denmark). The intra- and inter-assay coefficients of variation were 3.0 and 
4.3%, respectively. 
Urinary albumin excretion
We assessed UAE in two 24-hour urine samples. Urinary albumin concentration was 
measured with a standard immunoturbidimetric assay by an automatic analyzer (due to 
a change of supplier, by the Beckman Synchron LX20 and the Roche Cobas 6000) and 
multiplied by collection volume to obtain 24-hour UAE22. A urinary albumin concentration 
below the detection limit of the assay was set at 1.5mg/L (2mg/L for the Beckman Synchron 
LX20 and 3mg/L for the Roche Cobas 6000) before multiplying by collection volume. Only 
urine collections with a collection time between 20 and 28 hours were considered valid. 
If needed, UAE was extrapolated to 24-hour excretion. For this study, UAE was preferably 
based on the average of two (available in 91.3% of participants) 24-hour urine collections.
Flicker light-induced retinal arteriolar and venular dilation response
We measured retinal arteriolar and venular dilation response to flicker light exposure by the 
Dynamic Vessel Analyzer (Imedos, Jena, Germany), as previously described6, 27. A baseline 
recording of 50 seconds was followed by 40-second flicker light exposure followed by 
a 60-second recovery period. We calculated baseline diameters (in measurement units) 
as the average diameter during the 20-50 seconds recording. For both the arteriolar and 
venular dilation response, percentage dilation over baseline was calculated using the 
average dilation achieved at time points 10 and 40 seconds during the flicker stimulation 
period. 
Heat-induced skin hyperaemia
We measured heat-induced skin hyperaemia by laser Doppler flowmetry (Perimed, 
Järfälla, Sweden), as previously described6. We recorded unheated skin blood flow at the 
wrist, expressed in arbitrary perfusion units (PU), for two minutes to serve as a baseline. 
After two minutes, the temperature of the laser Doppler probe was rapidly and locally 
increased to 44°C and was kept constant until the end of the registration. Skin hyperaemia 
was expressed as the percentage increase in average PU during the 23 minutes heating 
phase over the two minutes average baseline PU. 
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Cognitive performance
We assessed cognitive performance by a concise neuropsychological test battery25. 
For statistical efficiency, we constructed a cognitive function score by summation of 
standardized test scores of three cognitive domains: memory, information processing 
speed and executive function. A detailed description of methods used to calculate 
domain-specific cognitive scores is provided in Item S2 (Supplementary material). We 
evaluated memory with the Verbal Learning Test28. Information processing speed was 
evaluated with the Stroop Color-Word Test Part I and II29, Concept Shifting Test Part A and 
B30, and Letter-Digit Substitution Test31. Executive function was evaluated with the Stroop 
Color-Word Test Part III and Concept Shifting Test Part C.
Covariates
We determined diabetes status according to the World Health Organization 2006 criteria 
as normal glucose metabolism, prediabetes or T2D25. Education level was classified into 
three groups: low (none, primary or lower vocational education only), intermediate 
(intermediate general secondary, intermediate vocational or higher general secondary 
education) and high (higher vocational education or university level of education). 
Alcohol consumption (none, low, high), smoking status (never, former, current), prior 
cardiovascular disease (CVD), medication use, body mass index (BMI), office and 
ambulatory blood pressure, plasma lipid levels were determined as described previously5, 
6, 25. Hypertension was defined as an office blood pressure ≥140/90mmHg and/or use of 
antihypertensive medication. The Mini-International Neuropsychiatric Interview was used 
to assess the presence of a current DSM-IV defined minor or major depressive episode, as 
described previously25. Plasma biomarkers of low-grade inflammation were determined 
as described previously32. These included high-sensitive C-reactive protein (CRP), serum 
amyloid A (SAA), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor alpha 
(TNF-α).
Statistical analysis
We selected all participants that had data available on all potential confounders, at least 
one individual MVD measure, and cognitive function. We did not impute missing values. We 
inversed total brain parenchyma volume, retinal arteriolar and venular dilation response 
and skin hyperaemia so higher values indicated MVD. White matter hyperintensity volume 
was log-transformed (base 2) to normalize its skewed distribution. We analyzed UAE as 
a categorically (<15 [reference], 15-<30, and ≥30mg/24h), because UAE and cognitive 
performance were non-linearly associated.
We calculated a MVD composite score (“MVD score”) of all individual MVD measures. 
For the total MVD score, the individual 12 MVD measures (i.e. four CSVD features, four 
plasma biomarkers of MVD, UAE, retinal arteriolar and venular dilation responses and 
skin hyperaemia) were standardized into z-scores. These z-scores were averaged, and 
this average was standardized into the MVD score. The MVD score was calculated only 
in participants with data available on at least nine of the 12 individual MVD measures. 
The Cronbach’s alpha for measuring internal consistency33 among the individual MVD 
measures was .52. This is considered acceptable internal consistency for different measures 
that may reflect, at least in part, the same underlying construct34.
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We used linear regression to investigate the association between the MVD score and the 
cognitive function score. All analyses were adjusted for age, education level, sex, T2D, BMI, 
smoking, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides and lipid-
modifying medication (model 1), and additionally for prior CVD, current depression and the 
plasma biomarkers of low-grade inflammation, i.e. CRP, SAA, IL-6, IL-8 and TNF-α (model 2). 
Prior CVD, current depression and low-grade inflammation were entered into a separate 
model, because of the risk of overadjustment bias: these factors may be confounders but 
may also mediate the association between MVD and cognitive performance. 
We tested interaction terms with age (dichotomized into <65 and ≥65 years), education 
level, sex and T2D to evaluate whether the association between MVD and cognitive 
performance differed according to these factors. Interaction with age and education 
level was tested because MVD may be more strongly associated with worse cognitive 
performance in individuals with lower cognitive reserve, i.e. in those with higher age and 
lower education level35. 
Several sensitivity analyses were performed. First, we repeated the analysis using 
domain-specific cognitive function scores as the outcome, i.e. memory, processing 
speed and executive function. Second, we repeated the analysis using each individual 
MVD measure as the determinant. Third, we repeated the analysis with the MVD score in 
participants with data available on at least one, eight and ten of the 12 individual MVD 
measures, respectively. Fourth, to test whether the association between the MVD score 
and cognitive function score was primarily determined by individual MVD measures, we 
repeated the analysis five times after consecutively excluding from the MVD score the 
CSVD features, plasma biomarkers of MVD, UAE, retinal arteriolar and venular dilation 
response and skin hyperaemia, respectively. Fifth, we calculated composite scores for 
the CSVD features, plasma biomarkers of MVD and retinal arteriolar and venular dilation 
response, respectively, and evaluated the association between these composite scores 
and cognitive function score. The CSVD composite score was calculated as described 
previously36. One point per CSVD feature was assigned for: 4th quartile lower total brain 
parenchyma volume and higher white matter hyperintensity volume; and presence of 
lacunar infarcts and cerebral microbleeds. The points for each feature were combined 
into the CSVD score (range 0-4). For the plasma biomarkers of MVD score and retinal 
arteriolar and venular dilation response scores, the z-scores of the four plasma biomarkers 
of MVD and the arteriolar and venular dilation responses were summed and standardized, 
respectively. Sixth, we repeated the analysis with additional adjustment for average 24-
hour ambulatory systolic blood pressure37, and class of antihypertensive medication (i.e. 
angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers versus 
other classes)38, 39. Ambulatory systolic blood pressure is a better predictor of cognitive 
decline than office blood pressure40. However, we did not adjust for ambulatory systolic 
blood pressure in the main analysis, because data on ambulatory systolic blood pressure 
were missing in a relatively large number of participants (n=424). Seventh, we repeated 
the analysis after stratification by T2D status, because by design individuals with T2D were 
oversampled in our cohort. 
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All analyses were performed with SPSS software (v22.0;IBM, Chicago, USA). A P value of 
<.05, and a P value for interaction of <.10 for interaction with sex and T2D were considered 
statistically significant. For interaction with age and education level, a Bonferroni-corrected 
P value of <.05 was used instead of <.10, because higher age and lower education level are 
considered reflections of the same construct, i.e. lower cognitive reserve.
Results
Figure 1 shows the derivation of the final study population. In total, 3011 participants had 
data available on all potential confounders and at least one individual MVD measure. The 
MVD score was available in 2034 participants, CSVD features in 2002, plasma biomarkers 
of MVD in 2991, UAE in 2987, retinal arteriolar and venular dilation response in 1998, and 
skin hyperaemia in 1457. These populations were comparable with regard to age, sex and 
cardiovascular risk profile (Supplementary Table S1). Table 1 shows the characteristics of 
the study population and according to tertiles of the cognitive function score. Population-
characteristics according to tertiles of memory, processing speed and executive function 
are provided in the Supplementary Material (Tables S2-S4). The study population had a 
mean age of 59.5 years, 48.9% were women, 26.5% had T2D (oversampled by design), and 
41.1% had a high education level.
The MVD score was statistically significantly associated with a worse cognitive function 
score (Figure 2, models 1 and 2). The regression coefficients of all covariates included in 
the fully adjusted model are provided in the Supplementary material (Table S5). The fully 
adjusted beta-coefficient of the association between one standard deviation higher MVD 
score and the cognitive function score was equivalent to two (range: one-three) years of 
aging.
Statistically significant interaction was found between the MVD score and age (P value 
for interaction .045), indicating that the association between MVD and worse cognitive 
function was stronger in participants aged ≥65 as compared to those aged <65 years. 
The association between the MVD score and cognitive function score stratified by age 
is provided in the Supplementary Material (Table S6). We found no interactions with 
education level, sex, and T2D.
Sensitivity analyses
The MVD score was statistically significantly associated with worse memory and processing 
speed, but not with executive function (Figure 3). The individual MVD measures lower total 
brain parenchyma volume, higher white matter hyperintensity volume, sE-selectin, and 
UAE >30 vs. <15mg/24h were statistically significantly associated with a worse cognitive 
function score, but not lacunar infarcts, microbleeds, sICAM-1, sVCAM-1, vWF, UAE 15-<30 
vs. <15mg/24h, retinal arteriolar and venular dilation responses or skin hyperaemia (Figure 
4 and Supplementary Table S7). Results were similar when we repeated the analyses in 
participants with data available on at least one (n=3011), eight (n=2364) or ten (n=1658) 
of the 12 individual MVD measures (Supplementary Table S8), and when we consecutively 
excluded, from the MVD score, the CSVD features, plasma biomarkers of MVD, UAE, retinal 
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arteriolar and venular dilation response or skin hyperaemia (Supplementary Table S9). 
The composite scores of CSVD features and plasma biomarkers of MVD, but not of retinal 
arteriolar and venular dilation responses, were statistically significantly associated with 
a worse cognitive function score (Supplementary Table S10). Results were similar when 
we additionally adjusted for ambulatory blood pressure (Supplementary Table S11), 
or for class of antihypertensive medication (Supplementary Table S12). Furthermore, 
no statistically significant interaction was found for T2D status in our main analysis (P 
value for interaction .94), and analysis stratified by T2D status showed that results were 
qualitatively similar in individuals with and without T2D (Supplementary Table S13).
Discussion
The present cross-sectional study found that MVD is associated with worse cognitive 
performance. This association was present for various MVD measures, including CSVD 
features, plasma biomarkers of MVD and UAE, but not retinal arteriolar and venular 
dilation responses or skin hyperaemia. Furthermore, this association was independent of 
age, education level, sex, lifestyle factors, cardiovascular risk factors, current depression 
and low-grade inflammation. The strength of the association of each standard deviation 
higher MVD score on the cognitive function score was equivalent to the effect of one to 
three years of aging. 
Our study agrees with previous studies that showed an association between individual 
MVD measures, i.e. CSVD features15, 41, plasma biomarkers of MVD11-14 and UAE16, and worse 
cognitive performance. Some of these studies, but not all, found an association between 
MVD and worse cognitive performance or cognitive impairment. Our study expands this 
knowledge, as it is the first to comprehensively evaluate the association between  MVD 
measures in various vascular beds and cognitive performance in a large population-based 
study with extensive adjustment for confounders.
The results were consistent across various MVD measures, except for retinal arteriolar and 
venular dilation responses and skin hyperaemia, which were not statistically significantly 
associated with cognitive performance. Retinal arteriolar and venular dilation response 
and skin hyperaemia may mostly reflect a more subtle form of endothelium-dependent 
MVD, which may change acutely and may be reversible27. For example, microvascular 
dilation responses in the retina or skin are transiently decreased directly after smoking42 
and consumption of caffeine43. In contrast, CSVD features, plasma biomarkers of MVD and 
UAE (all indirect measures of microvascular dysfunction) may reflect a more advanced 
stage of MVD10. However, this study is the first to evaluate the association between retinal 
arteriolar and venular dilation response and skin hyperaemia and cognitive function, and 
this issue, therefore, requires further study.
In the present study, the association between MVD and worse cognitive performance 
was stronger in participants aged ≥65 years vs. <65 years. This corresponds to our 
previous study on UAE and cognitive performance22, and may be explained by a higher 
susceptibility for the detrimental effects of MVD on cognitive performance in the presence 
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of a lower cognitive reserve with increasing age, in accordance with the cognitive reserve 
hypothesis35.
The observation that various MVD measures were associated with worse cognitive 
performance in our study supports the hypothesis that MVD may play a role in the 
pathophysiology of cognitive impairment. Earlier studies showed that impaired 
neurovascular coupling, cerebral autoregulation2, blood-brain barrier leakage44, and 
impaired neurogenesis45 are present in individuals with mild cognitive impairment and 
Alzheimer’s disease, and these disturbances may be the consequence of MVD2.
Other underlying mechanisms may, however, explain the observed associations. First, 
MVD often coexists with CVD, and CVD is associated with worse cognitive performance46. 
However, our results were independent of a large set of cardiovascular risk factors and 
prior CVD. Second, depression and low-grade inflammation are related to both MVD and 
worse cognitive performance. Our results remained, however, after adjustment for these 
factors. Third, other biological mechanisms may underlie both MVD and worse cognitive 
performance. For example, oxidative stress and lower brain-derived neurotrophic factor 
have been associated with both MVD and worse cognitive performance47-50. However, 
data on oxidative stress and brain-derived neurotrophic factor were unavailable in our 
study; this requires further study. 
Our study has several limitations. First, the cross-sectional observational design precludes 
reaching causal conclusions about the study findings. Second, the construction of the 
composite scores assumes that all its components reflect cerebral MVD, which is not 
necessarily true. Our a-priori defined composite score was calculated with use of indirect 
and direct measures, which may reflect different forms of microvascular dysfunction 
(acute and reversible vs. more advanced), and this may have led to an underestimation of 
the association between (a more advanced stage of ) microvascular dysfunction and worse 
cognitive function. Third, no data were available on Alzheimer’s disease pathologies, such 
as amyloid and tau deposition. It has been hypothesized that these pathologies and MVD 
may act synergistically (i.e. interact) in the development of cognitive impairment51. Such 
interaction might explain our observed association between MVD and worse memory, a 
domain most strongly associated with Alzheimer’s disease, and this issue requires further 
study. Fourth, lower total brain parenchyma volume is also determined by factors other 
than microvascular disease, particularly the process of neurodegeneration. Fifth, the 
study population consisted of middle and early-old aged participants without dementia 
who were relatively well-educated and whose cardiovascular risk factors were relatively 
well-controlled. This may have led to an underestimation of the reported findings due to 
lower variation in cognitive performance and relatively high cognitive reserve.
In conclusion, the present study shows that MVD is associated with worse cognitive 
performance. 
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Perspectives
This study supports the hypothesis that MVD contributes to the development cognitive 
impairment. MVD might therefore be a target for prevention strategies of cognitive 
impairment. Evidence suggests that lifestyle modifications, such as weight loss and 
exercise, may, at least in part, favorably influence MVD52. In addition, drugs, such as renin-
angiotensin-aldosterone system inhibitors and antihyperglycemic agents (i.e. metformin 
and glucagon-like peptide 1 receptor (GLP-1R) agonists), may improve microvascular 
function52, possibly beyond their blood pressure- or glucose-lowering effects52. Future 
longitudinal studies are needed to further evaluate the association of MVD and cognitive 
decline and dementia.
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Table 1. Characteristics of the study population
Baseline characteristics Total study 
population 
(n=3011)







Age, years 59.5 (8.2) 64.0 (6.8) 59.9 (7.3) 54.7 (7.8)

















































Body mass index (kg/m2) 27.1 (4.5) 28.0 (4.5) 27.0 (4.6) 26.2 (4.2)
Type 2 diabetes, % 26.5 (797) 41.2 (413) 25.0 (251) 13.2 (133)
Hypertension, % 55.4 (1667) 71.9 (721) 54.9 (551) 39.3 (395)
Total/HDL cholesterol ratio 3.7 (1.2) 3.7 (1.2) 3.8 (1.2) 3.6 (1.2)
Triglycerides (mmol/L) 1.4 (0.9) 1.5 (0.9) 1.4 (0.8) 1.3 (0.8)
Lipid-modifying medication, % 34.9 (1050) 50.3 (505) 33.9 (340) 20.4 (205)
Prior cardiovascular disease, % 16.1 (486) 24.6 (247) 13.9 (140) 9.9 (99)
Current depression, % 3.7 (112) 5.4 (54) 3.6 (36) 2.2 (22)
Plasma biomarkers of low-grade 
inflammation composite score (SD)*
0.0 (1.0) 0.2 (1.0) 0.0 (1.0) -0.3 (1.0)
Microvascular dysfunction measures†
Microvascular dysfunction composite 
score (SD)
0.0 (1.0) 0.4 (1.1) 0.0 (0.9) -0.4 (0.8)
Cerebral small vessel disease features
Total brain parenchyma volume (ml) 1138.4 (111.7) 1123.9 (111.8) 1150.3 (117.3) 1138.8 (104.6)
White matter hyperintensity volume (ml) 0.2 (0.1-0.7) 0.4 (0.1-1.3) 0.2 (0.1-0.8) 0.1 (<0.1-0.4)
Presence of cerebral microbleeds 11.8 (237) 9.2 (92) 10.5 (73) 9.9 (72)
Presence of lacunar infarcts 5.4 (110) 6.7 (40) 6.4 (45) 3.4 (25)
Plasma biomarkers of microvascular 
dysfunction
Soluble ICAM-1 (µg/l) 352.7 (98.1) 372.3 (116.4) 348.1 (86.7) 337.8 (84.7)
Soluble VCAM-1 (µg/l) 425.1 (99.8) 445.2 (111.4) 422.9 (97.9) 407.1 (84.6)
Soluble E-selectin (µg/l) 117.5 (64.2) 130.1 (76.4) 117.6 (56.3) 104.9 (55.4)
Von Willebrand Factor (%) 131.7 (47.8) 140.9 (51.1) 130.8 (45.9) 123.5 (44.7)
Urinary albumin excretion
Urinary albumin excretion ≥30mg/24h 8.1 (242) 13.4 (133) 7.0 (70) 3.9 (39)
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Baseline characteristics Total study 
population 
(n=3011)







Urinary albumin excretion 
15-<30mg/24h 
10.3 (308) 13.1 (130) 9.3 (93) 8.5 (85)
Flicker light-induced arteriolar and 
venular dilation response
Flicker light-induced arteriolar dilation 
response (%)
3.1 (2.8) 2.7 (2.9) 3.1 (2.7) 3.3 (2.7)
Flicker light-induced venular dilation 
response (%)
3.9 (2.2) 3.7 (2.2) 3.9 (2.1) 4.0 (2.2)
Heat-induced skin hyperaemia (%) 1133.2 (781.5) 1006.2 (760.5) 1208.6 (859.6) 1192.0 (701.6)
Data are presented as percentage of participants (n), mean ± standard deviation (SD) or median (interquartile 
range). *Expressed per standard deviation; †Data available for microvascular dysfunction composite score 
n=2034; total brain parenchyma volume and white matter hyperintensity volume n=2049; lacunar infarcts 
n=2046;cerebral microbleeds n=2012; sICAM-1; sVCAM-1; and sE-selectin n=3011; vWF n=2991; urinary albumin 
excretion n=2987; retinal arteriolar dilation response n=2018; retinal venular dilation response n=2049; and skin 
hyperaemia n=1457. 
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* * 
Figure 2. Association between microvascular dysfunction score and cognitive function score.
*Statistical significance (p<0.05). Data available in n=2,034. Results are expressed as SD (95% confidence interval) 
worse cognitive function score per SD higher microvascular dysfunction score. Results were adjusted for age, 
education level, sex, diabetes mellitus type 2, body mass index, smoking status, alcohol use, hypertension, total/
HDL cholesterol ratio, triglycerides, and lipid-modifying medication use (model 1), and additionally for prior 





Figure 3. Associations between microvascular dysfunction score and domain-specific cognitive function score.
*Statistical significance (p<0.05). Data available in n=2,034. Results are expressed as SD (95% confidence interval) 
worse domain-specific cognitive function score per SD higher microvascular dysfunction score. Adjustments as 
in Figure 2. 






Figure 4. Associations between individual measures of microvascular dysfunction and cognitive function score. 
*Statistical significance (p<0.05). Results are expressed as (SD (95% confidence interval) worse cognitive function 
score per SD lower total brain parenchyma volume and higher white matter hyperintensity volume, presence 
of lacunar infarcts and microbleeds, per SD higher plasma biomarkers of microvascular dysfunction, urinary 
albumin excretion ≥30 versus <15mg/24h, urinary albumin excretion between 15 and <30 versus <15mg/24h, 
per SD lower retinal arteriolar and venular dilation response, and per SD lower skin hyperaemia. Adjustments 
as in Figure 2, model 2. Abbreviations: TBV, total brain parenchyma volume; WMH, white matter hyperintensity 
volume.
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Supplemental material
Item S1. Brain magnetic resonance imaging
Brain magnetic resonance imaging (MRI) was performed on a 3T MRI scanner (Siemens 
Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany) by use of a 64-element 
head/neck coil for parallel imaging. The MRI protocol consisted of a 3D T1-weighted 
magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence (TR/TI/
TE 2300/900/2.98 ms, 176 slices, 256×240 matrix size, 1.00 mm cubic voxel size); a fluid-
attenuated inversion recovery (FLAIR) sequence (TR/TI/TE 5000/1800/394 ms, 176 slices, 
512×512 matrix size, 0.49×0.49×1.00 mm voxel size); a combined proton density (PD) 
and T2-weighted turbo spin echo (TSE) pulse sequence (TR/TE1/TE2 3200/9.4/94 ms, 30 
slices, 640×540 matrix size, 0.36×0.36×4.00 mm voxel size); and a susceptibility-weighted 
imaging (SWI) sequence (TR/TE 28/20 ms, 144 slices, 384×312 matrix size, 0.57×0.57×1.00 
mm voxel size).
Contra-indications for MRI assessments were the presence of a cardiac pacemaker or 
implantable cardioverter-defibrillator, neurostimulator, non-detachable insulin pump, 
metallic vascular clips or stents in the head, cochlear implant, metal-containing intra-
uterine device, metal splinters or shrapnel, dentures with magnetic clip, an inside bracket, 
pregnancy, epilepsy, and claustrophobia. 
T1-weighted images and FLAIR images were analyzed by use of an ISO-13485:2012 
certified, automated method (which included visual inspection)1, 2. T1-weighted images 
were segmented into grey matter, white matter and cerebrospinal fluid volumes (1 voxel 
= 1.00 mm3 = 0.001 ml)1. Intracranial volume was calculated as the sum of grey matter, 
white matter (including white matter hyperintensity volume) and cerebrospinal fluid 
volumes. Total brain parenchyma volume was calculated as the sum of grey and white 
matter volumes. White matter hyperintensities identified were summed to assess total 
white matter hyperintensities burden in milliliter. Lacunar infarcts were defined as focal 
brain parenchyma defects of ≥3 mm and <15 mm in size with a similar signal intensity 
as cerebrospinal fluid on all sequences and a hyperintense rim on T2 and FLAIR images
3. 
Cerebral microbleeds were rated on T2-weighted and SWI images by use of the Microbleed 
Anatomical Rating Scale4, and were defined as focal lesions of ≥2 mm and ≤10  mm in 
size with a hypointense signal3. The presence of lacunar infarcts and cerebral microbleeds 
was rated manually by three neuroradiologists. The two-way mixed effects, consistency, 
intraclass correlation coefficients for the three raters based on 50 randomly selected scans 
were 0.84 (95% confidence interval 0.74; 0.91) and 0.83 (0.72; 0.90) for the presence of 
lacunar infarcts and cerebral microbleeds, respectively.
Item S2. Cognitive assessment 
The composite memory score was derived from the Verbal Learning Test by weighting 
total immediate and delayed recall scores. The domain information processing speed 
included the Stroop Color-Word Test Part I and II, the Concept Shifting Test Part A and 
B, and the Letter-Digit Substitution Test. Executive function was assessed by the Stroop 
Color-Word Test Part III and the Concept Shifting Test Part C. A description of the individual 
tests is provided below.
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Raw test scores were transformed into z-scores. Standardized scores of the Stroop 
Color-Word Test and Concept Shifting Test were inverted so that higher scores indicated 
better cognitive performance. Thereafter, domain-specific scores were calculated as the 
standardized average of the z-scores from (sub)tests within that domain (e.g. memory = 
z-score of (z-score immediate recall + z-score delayed recall/ 2)). The standardized average 
of these domain scores was then considered a measure of overall cognitive performance 
(i.e. overall cognitive performance = z-score of (memory + information processing speed 
+ executive function / 3)). 
Description of the individual cognitive tests used in the present study 
Verbal Learning Test:5 
Fifteen unrelated, monosyllabic, words were presented on a computer screen in five 
subsequent trials. After each trial, participants were instructed to recall as many words as 
possible in any order. Twenty minutes after the last trial, participants were asked again to 
reproduce the words. Outcomes recorded included the total number of words correctly 
recalled over the five trials (total immediate recall) and the number of correctly recalled 
words during delayed recall (delayed recall).
Stroop Color-Word Test:6
In this test, which consisted of three parts, participants were firstly asked to read aloud 
color names (i.e.  red, blue, yellow, and green) that were printed in black ink (Part I). 
Secondly, they were instructed to name solid color patches (Part II). Finally, participants 
had to name the ink color of color names that were printed in an incongruent color (e.g. 
participants were asked to say red when the word yellow was printed in red) (Part III). The 
time needed to complete Part III was adjusted for the average time needed to complete 
Part I and II. 
Concept Shifting Test:7
This test, a modification of the Trailing Making Test, consisted of four subtasks. During each 
subtask, participants were shown 16 small circles aligned along a larger imaginary circle. 
The small circles contained (a combination of ) digits, letters, or were empty. Participants 
were instructed to cross-out as quickly as possible the digits in ascending order (Part A), 
the letters in alphabetic order (Part B), and the letters and digits in alternating order (Part 
C). Thereafter, participants were asked to cross-out empty circles in a clockwise fashion in 
two consecutive trials (Part 0). In this way, test results could be accounted for basic motor 
speed. The time needed to complete subtasks A and B was adjusted for the average time 
needed to complete Part 0, the time needed to completed Part C for the average time of 
Part A and B.    
Letter-Digit Substitution Test:8
Participants were requested to match digits to letters according to a given key. This key 
included the numbers 1 to 9, each paired with a different letter. The outcome of interest 
was the number of correct substitutions within 90 seconds.
4
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Age, years 59.5 (8.2) 62.5 (7.5) 59.6 (7.9) 56.5 (8.1)

















































Body mass index, kg/m2 27.1 (4.5) 27.9 (4.5) 26.9 (4.3) 26.4 (4.5)
Type 2 diabetes, % 26.5 (797) 36.4 (366) 27.4 (275) 15.6 (156)
Hypertension, % 55.4 (1,667) 68.9 (693) 53.8 (539) 43.4 (435)
Total/HDL cholesterol ratio 3.7 (1.2) 3.8 (1.2) 3.7 (1.2) 3.6 (1.2)
Triglycerides, mmol/L 1.4 (0.9) 1.5 (0.9) 1.4 (0.8) 1.3 (0.8)
Lipid-modifying medication, % 34.9 (1,050) 47.0 (473) 34.3 (344) 23.2 (233)
Prior cardiovascular disease, % 16.1 (486) 20.9 (210) 17.2 (172) 10.4 (104)
Current depression, % 3.7 (112) 4.7 (47) 3.4 (34) 3.1 (31)
Plasma biomarkers of low-grade 
inflammation composite score, SD*
0.0 (1.0) 0.2 (1.0) -0.1 (1.0) -0.2 (1.0)
Microvascular dysfunction measures†
Microvascular dysfunction composite 
score, SD
0.0 (1.0) 0.3 (1.1) 0.0 (0.9) -0.3 (0.8)
Cerebral small vessel disease features
Total brain parenchyma volume, ml 1,138.4 (111.7) 1,157.2 (114.2) 1,136.6 (112.9) 1,123.5 (105.8)
White matter hyperintensity volume, 
ml 
0.2 (0.1-0.7) 0.4 (0.1-1.3) 0.2 (0.1-0.6) 0.2 (<0.1-0.5)
Presence of cerebral microbleeds, % 11.8 (237) 15.1 (94) 11.4 (77) 9.2 (66)
Presence of lacunar infarcts, % 5.4 (110) 7.3 (46) 4.8 (33) 4.3 (31)
Plasma biomarkers of microvascular dysfunction
Soluble ICAM-1, µg/l 352.7 (98.1) 367.0 (112.1) 349.6 (91.9) 341.5 (86.9)
Soluble VCAM-1, µg/l 425.1 (99.8) 441.8 (109.4) 425.4 (100.6) 407.9 (84.9)
Soluble E-selectin, µg/l 117.5 (64.2) 127.8 (75.5) 116.3 (58.4) 108.5 (55.5)
Von Willebrand Factor, % 131.7 (47.8) 139.0 (49.6) 131.4 (47.7) 124.8 (45.0)
Urinary albumin excretion
Urinary albumin excretion 
≥30mg/24h, %
8.1 (242) 12.1 (121) 7.4 (74) 4.7 (47)
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Urinary albumin excretion 
15-<30mg/24h, % 
10.3 (308) 12.8 (127) 10.4 (103) 7.8 (78)
Flicker light-induced arteriolar and venular dilation response
Flicker light-induced arteriolar 
dilation response, %
3.1 (2.8) 3.1 (2.8) 3.2 (2.7) 3.1 (2.8)
Flicker light-induced venular dilation 
response,%
3.9 (2.2) 3.9 (2.2) 4.0 (2.2) 3.9 (2.2)
Heat-induced skin hyperaemia, % 1,133.2 (781.5) 1,005.1 (745.4) 1,164.3 (827.1) 1,230.4 (753.0)
Data are presented as percentage of participants (n), mean ± standard deviation or median (interquartile 
range). *Expressed per standard deviation (SD); †Data available for total brain parenchyma volume and white 
matter hyperintensity volume n=2,049; for lacunar infarctions n=2,046 and for cerebral microbleeds n=2,012; 
for sICAM-1; sVCAM-1; and sE-selectin n=3,011; for vWF n=2,991; for albuminuria n=2,987; for flicker light-
induced arteriolar dilation n=2,018; for flicker light-induced venular dilation n=2,049; and for heat-induced skin 
hyperaemia n=1,457.
Abbreviations: BMI: body mass index; sE-selectin: soluble E-selectin; sICAM-1: soluble intercellular adhesion 
molecule-1; sVCAM-1: soluble vascular adhesion molecule-1; MMSE: Mini Mental State Examination; SD: 
standard deviation; vWF: Von Willebrand Factor.
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Age, years 59.5 (8.2) 63.6 (7.1) 60.0 (7.3) 55.1 (7.9)

















































Body mass index, kg/m2 27.1 (4.5) 27.8 (4.6) 27.0 (4.4) 26.4 (4.3)
Type 2 diabetes, % 26.5 (797) 39.5 (396) 24.8 (249) 15.1 (152)
Hypertension, % 55.4 (1,667) 68.6 (688) 54.9 (551) 42.6 (428)
Total/HDL cholesterol ratio 3.7 (1.2) 3.7 (1.2) 3.7 (1.2) 3.7 (1.2)
Triglycerides, mmol/L 1.4 (0.9) 1.5 (0.9) 1.4 (0.9) 1.4 (0.8)
Lipid-modifying medication, % 34.9 (1,050) 48.0 (481) 33.8 (339) 22.9 (230)
Prior cardiovascular disease, % 16.1 (486) 23.8 (239) 13.6 (137) 11.0 (110)
Current depression, % 3.7 (112) 5.1 (51) 3.3 (33) 2.8 (28)
Plasma biomarkers of low-grade 
inflammation composite score, SD*
0.0 (1.0) 0.2 (1.0) 0.0 (1.0) -0.2 (1.0)
Microvascular dysfunction measures†
Microvascular dysfunction composite 
score, SD
0.0 (1.0) 0.4 (1.2) 0.0 (0.9) -0.3 (0.8)
Cerebral small vessel disease features
Total brain parenchyma volume, ml 1,138.4 (111.7) 1,115.5 (112.2) 1,148.0 (110.7) 1,148.8 (109.4)
White matter hyperintensity volume, ml 0.2 (0.1-0.7) 0.3 (0.1-1.2) 0.2 (0.1-0.8) 0.1 (<0.1-0.4)
Presence of cerebral microbleeds, % 11.8 (237) 15.2 (93) 11.4 (78) 9.2 (66)
Presence of lacunar infarcts, % 5.4 (110) 7.4 (46) 5.8 (40) 3.3 (24)
Plasma biomarkers of microvascular dysfunction
Soluble ICAM-1, µg/l 352.7 (98.1) 365.0 (112.4) 352.8 (95.4) 340.3 (82.8)
Soluble VCAM-1, µg/l 425.1 (99.8) 439.1 (109.4) 424.9 (99.6) 411.1 (87.2)
Soluble E-selectin, µg/l 117.5 (64.2) 126.4 (71.1) 119.2 (65.3) 107.0 (53.6)
Von Willebrand Factor, % 131.7 (47.8) 139.1 (50.9) 132.2 (47.6) 123.9 (43.4)
Urinary albumin excretion
Urinary albumin excretion ≥30mg/24h, 
%
8.1 (242) 12.6 (125) 7.4 (74) 4.3 (43)
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Urinary albumin excretion 
15-<30mg/24h, % 
10.3 (308) 11.9 (118) 10.2 (102) 8.8 (88)
Flicker light-induced arteriolar and venular dilation response
Flicker light-induced arteriolar dilation 
response, %
3.1 (2.8) 2.6 (2.8) 3.1 (2.8) 3.4 (2.7)
Flicker light-induced venular dilation 
response,%
3.9 (2.2) 3.7 (2.2) 4.0 (2.1) 4.0 (2.2)
Heat-induced skin hyperaemia, % 1,133.2 (781.5) 1,022.7 (728.4) 1,164.1 (791.6) 1,220.8 (813.5)
Data are presented as percentage of participants (n), mean ± standard deviation or median (interquartile 
range). *Expressed per standard deviation (SD); †Data available for total brain parenchyma volume and white 
matter hyperintensity volume n=2,049; for lacunar infarctions n=2,046 and for cerebral microbleeds n=2,012; 
for sICAM-1; sVCAM-1; and sE-selectin n=3,011; for vWF n=2,991; for albuminuria n=2,987; for flicker light-
induced arteriolar dilation n=2,018; for flicker light-induced venular dilation n=2,049; and for heat-induced skin 
hyperaemia n=1,457.
Abbreviations: BMI: body mass index; sE-selectin: soluble E-selectin; sICAM-1: soluble intercellular adhesion 
molecule-1; sVCAM-1: soluble vascular adhesion molecule-1; MMSE: Mini Mental State Examination; SD: 
standard deviation; vWF: Von Willebrand Factor.
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Age, years 59.5 (8.2) 63.2 (7.2) 59.4 (7.8) 56.0 (8.0)

















































Body mass index, kg/m2 27.1 (4.5) 27.7 (4.5) 26.9 (4.5) 26.5 (4.4)
Type 2 diabetes, % 26.5 (797) 37.2 (373) 24.4 (245) 17.8 (179)
Hypertension, % 55.4 (1,667) 68.4 (686) 52.6 (528) 45.1 (453)
Total/HDL cholesterol ratio 3.7 (1.2) 3.7 (1.2) 3.7 (1.2) 3.7 (1.2)
Triglycerides, mmol/L 1.4 (0.9) 1.5 (0.9) 1.4 (0.9) 1.4 (0.8)
Lipid-modifying medication, % 34.9 (1,050) 47.2 (473) 30.4 (305) 27.1 (272)
Prior cardiovascular disease, % 16.1 (486) 21.4 (215) 15.2 (153) 11.8 (118)
Current depression, % 3.7 (112) 5.0 (50) 3.5 (35) 2.7 (27)
Plasma biomarkers of low-grade 
inflammation composite score, SD*
0.0 (1.0) 0.2 (1.0) 0.0 (1.0) -0.2 (1.0)
Microvascular dysfunction measures†
Microvascular dysfunction composite 
score, SD
0.0 (1.0) 0.3 (1.1) 0.0 (1.0) -0.2 (0.9)
Cerebral small vessel disease features
Total brain parenchyma volume, ml 1,138.4 (111.7) 1,110.7 (109.4) 1,144.2 (113.0) 1,156.0 (108.0)
White matter hyperintensity volume, ml 0.2 (0.1-0.7) 0.4 (0.1-1.1) 0.2 (0.1-0.7) 0.2 (<0.1-0.5)
Presence of cerebral microbleeds, % 11.8 (237) 13.8 (84) 11.8 (80) 10.0 (73)
Presence of lacunar infarcts, % 5.4 (110) 6.3 (39) 5.6 (38) 4.4 (33)
Plasma biomarkers of microvascular dysfunction
Soluble ICAM-1, µg/l 352.7 (98.1) 365.3 (105.4) 353.4 (98.2) 339.4 (88.4)
Soluble VCAM-1, µg/l 425.1 (99.8) 436.7 (106.6) 423.1 (97.5) 415.4 (93.7)
Soluble E-selectin, µg/l 117.5 (64.2) 127.6 (72.5) 119.4 (64.8) 105.5 (51.8)
Von Willebrand Factor, % 131.7 (47.8) 138.6 (49.8) 129.9 (47.1) 126.8 (45.7)
Urinary albumin excretion
Urinary albumin excretion ≥30mg/24h, % 8.1 (242) 11.7 (116) 7.6 (76) 5.0 (50)
Urinary albumin excretion 15-<30mg/24h, % 10.3 (308) 12.6 (125) 9.5 (95) 8.8 (88)
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Flicker light-induced arteriolar and venular dilation response
Flicker light-induced arteriolar dilation 
response, %
3.1 (2.8) 2.8 (2.8) 3.1 (2.8) 3.2 (2.7)
Flicker light-induced venular dilation 
response,%
3.9 (2.2) 3.8 (2.1) 3.9 (2.2) 3.9 (2.2)
Heat-induced skin hyperaemia, % 1,133.2 (781.5) 1,097.9 (828.3) 1,159.8 (793.4) 1,144.2 (716.6)
Data are presented as percentage of participants (n), mean ± standard deviation or median (interquartile 
range). *Expressed per standard deviation (SD); †Data available for total brain parenchyma volume and white 
matter hyperintensity volume n=2,049; for lacunar infarctions n=2,046 and for cerebral microbleeds n=2,012; 
for sICAM-1; sVCAM-1; and sE-selectin n=3,011; for vWF n=2,991; for albuminuria n=2,987; for flicker light-
induced arteriolar dilation n=2,018; for flicker light-induced venular dilation n=2,049; and for heat-induced skin 
hyperaemia n=1,457.
Abbreviations: BMI: body mass index; sE-selectin: soluble E-selectin; sICAM-1: soluble intercellular adhesion 
molecule-1; sVCAM-1: soluble vascular adhesion molecule-1; MMSE: Mini Mental State Examination; SD: 
standard deviation; vWF: Von Willebrand Factor.
Table S5. Associations between the individual covariates and cognitive function score
Covariates β 95% Confidence Interval P value
Lower Bound Upper Bound
Microvascular dysfunction score (per SD) -0.088 -0.131 -0.046 <0.001
Age (per year) -0.045 -0.050 -0.041 <0.001
Education level (per category) 0.419 0.369 0.469 <0.001
Sex (men vs. women) 0.351 0.279 0.423 <0.001
T2D (without T2D vs. with T2D) -0.099 -0.197 -0.001 0.047
Body Mass Index (per point) -0.003 -0.012 0.006 0.486
Active smoker (non-smoker vs. active smoker) -0.141 -0.252 -0.030 0.013
Former smoker (non-smoker vs. former smoker) 0.091 0.018 0.163 0.014
Alcohol use (per category) 0.042 -0.011 0.094 0.123
Hypertension (without hypertension vs. with 
hypertension)
-0.054 -0.129 0.021 0.160
Total/HDL cholesterol ratio (per point) -0.024 -0.062 0.013 0.200
Triglycerides (per mmol) -0.008 -0.061 0.045 0.761
Lipid-modifying medication (without medication 
use vs. with medication 4use)
0.000 -0.091 0.091 0.999
Prior CVD (without prior CVD vs. with prior CVD) 0.020 -0.088 0.128 0.717
Current depression (without current depression 
vs. with current depression)
-0.121 -0.303 0.061 0.191
Plasma markers of low-grade inflammation score 
(per SD)
0.004 -0.057 0.065 0.901
Results are expressed as standard deviation difference in the cognitive function score per unit difference in 
covariate. Abbreviations: CVD: cardiovascular disease; T2D: type 2 diabetes.
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Table S6. Associations between the microvascular dysfunction score and cognitive function score in individuals 
<65 years and ≥65 years
Participants <65 years (n=1,459) Participants ≥65 years (n=575)
Model β 95% Confidence Interval P value β 95% Confidence Interval P value
Lower Bound Upper Bound Lower Bound Upper Bound
1 -0.067 -0.117 -0.016 0.003 -0.118 -0.185 -0.051 0.003
2 -0.063 -0.116 -0.010 0.004 -0.134 -0.207 -0.060 0.004
Results are expressed as standard deviation worse cognitive function score per standard deviation higher 
microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, 
body mass index, smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, and lipid-
modifying medication use (model 1), and additionally for prior cardiovascular disease, current depression and 
plasma biomarkers of low-grade inflammation (model 2). 
Table S7. Associations between individual measures of microvascular dysfunction and cognitive function score
Individual microvascular dysfunction 
measure
Model β 95% Confidence Interval P value
Lower Bound Upper Bound
Total brain parenchyma volume (per lower 
SD) (n=2,049)
1 -0.059 -0.099 -0.019 0.004
2 -0.057 -0.097 -0.017 0.005
White matter hyperintensities (per higher 
SD) (n=2,049)
1 -0.087 -0.124 -0.050 <0.001
2 -0.085 -0.122 -0.048 <0.001
Cerebral microbleeds (presence vs. 
absence) (n=2,012)
1 -0.072 -0.174 0.031 0.170
2 -0.067 -0.170 0.037 0.206
Lacunar infarcts (presence vs. absence) 
(n=2,046)
1 -0.044 -0.190 0.101 0.550
2 -0.037 -0.183 0.109 0.619
Soluble intercellular adhesion molecule-1 
(per SD) (n=3,011)
1 -0.024 -0.053 0.006 0.113
2 -0.016 -0.048 0.016 0.330
Soluble vascular adhesion molecule-1 (per 
SD) (n=3,011)
1 -0.014 -0.043 0.015 0.341
2 -0.008 -0.038 0.022 0.603
Soluble E-selectin (per SD) (n=3,011) 1 -0.058 -0.089 -0.028 <0.001
2 -0.054 -0.084 -0.023 0.001
Von Willebrand factor (per SD) (n=2,991) 1 -0.005 -0.034 0.023 0.714
2 0.000 -0.029 0.030 0.986
Urinary albumin excretion (≥30 mg/24h vs. 
<15 mg/24h) (n=2,987)
1 -0.131 -0.237 -0.025 0.015
2 -0.117 -0.223 -0.011 0.031
Urinary albumin excretion (15-<30 mg/24h 
vs. <15 mg/24h) (n=2,987)
1 -0.032 -0.124 0.061 0.505
2 -0.018 -0.111 0.075 0.701
Flicker light-induced retinal arteriolar 
dilation (per lower SD) (n=2,018)
1 -0.016 -0.050 0.018 0.349
2 -0.016 -0.050 0.019 0.371
Flicker light-induced retinal venular dilation 
(per lower SD) (n=2,049)
1 -0.023 -0.057 0.010 0.173
2 -0.022 -0.056 0.011 0.190
Skin hyperemic response (per lower SD) 
(n=1,457)
1 0.010 -0.031 0.052 0.626
2 0.013 -0.029 0.054 0.552
Results are expressed as standard deviation worse cognitive function score per standard deviation higher 
microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, 
body mass index, smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, lipid-
modifying medication use (model 1), and additionally for prior cardiovascular disease, current depression and 
plasma biomarkers of low-grade inflammation (model 2). 
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Table S8. Associations between the microvascular dysfunction score and cognitive function in individuals with 
data available on at least one, eight and ten of the 12 individual measures of microvascular dysfunction
Determinant Model β 95% Confidence Interval P value
Lower Bound Upper Bound
Microvascular dysfunction score calculated 
in individuals with data on at least one of the 
12 measures (per higher SD) (n=3,011)
1 -0.077 -0.111 -0.044 <0.001
2 -0.073 -0.109 -0.037 <0.001
Microvascular dysfunction score calculated 
in individuals with data on at least eight of 
the 12 measures (per higher SD) (n=2,364)
1 -0.087 -0.124 -0.050 <0.001
2 -0.083 -0.123 -0.043 <0.001
Microvascular dysfunction score calculated 
in individuals with data on at least ten of the 
12 measures (per higher SD) (n=1,658)
1 -0.077 -0.121 -0.033 0.001
2 -0.079 -0.126 -0.033 0.001
Results are expressed as standard deviation worse cognitive function score per standard deviation higher 
microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, 
body mass index, smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, lipid-
modifying medication use (model 1), and additionally for prior cardiovascular disease, current depression and 
plasma biomarkers of low-grade inflammation (model 2).
Table S9. Associations between the microvascular dysfunction score and cognitive function after excluding 
consecutively each individual measure of microvascular dysfunction 
Variable excluded from the 
microvascular dysfunction score†
Model β 95% Confidence Interval P value
Lower Bound Upper Bound
Cerebral small vessel disease features 1 -0.046 -0.081 -0.012 0.009
2 -0.042 -0.079 -0.005 0.026
Plasma biomarkers of microvascular 
dysfunction 
1 -0.087 -0.130 -0.043 <0.001
2 -0.085 -0.129 -0.042 <0.001
Urinary albumin excretion 1 -0.079 -0.119 -0.040 <0.001
2 -0.080 -0.122 -0.038 <0.001
Flicker light-induced retinal arteriolar and 
venular dilation responses
1 -0.090 -0.130 -0.051 <0.001
2 -0.090 -0.132 -0.048 <0.001
Heat-induced skin hyperaemia 1 -0.092 -0.131 -0.052 <0.001
2 -0.094 -0.136 -0.052 <0.001
†Data available for analyses after excluding cerebral small vessel disease features n=2,426; for plasma biomarkers 
of microvascular dysfunction n=1,659, for urinary albumin excretion n=2,039; for flicker light-induced retinal 
arteriolar and venular dilation response n=2,050 and for heat-induced skin hyperaemia n=2,051. Results are 
expressed as standard deviation worse cognitive function score per standard deviation higher microvascular 
dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, body mass index, 
smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, lipid-modifying medication 
use (model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of 
low-grade inflammation (model 2).
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Table S10. Associations between composite scores of cerebral small vessel disease features, plasma biomarkers 
of microvascular dysfunction and retinal arteriolar and venular dilation responses and cognitive function
Determinant Model β 95% Confidence Interval P value
Lower Bound Upper Bound
Cerebral small vessel disease features (per 
point) (n=2,002)
1 -0.085 -0.133 -0.038 <0.001
2 -0.082 -0.129 -0.035 0.001
Plasma biomarkers of microvascular 
dysfunction (per SD) (n=2,991)
1 -0.040 -0.071 -0.009 0.010
2 -0.035 -0.069 -0.001 0.042
Flicker light-induced retinal arteriolar 
and venular dilation responses (per SD) 
(n=1,998)
1 -0.026 -0.060 0.008 0.136
2 -0.025 -0.059 0.009 0.152
Results are expressed as standard deviation worse cognitive function score per standard deviation higher 
microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, 
body mass index, smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, lipid-
modifying medication use (model 1), and additionally for prior cardiovascular disease, current depression and 
plasma biomarkers of low-grade inflammation (model 2).
Table S11. Associations between the microvascular dysfunction score and cognitive function additionally 
adjusted for ambulatory blood pressure
Model Β 95% Confidence Interval P value
Lower Bound Upper Bound
1 -0.092 -0.135 -0.050 <0.001
2 -0.101 -0.147 -0.056 <0.001
†Data available for analyses n=1,799. Results are expressed as standard deviation worse cognitive function 
score per standard deviation higher microvascular dysfunction score. Results were adjusted for age, education 
level, sex, diabetes mellitus type 2, body mass index, smoking status, alcohol use, total/HDL cholesterol ratio, 
triglycerides, lipid-modifying medication use, antihypertensive medication use, and ambulatory blood pressure 
(model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-
grade inflammation (model 2). 
Table S12. Associations between the microvascular dysfunction score and cognitive function additionally 
adjusted for class of antihypertensive medication
Model Β 95% Confidence Interval P value
Lower Bound Upper Bound
1 -0.083 -0.123 -0.043 <0.001
2 -0.084 -0.127 -0.041 <0.001
†Data available for analyses n=2,034. Results are expressed as standard deviation worse cognitive function 
score per standard deviation higher microvascular dysfunction score. Results were adjusted for age, education 
level, sex, diabetes mellitus type 2, body mass index, smoking status, alcohol use, total/HDL cholesterol ratio, 
triglycerides, lipid-modifying medication use, use of angiotensin-converting-enzyme inhibitors or angiotensin II 
receptor blockers, use of other antihypertensive medications, office systolic and diastolic blood pressure (model 
1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-grade 
inflammation (model 2). This additional analysis was performed, because angiotensin-converting enzyme 
inhibitors and angiotensin II receptor blockers have additional beneficial effects on microvascular function 
independent of their antihypertensive properties.1 
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Table S13. Associations between the microvascular dysfunction score and cognitive function score, stratified by 
diabetes status (without type 2 diabetes and with type 2 diabetes)
Participants without type 2 diabetes (n=1,598) Participants with type 2 diabetes (n=436)
Model β 95% Confidence Interval P value β 95% Confidence Interval P value
Lower Bound Upper Bound Lower Bound Upper Bound
1 -0.081 -0.130 -0.032 0.001 -0.099 -0.171 -0.028 0.007
2 -0.073 -0.124 -0.021 0.005 -0.140 -0.222 -0.058 0.001
Results are expressed as standard deviation worse cognitive function score per standard deviation higher 
microvascular dysfunction score.  Results were adjusted for age, education level, sex, body mass index, smoking 
status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, and lipid-modifying medication use 
(model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-
grade inflammation (model 2). 
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Abstract
Background and aims
The mechanisms underlying cognitive impairment and dementia are incompletely 
understood but may include arterial stiffness and microvascular dysfunction. We 
investigated, in the population-based Maastricht Study, the association between greater 
arterial stiffness and worse cognitive performance, and whether any such association was 
statistically explained, or mediated, by various measures of microvascular dysfunction. 
Materials and methods
We included cross-sectional data of 2,544 participants (age 59.7 years; 51.0% men; 
26.0% type 2 diabetes [oversampled by design]). We used carotid-femoral pulse wave 
velocity and carotid distensibility coefficient as measures of aortic and carotid stiffness, 
respectively. We calculated a composite score of microvascular dysfunction based on 
MRI features of cerebral small vessel disease (lower total brain parenchymal volume, 
higher white matter hyperintensity volume, lacunar infarcts and cerebral microbleeds), 
retinal arteriolar and venular dilation response, albuminuria, and plasma biomarkers of 
microvascular dysfunction (sICAM-1, sVCAM-1, sE-selectin and von Willebrand Factor). 
Cognitive domains assessed were memory, processing speed and executive function. A 
cognitive function composite score was calculated as the average of the scores on these 
three cognitive domains.
Results
Higher carotid-femoral pulse wave velocity was associated with a lower cognitive function 
composite score after adjustment for age, sex, education level, glucose metabolism 
status, body mass index, smoking, alcohol use, total/high density cholesterol ratio, 
triglycerides, mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-
modifying medication. Higher carotid stiffness was not associated with the cognitive 
function composite score. Mediation analysis showed that higher carotid-femoral pulse 
wave velocity was associated with a higher microvascular dysfunction score, and a 
higher microvascular dysfunction score was associated with a lower cognitive function 
composite score. Thus, a higher microvascular dysfunction score statistically significantly 
explained 16.2% of the total effect of carotid-femoral pulse wave velocity on the cognitive 
function composite score. 
Conclusion
The present study found that aortic stiffness, but not carotid stiffness, is independently 
associated with worse cognitive performance, and that this association is in part explained 
by microvascular dysfunction.
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Introduction
Cognitive impairment and dementia have an enormous impact on patients, their families 
and society, and the prevalence of dementia is rising.2 The mechanisms underlying 
cognitive impairment and dementia remain, however, incompletely understood, but may 
include arterial stiffness and microvascular dysfunction (MVD).3
Greater arterial stiffness leads to excessive intra-arterial pressure and flow pulsatility 
which may transmit distally and damage the cerebral microcirculation.4, 5 The cerebral 
microvasculature is involved in the regulation of many processes potentially affecting 
cognition, i.e. cerebral perfusion, neurogenesis, neurovascular coupling, blood-brain 
barrier permeability and cerebral autoregulation.6 Impairment of these processes may 
lead to neuronal dysfunction and ischemia, which may ultimately lead to lower cognitive 
performance.3, 6-8 In accordance, previous studies3 9-22 have shown an association between 
greater arterial stiffness and both cognitive decline and incident dementia. Most of these 
studies3, 9-16, 19-22 focused on carotid-femoral pulse wave velocity (cfPWV), a measure of 
aortic stiffness, but only some17-22 on carotid stiffness. In addition, MVD has been associated 
with worse cognitive performance.8, 23 However, whether any association between aortic 
or carotid stiffness and worse cognitive performance is explained, or mediated, by MVD 
remains largely unknown. 
Microvascular function and structure can be measured noninvasively in various organs. 
These measures include magnetic resonance imaging (MRI) features of cerebral small 
vessel disease (CSVD, e.g. lower total brain parenchyma volume, higher white matter 
hyperintensity volume, and presence of lacunar infarcts and cerebral microbleeds);24 flicker 
light-induced retinal arteriolar and venular dilation response;25 albuminuria (“urinary 
albumin excretion”, UAE);26 and plasma biomarkers of MVD (e.g. soluble intercellular 
adhesion molecule-1 [sICAM-1], soluble vascular adhesion molecule-1 [sVCAM-1], soluble 
E-selectin [sE-selectin] and von Willebrand factor [vWF]).27 
These various measures of MVD (i.e. CSVD features, retinal arteriolar and venular 
dilation response, UAE and plasma biomarkers of MVD) can be summarized into a total 
MVD composite score. The CSVD features and the retinal arteriolar and venular dilation 
responses are closely linked to the cerebral microvasculature and, thus, may reflect its 
function.28, 29 In addition, to the extent that MVD is a generalised phenomenon, UAE, and 
plasma biomarkers of MVD may also reflect cerebral MVD.30 We previously showed that 
such a total MVD composite score is associated with worse cognitive performance. 
In view of the above, the aims of the present study were to investigate the associations 
between aortic and carotid stiffness and cognitive performance, and whether any such 
associations are statistically mediated by a composite score of various MVD measures, 
including CSVD features, retinal arteriolar and venular dilation response, UAE and plasma 
biomarkers of MVD. 
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Material and methods
Study population and design 
We used data from The Maastricht Study, an observational population-based cohort 
study. The rationale and methodology have been described previously.31 In brief, the 
study focuses on the aetiology, pathophysiology, complications and comorbidities 
of diabetes mellitus type 2 (T2D) and is characterized by an extensive phenotyping 
approach. Eligible for participation were all individuals aged between 40 and 75 years and 
living in the southern part of the Netherlands. Participants were recruited through mass 
media campaigns, the municipal registries and the regional Diabetes Patient Registry via 
mailings. Recruitment was stratified according to known T2D status, with an oversampling 
of individuals with T2D for reasons of efficiency. The present report includes cross-sectional 
data from 3,451 participants who completed the baseline survey between November 
2010 and September 2013. The examinations of each participant were performed within 
a time window of three months. The study has been approved by the institutional medical 
ethical committee (NL31329.068.10) and the Ministry of Health, Welfare, and Sports of the 
Netherlands (Permit 131088-105234-PG). All participants gave written informed consent.
Vascular measures
For all vascular measures, participants were asked to refrain from smoking and drinking 
caffeine-containing beverages three hours before the measurement.32 A light meal was 
allowed until ≥90 minutes prior to the examination.  For retinal measurements, pupils 
were dilated with 0.5% tropicamide and 2.5% phenylephrine ≥15 minutes before the start 
of the examination. 
Assessment of arterial stiffness
A more detailed description of the arterial stiffness measures is provided in the 
Supplementary Material (Item S1), and has been described previously.33, 34 During the 
arterial stiffness measurements, brachial blood pressure and heart rate were obtained 
with a validated commercial oscillometric device (Accutorr Plus, Datascope Inc., Montvale, 
NJ, USA). 
Carotid-femoral pulse wave velocity 
We determined cfPWV with the use of applanation tonometry (SphygmoCor, Atcor 
Medical, Sydney, Australia).35 Pressure waveforms were determined at the right common 
carotid and right common femoral arteries. Difference in the time of pulse wave arrival 
from the R-wave of the electrocardiogram between the two sites (transit time) was 
determined. The pulse wave travel distance was calculated as 80% of the direct straight 
distance between the two arterial sites. The median of three consecutive cfPWV (defined 
as traveled distance/transit time) recordings was used in the analyses.
Carotid stiffness
We assessed local diameter, distension and intima-media thickness of the left common 
carotid artery with the use of an ultrasound scanner equipped with a 7.5-MHz linear 
probe (MyLab 70, Esaote Europe B.V., Maastricht, the Netherlands).36 We quantified carotid 
stiffness by calculating the carotid distensibility coefficient (carDC) based on the following 
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formula: carDC = (2*DD*D + DD2)/(PP*D2), where D is arterial diameter, DD distension, and 
PP brachial pulse pressure.37 Carotid compliance coefficient and Young’s elastic modulus 
were also determined.
Microvascular dysfunction measures
Features of cerebral small vessel disease
Brain MRI measurements were implemented from December 2013 onwards and 
were available in 2,313 of 3,451 participants (67%). Brain MRI was performed on a 3T 
MRI scanner (Siemens Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany). 
We evaluated four CSVD features, i.e. lower total brain parenchyma volume, higher 
white matter hyperintensity volume, and presence of lacunar infarcts and cerebral 
microbleeds.24 A detailed description of the MRI protocol and the definitions of the CSVD 
features is provided in the Supplementary Material (Item S2), and has been described 
previously.38 The MRI protocol consisted of a 3D T1-weighted sequence, a fluid-attenuated 
inversion recovery sequence, a combined proton density and T2-weighted turbo spin echo 
sequence and a susceptibility-weighted imaging sequence.38 Volumes were determined 
semi-automatically, and lacunar infarcts and cerebral microbleeds were scored manually.
Flicker light-induced retinal arteriolar and venular dilation response
We measured retinal arteriolar and venular dilation response to flicker light exposure by the 
Dynamic Vessel Analyzer (Imedos, Jena, Germany), as previously described.25, 39 A baseline 
recording of 50 seconds was followed by 40-second flicker light exposure followed by 
a 60-second recovery period. We calculated baseline diameters (in measurement units) 
as the average diameter during the 20-50 seconds recording. For both the arteriolar and 
venular dilation, percentage dilation over baseline was calculated using the average 
dilation achieved at time points 10 and 40 seconds during the flicker light stimulation 
period. 
Urinary albumin excretion 
We assessed UAE in two 24-hour urine samples. Urinary albumin concentration was 
measured with a standard immunoturbidimetric assay by an automatic analyzer (due to 
a change of supplier, by the Beckman Synchron LX20 and the Roche Cobas 6000) and 
multiplied by collection volume to obtain 24-hour UAE.40 A urinary albumin concentration 
below the detection limit of the assay was set at 1.5mg/L (2mg/L for the Beckman Synchron 
LX20 and 3mg/L for the Roche Cobas 6000) before multiplying by collection volume. Only 
urine collections with a collection time between 20 and 28 hours were considered valid. 
If needed, UAE was extrapolated to 24-hour excretion. For this study, UAE was preferably 
based on the average of two (available in 91.3% of participants) 24-hour urine collections.
Plasma biomarkers of microvascular dysfunction
We measured four plasma biomarkers of MVD: sICAM-1, sVCAM-1, sE-selectin and 
vWF.30 sICAM-1, sVCAM-1 and sE-selectin were measured in EDTA plasma samples with 
commercially available 4-plex sandwich immunoassay kits with different standards 
and antibodies (Meso Scale Discovery, Rockville, Maryland, United States of America). 
For this technique in this study, the intra- and inter-assay coefficients of variation were 
10.3 and 8.4% for sICAM-1, 5.0 and 4.7% for sVCAM-1, and 2.9 and 7.4% for sE-selectin, 
172   |   Chapter 5
respectively. Von Willebrand Factor (vWF) was quantified in citrate plasma using ELISA 
(Dako, Glostrup, Denmark). The intra- and inter-assay coefficients of variation were 3.0 and 
4.3%, respectively. 
Cognitive performance
We assessed cognitive performance using a concise neuropsychological test battery, 
as described previously.31 For statistical efficiency, we constructed a cognitive function 
composite score by averaging of standardized test scores in three cognitive domains: 
memory, processing speed and executive function. A detailed description of methods 
used to calculate domain-specific cognitive function scores is provided in Item S3 
(Supplementary material). We evaluated memory with the Verbal Learning Test;41 
processing speed with the Stroop Color-Word Test Part I and II,42 Concept Shifting Test 
Part A and B,43 and Letter-Digit Substitution Test;44 and executive function with the Stroop 
Color-Word Test Part III42 and Concept Shifting Test Part C.43
Covariates
We determined glucose metabolism status according to the World Health Organization 
2006 criteria as normal glucose metabolism, prediabetes or T2D.45 Education level was 
classified into three groups: low (none, primary or lower vocational education only), 
intermediate (intermediate general secondary, intermediate vocational or higher 
general secondary education) and high (higher vocational education or university level 
of education). Body mass index (BMI), smoking status (never, former, current), alcohol 
use (none, low, high), office blood pressure, plasma lipid levels, medication use and 
prior cardiovascular disease (CVD) were determined as described previously.25, 26, 31 We 
used questionnaires to assess adherence to the Mediterranean diet score (“diet score“),46 
moderate-to-vigorous physical activity (CHAMPS questionnaire),31 and socio-economic 
status (income level and occupational status).47 The Mini-International Neuropsychiatric 
Interview (MINI) was used to assess the presence of a current DSM-IV defined major 
depressive episode.31 Plasma biomarkers of low-grade inflammation were determined as 
described previously.31, 48 These included high-sensitive C-reactive protein (CRP), serum 
amyloid A (SAA), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor alpha 
(TNF-α). In addition, 24-hour ambulatory systolic blood pressure was determined.49
Statistical analysis
We inversed (multiplying by -1) total brain parenchyma volume, and the flicker light-
induced retinal arteriolar and venular dilation responses so that higher values indicated 
worse microvascular function. White matter hyperintensity volume and UAE were log-
transformed (base 2) to normalize their skewed distribution. 
We summarized the 11 MVD measures (i.e. four CSVD features, flicker light-induced 
retinal arteriolar and venular dilation responses, UAE and four plasma biomarkers of 
MVD) into a MVD composite score, as done previously. We hypothesized that each MVD 
measure is associated with arterial stiffness and cognitive performance according to 
similar underlying mechanisms. The use of a composite score reduces the influence of the 
biological variability of its components50 and it reduces the chance of a type 1 error. The 
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MVD composite score was calculated when at least data on one of the 11 MVD measures 
were available. The composite score was calculated by averaging the 11 standardized 
MVD measures, respectively. On average, individuals included in the analysis had data 
available on nine of the 11 measures (Figure S1).
The statistical analysis proceeded in two stages. First, we used linear regression analysis 
to evaluate associations between cfPWV and carDC and the cognitive function composite 
score. We adjusted for the following potential confounders: age, sex, and education level 
(model 1), additionally for glucose metabolism status, BMI, smoking, alcohol use, total/
high density cholesterol (HDL) ratio and triglycerides (model 2) and then additionally for 
mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying 
medication (model 3). Second, we performed a formal mediation analysis to test the 
hypothesis that MVD explains the association between greater arterial stiffness and worse 
cognitive performance.51 The mediation model quantifies the degree to which a variable 
statistically explains the association between a determinant and an outcome variable. We 
used bootstrapping (10,000 samples) to calculate bias-corrected 95% confidence intervals 
(95% CIs) of the explained associations using the PROCESS statistical package for PASW 
statistics.51 The magnitude of the explained association was calculated as a percentage of 
the total association.
We tested interaction terms with age,52 sex,53 education level54 and glucose metabolism 
status16 to evaluate whether the association between arterial stiffness and cognitive 
performance differed according to these factors. 
We performed several additional analyses. First, we repeated the analysis using carotid 
compliance coefficient and Young’s elastic modulus instead of carDC as the determinant. 
Second, we repeated the analysis using domain-specific cognitive function scores, i.e. 
memory, processing speed and executive function, as the outcome. Third, to test whether 
the association between the MVD score and cognitive function composite score was 
primarily determined by any individual MVD measure, we repeated the analysis five times 
after consecutively excluding from the MVD score the four CSVD features, the retinal 
arteriolar and venular dilation responses, UAE and the four plasma biomarkers of MVD. 
Fifth, we repeated the analysis additionally adjusting for prior CVD, current depression 
and the plasma biomarkers of low-grade inflammation. Adjustments for these covariates 
were not included in the main analysis, because of the risk of overadjustment bias: these 
factors may be confounders but may also mediate the associations between arterial 
stiffness, MVD and cognitive performance. Sixth, we repeated the analysis additionally 
adjusting for type of antihypertensive medication (i.e. beta blockers, diuretics, calcium 
channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor 
blockers). Seventh, we repeated the analysis additionally adjusting for the diet score, 
for moderate-to-vigorous physical activity and for the socio-economic status variables 
income level and occupational status. Adjustments for these covariates were not included 
in the main analysis, because data were missing in a relatively large number of participants 
(n=774 missed data on one or more of these variables).
All analyses were performed with SPSS software (v22.0, IBM, Chicago, USA). A P value of 
<.05 was considered statistically significant. 
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Results
Figure 1 shows the derivation of the final study population. In total, 2,544 participants 
had data available on arterial stiffness, at least one MVD measure, the cognitive function 
composite score and all potential confounders. Table 1 shows the characteristics of the 
study population and according to tertiles of the cognitive function composite score. 
Characteristics of the individuals excluded from the analyses due to missing values are 
provided in the Supplementary Material (Table S1). On average, these individuals were 
older, more often male, had received lower education and had a worse cardiovascular risk 
profile. The study population for current analyses had a mean age of 59.7 years, 51.0% were 
men, 26.0% had T2D (oversampled by design) and 41.5% had received a high education.
Higher cfPWV was associated with a lower cognitive function composite score after 
adjustments for all potential confounders but without adjustment for the total MVD score 
(Table 2). CarDC was not associated with the cognitive function composite score after 
adjustment for all potential confounders (Table 2). 
Mediation analysis showed that higher cfPWV was associated with a higher MVD score, 
and a higher MVD score was associated with a lower cognitive function composite 
score (Figure 2). When we additionally adjusted the association between cfPWV and the 
cognitive function composite score for the MVD score, the association was attenuated and 
no longer statistically significant. The effect explained by the MVD score was statistically 
significant and was 16.2% of the total direct effect of cfPWV on the cognitive function 
composite score (Figure 2). CarDC was not associated with a higher MVD score, and the 
MVD score did not statistically significantly mediate the association between CarDC and 
the cognitive function composite score (Figure S2).
We found no interactions with age, sex, education level and glucose metabolism status (P 
values for interaction >.10).
Additional analyses
The carotid compliance coefficient and Young’s elastic modulus were not statistically 
significantly associated with the cognitive function composite score (Table S2). CfPWV 
and carDC were not statistically significantly associated with domain-specific cognitive 
function scores, i.e. memory, processing speed and executive function (Table S3). Results 
were similar when we consecutively excluded from the MVD score the CSVD features, 
the retinal arteriolar and venular dilation responses, UAE and the plasma biomarkers of 
MVD (Table S4). Results did not materially change when we additionally adjusted for prior 
CVD, current depression or the plasma biomarkers of low-grade inflammation (Table S5), 
type of antihypertensive medication (Table S6), or the diet score, moderate-to-vigorous 
physical activity or income level and occupational status (Table S7).
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Discussion
In this cross-sectional study, higher cfPWV, but not lower carDC, was associated with a 
lower cognitive function composite score. In addition, the association between cfPWV 
and the cognitive function composite score was in part (16.2%) explained or mediated by 
a composite score of various MVD measures, including CSVD features, flicker light-induced 
retinal arteriolar and venular dilation response, UAE and plasma biomarkers of MVD. 
The study findings are in accordance with the hypothesis that higher aortic stiffness 
increases the risk of worse cognitive performance in part via cerebral MVD.3, 55 Higher aortic 
stiffness may lead to MVD via an increased pulsatile load on the microcirculation. This 
increased load may cause direct microvascular damage and may induce a microvascular 
remodelling response. This response initially serves to limit the penetration of the pulsatile 
load into the microvasculature by raising vascular resistance.56 However, this protective 
response may ultimately become unfavorable, leading to cerebral hypoperfusion, 
impaired neurogenesis and vasoreactivity, and blood-brain barrier hyperpermeability. 
Previous studies have shown associations between higher cfPWV and various measures 
of MVD, including MRI features of CSVD3 and albuminuria.57-60  In addition, previous 
studies have shown an association between various MVD measures (i.e. CSVD features, 
albuminuria and plasma biomarkers of MVD) and worse cognitive performance,8, 61-69 and 
higher cfPWV and worse cognitive performance.3, 16, 70 However, only one previous study7 
evaluated arterial stiffness, cognitive performance and MVD at the same time. This study 
found an association between higher cfPWV and worse memory, and showed that this 
association was attenuated after adjustments for higher white matter hyperintensity 
volume.7 The present study extends previous research by showing, with use of a formal 
mediation analysis, that the association between higher cfPWV and worse cognitive 
performance is in part mediated, or explained, by a composite score of various direct and 
indirect measures of MVD. It thereby provides additional evidence consistent with the role 
of arterial stiffness as a contributor to MVD and cognitive decline.
Surprisingly, carotid stiffness was not associated with worse cognitive performance in our 
study, although the 95% confidence intervals of the effect estimates do not exclude the 
possibility of such an association. In contrast, we previously found, in a smaller dataset of The 
Maastricht Study of the first 866 individuals included in the study i.e. from November 2010 
to March 2012, that greater carotid stiffness was weakly associated with worse cognitive 
performance.22 We cannot fully explain this difference, although it may be related to the 
slightly different characteristics of the two data samples. Although individuals included in 
the first study period were of the same age (60 years), they were more often men (54.6% 
vs 51.0%) and had a slightly worse cardiovascular risk profile, i.e. had more often type 
2 diabetes (27.2% vs. 26.0%), were more often current smokers (15.9% vs. 13.4%), and 
more often had a high level of alcohol consumption (30.9% vs. 26.9%) and prior CVD 
(17.2% vs. 16.2%). Although both analyses adjusted for these potential confounders, we 
cannot exclude the possibility of residual confounding. In addition, we cannot exclude 
that the difference in results are due to the play of chance. Only six other studies17-21, 71 
evaluated the association between carotid stiffness and cognitive performance and also 
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had inconsistent results. Some,17-19, 21 but not all,20 71 studies found an association between 
higher carotid stiffness and worse cognitive performance. These conflicting results may be 
due to the differences in cognitive tests used and inconsistent adjustments for potential 
confounders (e.g. only one20 study adjusted for heart rate, whereas the others17-19, 21, 71 did 
not). The association between carotid stiffness and cognitive performance, therefore, 
remains unclear, and requires further study. 
A relatively large part of the association between cfPWV and cognitive performance 
remained unexplained after taking into account the effect of MVD. This remaining 
association may be due to MVD that is not directly captured in our MVD composite score 
(e.g. blood-brain barrier leakage and altered cerebrovascular reactivity). In addition, it is 
possible that only a subset of individuals with cognitive impairment have vascular-related 
disease. Finally, although we adjusted for a large set of potential confounders, we cannot 
exclude the possibility of residual confounding. 
Strengths of the present study are the large population-based sample, the comprehensive 
assessment of various measures of MVD, and the extensive characterization of participants, 
which enabled us to adjust for a series of potential confounders. 
Our study has certain limitations. First, the cross-sectional observational design precludes 
reaching strong causal conclusions about the study findings. Second, the construction of 
the composite scores assumes that all its components either directly or indirectly reflect 
cerebral MVD, which is not necessarily true. However, results did not materially change 
after exclusion of individual MVD measures from the MVD composite score. Third, the 
study population consisted mostly of middle-aged participants without dementia who 
were relatively well-educated and whose cardiovascular risk factors were relatively well-
controlled. This may have led to an underestimation of the reported findings due to lower 
variation in cognitive performance and relatively high cognitive reserve.
From a clinical point of view, the present study is important, because insight in 
the pathophysiological mechanisms between arterial stiffness, MVD and cognitive 
performance might help to design prevention strategies of cognitive impairment. Evidence 
suggests that lifestyle modifications, such as weight loss and exercise, may favorably 
influence arterial stiffness and MVD.72, 73 In addition, drugs, such as renin-angiotensin-
aldosterone system inhibitors, antihyperglycemic agents (i.e. metformin and glucagon-
like peptide 1 receptor (GLP-1R) agonists) and statins, may improve arterial elasticity and 
microvascular function,72, 74-76 possibly beyond their blood pressure- , glucose- or lipid-
lowering effects.72, 76
In conclusion, the present study found that aortic stiffness, but not carotid stiffness, is 
independently associated with worse cognitive performance, and that this association is 
in part explained by MVD.
5
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Missing data on (micro)vascular measures 
(n=625)* 
Carotid-femoral pulse wave velocity (n=564) 
Carotid artery - distensibility coefficient (n=521) 
Microvascular dysfunction score (n=0) 
 
Population with data on (micro)vascular 
measures (n=2,826) 
The Maastricht Study (n=3,451) 
Population with data on (micro)vascular 




Population with data on (micro)vascular 
measures, cognitive function and all potential 
confounders (n=2,576) 
Missing data on cognitive function (n=187)* 
Memory function (n=148) 
Processing speed (n=188) 
Executive function (n=208) 
Missing data on potential confounders (n=63)* 
Body mass index (n=1) 
Smoking status (n=45) 
Alcohol use (n=49) 
Total/HDL cholesterol ratio (n=3) 
Serum triglycerides (n=3)  
Mean arterial pressure (n=1) 
Anti-hypertensive medication (n=3) 




Excluded due to a diabetes type other than  
type 2 (n=32) 
Figure 1. Flowchart showing the derivation of the total study population. *Missings not mutually exclusive.
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Table 1 General study population characteristics











Age, years 59.7 ± 8.1 64.1 ± 6.7 60.2 ± 7.1 54.9 ± 7.7





















































Low, women ≤7; men ≤14 units/week













Total/HDL cholesterol ratio 3.7 ± 1.2 3.8 ± 1.2 3.8 ± 1.2 3.6 ± 1.2
Triglycerides, mmol/L 1.4 ± 0.9 1.5 ± 0.9 1.4 ± 0.9 1.3 ± 0.8
Office systolic pressure, mmHg 134.9 ± 18.2 139.6 ± 18.8 135.7 ± 17.6 129.3 ± 16.6
Office diastolic pressure, mmHg 76.2 ± 9.9 76.4 ± 9.9 76.6 ± 9.6 75.7 ± 10.2
Heart rate during vascular measurement, 
bpm
62.5 ± 9.3 63.0 ± 9.8
62.0 ± 9.0 62.6 ± 9.0
Use of antihypertensive medication 37.7 (959) 53.7 (455) 35.7 (303) 23.7 (201)
Use of lipid-modifying medication 35.1 (893) 49.5 (420) 35.1 (298) 20.6 (175)
Prior cardiovascular disease 16.2 (405) 24.5 (204) 14.7 (123) 9.3 (78)
Current depression 3.5 (88) 4.8 (40) 3.6 (30 2.1 (18)
Composite score of plasma biomarkers 
of low-grade inflammation, SD
0.0 ± 1.0 0.2 ± 0.7 0.0 ± 0.6 -0.2 ± 0.6
Measures of arterial stiffness
Carotid-femoral pulse wave velocity, m/s
Carotid distensibility coefficient, 10-3/kPa
Carotid compliance coefficient, mm2/kPa

















Measures of microvascular dysfunction*
Microvascular dysfunction composite 
score
0.0 ± 1.0 0.4 ± 1.2 -0.1 ± 0.8 -0.3 ± 0.7
Cerebral small vessel disease features
Total brain parenchyma volume, ml
White matter hyperintensity volume, ml
Presence of cerebral microbleeds
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Flicker light-induced arteriolar and 
venular dilation
Flicker light-induced arteriolar dilation, 
%




































































Data are presented as mean ± standard deviation (SD), median [interquartile range] or n (%).
*We calculated a microvascular dysfunction (MVD) composite score (“MVD composite score”) of all individual 
MVD measures. For the total MVD composite score, the individual 11 MVD measures (i.e. four cerebral small 
vessel disease features, the flicker light-induced retinal arteriolar and venular dilation responses, urinary albumin 
excretion and the four plasma biomarkers of MVD) were standardized into z-scores. These z-scores were then 
averaged into the MVD composite score. The MVD composite score was calculated when data were available 
on at least one of the 11 individual MVD measures. Data available for: total brain parenchyma volume, n=1,726; 
white matter hyperintensity volume, n=1,726; cerebral microbleeds, n=1,697; lacunar infarcts, n=1,724; flicker 
light-induced arteriolar dilation, n=1,649; flicker light-induced venular dilation, n=1679; urinary albumin 
excretion, n=2,522; soluble intercellular adhesion molecule-1, n=2,520; soluble vascular adhesion molecule-1, 
n=2,520; soluble E-selectin, n=2,520; von Willebrand factor, n=2,517. 
Abbreviations: HDL, high-density lipoprotein; ICAM-1: intracellular adhesion molecule-1; VCAM-1: vascular 
adhesion molecule-1.
Table 2. Associations between arterial stiffness and the cognitive function composite score
Cognitive function composite score, per SD
Arterial stiffness measure Model β (95% CI)
Carotid-femoral pulse wave velocity, m/s 1 -0.032 (-0.048; -0.016)
2 -0.019 (-0.035; -0.003)
3 -0.018 (-0.036; -0.000)
Carotid distensibility coefficient, 10-3/kPa 1 -0.007 (-0.014; -0.000)
2 -0.005 (-0.012; 0.002)
3 -0.004 (-0.012; 0.003)
Results indicate SD (95% confidence intervals) lower cognitive function composite score per m/s higher carotid-
femoral pulse wave velocity and per 10-3/kPa lower in carotid distensibility. Model 1: adjusted for age, sex, 
education level, Model 2: additionally adjusted for glucose metabolism status, body mass index, smoking, 
alcohol use, total/high density cholesterol ratio and triglycerides, and Model 3: additionally adjusted for mean 
arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication. Abbreviations: CI = 
confidence interval; SD = standard deviation.
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Adjusted for potential confounders: 










Additionally adjusted for the microvascular dysfunction score: 
β -0.015 (95% CI -0.033; 0.025)
Figure 2. Association between carotid-femoral pulse wave velocity (per m/s) and the cognitive function 
composite score (per SD), and the proportion explained by the microvascular dysfunction score (per SD). 
Solid lines indicate associations that are statistically signifi cant; dashed lines indicate associations that are 
not statistically signifi cant. Associations are presented as regression coeffi  cients (β) and corresponding 95% 
confi dence intervals. All associations are adjusted for potential confounders: age, sex, education level, glucose 
metabolism status, body mass index, smoking, alcohol use, total/high density cholesterol ratio, triglycerides, 
mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication. 
5
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Supplemental Material
Item S1. Assessment of arterial stiffness
All measurements were done by trained vascular technicians unaware of the participants’ 
clinical or diabetes status, in a dark, quiet, temperature-controlled room (21-23°C). 
Participants were asked to refrain from smoking and drinking coffee or tea or alcoholic 
beverages three hours prior to the study. Participants were allowed to have a light meal 
(breakfast and(or) lunch). All measurements were performed in a supine position after 10 
minutes of rest. Talking or sleeping was not allowed during the examination. During the 
vascular measurements (approximately 45 minutes), brachial systolic, diastolic and mean 
arterial pressure (MAP) were determined every five minutes with an oscillometric device 
(Accutorr Plus, Datascope Inc., Montvale, NJ, USA). The mean MAP and heart rate (HR) of 
these measurements were used in the statistical analysis. A three-lead electrocardiogram 
was recorded continuously during the measurements to facilitate automatic signal 
processing. 
Carotid-femoral pulse wave velocity
Carotid-femoral pulse wave velocity (cfPWV) was determined according to recent 
guidelines1 with the use of applanation tonometry (SphygmoCor, Atcor Medical, Sydney, 
Australia). Pressure waveforms were determined at the right common carotid and right 
common femoral arteries. Difference in the time of pulse arrival from the R-wave of 
the electrocardiogram between the two sites (transit time) was determined with the 
intersecting tangents algorithm. The pulse wave travel distance was calculated as 80% 
of the direct straight distance (measured with an infantometer) between the two arterial 
sites. The median of three consecutive cfPWV (defined as traveled distance/transit time) 
recordings was used in the analyses. 
Local arterial elastic properties
Data acquisition. Measurements were done at the left common carotid (10 mm proximal 
to the carotid bulb) artery, with the use of an ultrasound scanner equipped with a 7.5-
MHz linear probe (MyLab 70, Esaote Europe B.V., Maastricht, the Netherlands). This setup 
enables the measurement of diameter, distension and intima-media thickness (IMT) as 
described previously. 2, 3 Briefly, during the ultrasound measurements a B-mode image 
on the basis of 19 M-lines was depicted on screen and an online echo-tracking algorithm 
showed real-time anterior and posterior arterial wall displacements. The M-mode 
recordings were composed of 19 simultaneous recordings at a frame rate of 498 Hz. The 
distance between the M-line recording positions was 0.96 mm; thus, a total segment 
of 18.24 mm of each artery was covered by the scan plane. For offline processing, the 
radiofrequency signal was fed into a dedicated PC-based acquisition system (ART.LAB, 
Esaote Europe B.V. Maastricht, the Netherlands) with a sampling frequency of 50 MHz 
Data processing was performed in MatLab (version 7.5, Mathworks, Natick, MA, USA). The 
distension waveforms were obtained from the radio frequency data with the use of a wall 
track algorithm.2 Carotid IMT was defined as the distance of the posterior wall from the 
leading edge interface between lumen and intima to the leading edge interface between 
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media and adventitia.3 The median diameter, distension, and IMT of three measurements 
were used in the analyses.
Data analysis. Local arterial elastic properties were quantified by calculating the following 
indices:4 
• Carotid Distensibility Coefficient (CarDC) 
• DC = (2DD * D + DD2) / (PP * D2) (10-3 kPa-1)
• Carotid Young’s elastic modulus (CarYEM)
• YEM = D / (IMT * DC) (103 kPa)
• Carotid Compliance Coefficient (CarCC)
• CC = p * (2D * DD + DD2) / 4PP (mm2 kPa-1)
Where D is arterial diameter; DD distension; IMT intima-media thickness; and PP brachial 
pulse pressure (calculated as systolic minus diastolic blood pressure). 
CarDC represents arterial stiffness; CarYEM, the stiffness of the arterial wall material at 
operating pressure; and CarCC, arterial buffering capacity.
Reproducibility
Reproducibility was assessed in 12 individuals (6 men; 60.8±6.8 years; 6 type 2 diabetes) 
who were examined by two observers at two occasions spaced one week apart. The intra- 
and inter-observer intra-class correlation coefficients were for cfPWV 0.87 and 0.69; for 
carDC 0.85 and 0.73; for CarYEM 0.72 and 0.71; for CarCC 0.95 and 0.72.
5
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Item S2. Brain magnetic resonance imaging measures
Brain magnetic resonance imaging (MRI) was performed on a 3T MRI scanner (Siemens 
Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany) by use of a 64-element 
head/neck coil for parallel imaging. The MRI protocol consisted of a 3D T1-weighted 
magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence (TR/TI/
TE 2300/900/2.98 ms, 176 slices, 256×240 matrix size, 1.00 mm cubic voxel size); a fluid-
attenuated inversion recovery (FLAIR) sequence (TR/TI/TE 5000/1800/394 ms, 176 slices, 
512×512 matrix size, 0.49×0.49×1.00 mm voxel size); a combined proton density (PD) 
and T2-weighted turbo spin echo (TSE) pulse sequence (TR/TE1/TE2 3200/9.4/94 ms, 30 
slices, 640×540 matrix size, 0.36×0.36×4.00 mm voxel size); and a susceptibility-weighted 
imaging (SWI) sequence (TR/TE 28/20 ms, 144 slices, 384×312 matrix size, 0.57×0.57×1.00 
mm voxel size).
Contra-indications for MRI assessments were the presence of a cardiac pacemaker or 
implantable cardioverter-defibrillator, neurostimulator, non-detachable insulin pump, 
metallic vascular clips or stents in the head, cochlear implant, metal-containing intra-
uterine device, metal splinters or shrapnel, dentures with magnetic clip, an inside bracket, 
pregnancy, epilepsy, and claustrophobia. 
T1-weighted images and FLAIR images were analyzed by use of an ISO-13485:2012 
certified, automated method (which included visual inspection).5, 6 T1-weighted images 
were segmented into grey matter, white matter and cerebrospinal fluid volumes (1 voxel 
= 1.00 mm3 = 0.001 ml).5 Intracranial volume was calculated as the sum of grey matter, 
white matter (including white matter hyperintensity volume) and cerebrospinal fluid 
volumes. Total brain parenchyma volume was calculated as the sum of grey and white 
matter volumes. White matter hyperintensities identified were summed to assess total 
white matter hyperintensities burden in milliliter. Lacunar infarcts were defined as focal 
brain parenchyma defects of ≥3 mm and <15 mm in size with a similar signal intensity 
as cerebrospinal fluid on all sequences and a hyperintense rim on T2 and FLAIR images
7. 
Cerebral microbleeds were rated on T2-weighted and SWI images by use of the Microbleed 
Anatomical Rating Scale8, and were defined as focal lesions of ≥2 mm and ≤10  mm in 
size with a hypointense signal7. The presence of lacunar infarcts and cerebral microbleeds 
was rated manually by three neuroradiologists. The two-way mixed effects, consistency, 
intraclass correlation coefficient for the three raters based on 50 randomly selected scans 
was 0.84 (95% confidence interval 0.74; 0.91) and 0.83 (0.72; 0.90) for the presence of 
lacunar infarcts and cerebral microbleeds, respectively.
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Item S3. Assessment of cognitive performance
The composite memory score was derived from the Verbal Learning Test by weighting 
total immediate and delayed recall scores. The domain information processing speed 
included the Stroop Color-Word Test Part I and II, the Concept Shifting Test Part A and 
B, and the Letter-Digit Substitution Test. Executive function was assessed by the Stroop 
Color-Word Test Part III and the Concept Shifting Test Part C. A description of the individual 
tests is provided below.
Raw test scores were transformed into z-scores. Standardized scores of the Stroop Color-
Word Test and Concept Shifting Test were inverted so that higher scores indicated better 
cognitive function. Thereafter, domain-specific scores were calculated as the standardized 
average of the z-scores from (sub)tests within that domain (e.g. memory = z-score of 
(z-score immediate recall + z-score delayed recall/ 2)). The standardized average of these 
domain scores was then considered a measure of overall cognitive function (i.e. overall 
cognitive function = z-score of (memory + information processing speed + executive 
function / 3)). 
Description of the individual cognitive tests used in the present study 
Verbal Learning Test:9 
Fifteen unrelated, monosyllabic, words were presented on a computer screen in five 
subsequent trials. After each trial, participants were instructed to recall as many words as 
possible in any order. Twenty minutes after the last trial, participants were asked again to 
reproduce the words. Outcomes recorded included the total number of words correctly 
recalled over the five trials (total immediate recall) and the number of correctly recalled 
words during delayed recall (delayed recall).
Stroop Color-Word Test:10
In this test, which consisted of three parts, participants were firstly asked to read aloud 
color names (i.e.  red, blue, yellow, and green) that were printed in black ink (Part I). 
Secondly, they were instructed to name solid color patches (Part II). Finally, participants 
had to name the ink color of color names that were printed in an incongruent color (e.g. 
participants were asked to say red when the word yellow was printed in red) (Part III). The 
time needed to complete Part III was adjusted for the average time needed to complete 
Part I and II. 
Concept Shifting Test:11
This test, a modification of the Trailing Making Test, consisted of four subtasks. During each 
subtask, participants were shown 16 small circles aligned along a larger imaginary circle. 
The small circles contained (a combination of ) digits, letters, or were empty. Participants 
were instructed to cross-out as quickly as possible the digits in ascending order (Part A), 
the letters in alphabetic order (Part B), and the letters and digits in alternating order (Part 
C). Thereafter, participants were asked to cross-out empty circles in a clockwise fashion in 
two consecutive trials (Part 0). In this way, test results could be accounted for basic motor 
speed. The time needed to complete subtasks A and B was adjusted for the average time 
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needed to complete Part 0, the time needed to completed Part C for the average time of 
Part A and B.
Letter-Digit Substitution Test:12
Participants were requested to match digits to letters according to a given key. This key 
included the numbers 1 to 9, each paired with a different letter. The outcome of interest 
was the number of correct substitutions within 90 seconds.
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Age, years 59.7 ± 8.1 59.9 ± 8.7



































Low, women ≤7; men ≤14 units/week







Total/high-density lipoprotein cholesterol ratio 3.7 ± 1.2 3.5 ± 1.1*
Triglycerides, mmol/L 1.4 ± 0.9 1.5 ± 0.8
Office systolic pressure, mmHg 134.9 ± 18.2 135.6 ± 18.3
Office diastolic pressure, mmHg 76.2 ± 9.9 75.8 ± 9.6
Heart rate during vascular measurement, bpm 62.5 ± 9.3 64.1 ± 9.9*
Use of antihypertensive medication 37.7 (959) 46.4 (419)*
Use of lipid-modifying medication 35.1 (893) 40.4 (365)*
Prior cardiovascular disease 16.2 (405) 18.3 (153)
Current depression 3.5 (88) 34 (4.4)
Composite score of plasma biomarkers of low-grade inflammation, SD 0.0 ± 1.0 0.0 ± 0.6
Measures of arterial stiffness
Carotid-femoral pulse wave velocity, m/s
Carotid artery – distensibility coefficient, 10-3kPa
Carotid artery – compliance coefficient, mm2/kPa









Measures of microvascular dysfunction
Microvascular dysfunction composite score 0.0 ± 1.0 -
Cerebral small vessel disease features
Total brain parenchyma volume, ml
White matter hyperintensity volume, ml
Presence of cerebral microbleeds
Presence of lacunar infarcts








Flicker light-induced arteriolar and venular dilation
Flicker light-induced arteriolar dilation, %














































Data are presented as mean ± standard deviation, median [interquartile range] or n(%). *denotes a statistically 
significantly difference from the complete group, assessed by the student’s t-test for normally distributed 
variables, Mann-Whitney U-test for skewed variables or Chi-square test for categorical variables. 
Table S2. Associations between carotid artery compliance coefficient and Young’s elastic modulus and the 
cognitive function composite score
Cognitive function composite score, per SD
Carotid stiffness measure Model β (95% CI)
Compliance coefficient, 10-3/kPa 1 -0.086 (-0.209; 0.037)
2 -0.075 (-0.197; 0.046)
3 -0.062 (-0.189; 0.066)
Young’s elastic modulus, 103/kPa 1 -0.096 (-0.183; -0.008)
2 -0.058 (-0.145; 0.029)
3 -0.045 (-0.137; 0.048)
Participants included in the analyses were n=2,544. Model 1: adjusted for age, sex, education level, Model 2: 
additionally adjusted for glucose metabolism status, body mass index, smoking, alcohol use, total/high-density 
lipoprotein ratio, triglycerides, and Model 3: additionally adjusted for mean arterial pressure, heart rate and use 
of anti-hypertensive and/or lipid-modifying medication. Abbreviations: CI = confidence interval; SD = standard 
deviation.
Table S3. Associations between arterial stiffness and domain-specific cognitive function scores
Memory function, 
per SD
Processing speed, per 
SD
Executive function, per 
SD




1 -0.022 (-0.04; -0.004) -0.024 (-0.041; -0.007) -0.030 (-0.048; -0.012)
2 -0.016 (-0.034; 0.002) -0.013 (-0.030; 0.004) -0.017 (-0.035; 0.001)





1 -0.001 (-0.008; 0.007) -0.006 (-0.013; 0.001) -0.010 (-0.018; -0.003)
2 0.000 (-0.007; 0.008) -0.004 (-0.011; 0.003) -0.008 (-0.016; -0.001)
3 0.003 (-0.005; 0.012) -0.007 (-0.015; 0.001) -0.007 (-0.015; 0.002)
Participants included in the analyses were n=2,544. Model 1: adjusted for age, sex, education level, Model 2: 
additionally adjusted for glucose metabolism status, body mass index, smoking, alcohol use, total/high-density 
lipoprotein ratio, triglycerides, and Model 3: additionally adjusted for mean arterial pressure, heart rate and use 
of anti-hypertensive and/or lipid-modifying medication. Abbreviations: CI = confidence interval; SD = standard 
deviation.
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Table S4. Associations between arterial stiffness and the cognitive function composite score, and the proportion 
explained by the microvascular dysfunction score after consecutively excluding from the microvascular 
dysfunction score each individual measure of microvascular dysfunction
Cognitive function 
composite score, per 
SD










Cerebral small vessel disease 
features
-0.018 (-0.036; -0.000) 10.8%
Flicker light-induced retinal 
arteriolar and venular dilation 
response
-0.018 (-0.036; -0.000) 14.1%
Urinary albumin excretion -0.018 (-0.036; -0.000) 11.5%
Plasma biomarkers of 
microvascular disease
-0.018 (-0.036; -0.000) 9.4%
Carotid distensibility 
coefficient, 10-3/kPa
Cerebral small vessel disease 
features
-0.004 (-0.012; 0.003) -
Flicker light-induced retinal 
arteriolar and venular dilation 
response
-0.004 (-0.012; 0.003) -
Urinary albumin excretion -0.004 (-0.012; 0.003) -
Plasma biomarkers of 
microvascular disease
-0.004 (-0.012; 0.003) -
*The effect explained by the ‘total’ microvascular dysfunction score was 16.2% of the total direct effect of cfPWV on 
the cognitive function composite score. †Data available for analyses after excluding cerebral small vessel disease 
features n=2,544; after excluding flicker light-induced retinal arteriolar and venular dilation response n=2,544; after 
excluding urinary albumin excretion n=2,541; and after excluding plasma biomarkers of microvascular dysfunction 
n=2,541. Results were adjusted for age, sex, education level, glucose metabolism status, body mass index, smoking, 
alcohol use, total/high density cholesterol ratio, triglycerides, mean arterial pressure, heart rate and use of anti-
hypertensive and/or lipid-modifying medication. Abbreviations: CI = confidence interval; SD = standard deviation.
Table S5. Associations between arterial stiffness and the cognitive function composite score additionally 
adjusted for prior cardiovascular disease, current depression, and plasma biomarkers of low-grade inflammation
Cognitive function composite score, per SD
Arterial stiffness Model β (95% CI)
Carotid-femoral pulse wave velocity, per m/s 1 -0.032 (-0.048; -0.016)
2 -0.019 (-0.035; -0.003)
3 -0.018 (-0.036; -0.000)
4a -0.019 (-0.037; -0.001)
4b -0.016  (-0.034; 0.002)
4c -0.019 (-0.037; -0.001)
Carotid artery distensibility coefficient, 10-3/kPa 1 -0.007 (-0.014; -0.000)
2 -0.005 (-0.012; 0.002)
3 -0.004 (-0.012; 0.003)
4a -0.004 (-0.011; 0.004)
4b -0.004 (-0.011; 0.004)
4c -0.005 (-0.012; 0.003)
Participants included in the analyses in model 1 to 3 were n=2,544. For analysis adjusted for prior cardiovascular 
disease, n=2,505; for analysis adjusted for current depression n=2,526; and for analysis adjusted for plasma 
biomarkers of low-grade inflammation n=2520. Model 1: adjusted for age, sex, education level, Model 2: 
additionally adjusted for glucose metabolism status, body mass index, smoking, alcohol use, total/high-density 
lipoprotein ratio, triglycerides,  Model 3: additionally adjusted for mean arterial pressure, heart rate and use of 
anti-hypertensive and/or lipid-modifying medication, Model 4a: Model 3 + prior cardiovascular disease, Model 
4b: Model 3 + current depression, and Model 4c: Model 3 + plasma biomarkers of low-grade inflammation. 
Abbreviations: CI = confidence interval; SD = standard deviation.
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Table S6. Associations between arterial stiffness and the cognitive function composite score additionally 
adjusted for type of antihypertensive medication
Cognitive function composite score, per SD
Arterial stiffness Model β (95% CI)
Carotid-femoral pulse wave velocity, per m/s 1 -0.032 (-0.048; -0.016)
2 -0.019 (-0.035; -0.003)
3 -0.018 (-0.036; 0.000)
Carotid artery distensibility coefficient, 10-3/kPa 1 -0.007 (-0.014; -0.000)
2 -0.005 (-0.012; 0.002)
3 -0.004 (-0.012; 0.003)
Participants included in the analyses were n=2,544. Model 1: adjusted for age, sex, education level, Model 2: 
additionally adjusted for glucose metabolism status, body mass index, smoking, alcohol use, total/high-density 
lipoprotein ratio, triglycerides, Model 3: additionally adjusted for mean arterial pressure, heart rate, use of lipid-
modifying medication and the individual classes of antihypertensive medication (i.e. beta blockers, diuretics, 
calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers). 
Abbreviations: CI = confidence interval; SD = standard deviation.
Table S7. Associations between arterial stiffness and the cognitive function composite score additionally 
adjusted for the diet score, moderate-to-vigorous physical activity, income level and occupational status
Cognitive function composite score, per SD
Arterial stiffness Model β (95% CI)
Carotid-femoral pulse wave velocity, per m/s 1 -0.036 (-0.055; -0.016)
2 -0.024 (-0.043; -0.004)
3 -0.028 (-0.050; -0.007)
4 -0.029 (-0.051; -0.007)
Carotid artery distensibility coefficient, 10-3/kPa 1 -0.003 (-0.011; 0.005)
2 -0.000 (-0.008; 0.008)
3 -0.000 (-0.009; 0.009)
4 -0.000 (-0.009; 0.009)
Participants included in the analyses were n=1,752. Model 1: adjusted for age, sex, education level, Model 2: 
additionally adjusted for glucose metabolism status, body mass index, smoking, alcohol use, total/high-density 
lipoprotein ratio, triglycerides, Model 3: additionally adjusted for mean arterial pressure, heart rate and use of 
anti-hypertensive and/or lipid-modifying medication, and Model 4: additionally adjusted for the diet score, 
moderate-to-vigorous physical activity and income level and occupational status. Abbreviations: CI = confidence 
interval; SD = standard deviation.
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Figure S1. Cumulative percentage of participants with data available on microvascular dysfunction measures
Adjusted for potential confounders: 










Additionally adjusted for the microvascular dysfunction score: 
β -0.004 (95% CI -0.012; 0.003)
Figure S2. Association between lower carotid artery distensibility coeffi  cient (per 10-3/kPa) and a lower cognitive 
function composite score (per SD), and the proportion explained by the microvascular dysfunction score (per 
SD). Solid lines indicate associations that are statistically signifi cant; dashed lines indicate associations that are 
not statistically signifi cant. Associations are presented as regression coeffi  cients (β) and corresponding 95% 
confi dence intervals. All associations are adjusted for the potential confounders age, sex, education level, glucose 
metabolism status, body mass index, smoking, alcohol use, total/high-density lipoprotein ratio, triglycerides, 
mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication. 
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Abstract
Microvascular dysfunction (MVD) contributes to stroke, dementia, depression, retinopathy 
and chronic kidney disease. The determinants of MVD, however, are incompletely 
identified. Greater blood pressure variability (BPV) may be such a determinant. To 
investigate whether greater very short- to mid-term BPV is associated with various MVD 
measures, we used cross-sectional data of The Maastricht Study (n=2,773, age 59.9 years; 
51.9% men; 28.2% type 2 diabetes mellitus [oversampled by design]). We standardized 
and averaged within-visit, 24-hour and 7-day BPV into a systolic and a diastolic BPV 
composite score. Measures of MVD included a composite score of MRI cerebral small vessel 
disease (CSVD) features (total brain parenchymal volume, white matter hyperintensity 
volume, lacunar infarcts and cerebral microbleeds), a composite score of retinal arteriolar 
and venular dilation response, albuminuria, skin hyperaemia and a composite score of 
plasma biomarkers of MVD (sICAM-1, sVCAM-1, sE-selectin and von Willebrand Factor). 
We used linear regression analyses with adjustments for age, sex, glucose metabolism 
status, mean 24-hour systolic or diastolic blood pressure and cardiovascular risk factors. 
We found that higher systolic and diastolic BPV composite scores (per SD) were associated 
with higher albuminuria (higher ratio in albuminuria, 1.04 [95%CI 1.00-1.08] and 1.07 
[1.03-1.11], respectively), but not with other MVD measures. In conclusion, greater systolic 
and diastolic BPV was associated with higher albuminuria, but not with CSVD features, 
retinal arteriolar and venular dilation response, skin hyperaemia and plasma biomarkers 
of MVD. This may suggest that the microvasculature of the kidneys is most vulnerable to 
the detrimental effects of greater BPV.
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Introduction 
Microvascular dysfunction (MVD) is an important contributor to various diseases that are (in 
part) of microvascular origin, including stroke,1 dementia,1 depression,1 retinopathy,2 and 
chronic kidney disease.3 However, the determinants of MVD are incompletely identified, but 
greater blood pressure variability (BPV), i.e. greater fluctuations of blood pressure over time, 
may be involved. 
Greater BPV may lead to MVD both via increases in pulsatile pressure that can penetrate 
distally and damage the microcirculation,4 and sudden falls in blood pressure leading to 
reduced microvascular perfusion.5 The microvascular beds of organs with low vascular 
impedance (i.e. the microvasculature of the brain, eyes and kidneys) may be particularly 
vulnerable for these fluctuations in blood pressure.4
Microvascular function can be measured noninvasively in various organs. These measures 
include magnetic resonance imaging (MRI) features of cerebral small vessel disease (CSVD, 
i.e. lower total brain parenchyma volume, higher white matter hyperintensity volume, 
and presence of lacunar infarcts and cerebral microbleeds);6 flicker light-induced retinal 
arteriolar and venular dilation response;7 albuminuria (“urinary albumin excretion”, UAE);8 
heat-induced skin hyperaemia;7 and plasma biomarkers of MVD (i.e. soluble intercellular 
adhesion molecule-1 [sICAM-1], soluble vascular adhesion molecule-1 [sVCAM-1], soluble 
E-selectin [sE-selectin] and von Willebrand factor [vWF]).9 
The associations between BPV and most of these various MVD measures remain, however, 
incompletely understood. To date, only five studies have evaluated the association 
between BPV and CSVD features. These studies found an association between greater 
very short- to short-term systolic and diastolic BPV and cerebral atrophy,10, 11 higher white 
matter hyperintensity volume,10-13 lacunar infarcts,10, 12 and enlarged perivascular spaces.10, 
14 However, these studies were relatively small (n=<155),11, 13 done in selected populations 
(i.e. individuals with hypertension,12 aged 70 years and older,15 or admitted to the hospital10, 
14) or did not adjust for potentially important confounders (i.e. mean blood pressure11, 13 or 
lifestyle factors12). For UAE, most previous studies,16-27 but not all,28-30 found an association 
with greater very short-to mid-term systolic or diastolic BPV. However, these studies did 
not adjust for potentially important confounders, including dietary habits and physical 
activity. For plasma biomarkers of MVD, only one study has been done, which included 
190 individuals with newly diagnosed hypertension. This study found an association 
between greater short-term systolic BPV and higher sE-selectin.31 Currently, no studies have 
investigated the association between BPV and retinal arteriolar and venular dilation or skin 
hyperaemia.
In view of the above, we investigated, in a large population-based cohort, whether very 
short- to mid-term BPV (i.e. within-visit, 24-hour and 7-day BPV) is associated with a 
comprehensive set of MVD measures, including CSVD features, retinal arteriolar and venular 
dilation response, UAE, skin hyperaemia and plasma biomarkers of MVD. We hypothesized 
that greater BPV would be more strongly associated with MVD in organs with a low vascular 
impedance, i.e. brain, eyes and kidneys, and would not be associated with MVD in organs 
with a high vascular impedance, e.g. skin.
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Material and methods
Study population and design 
We used data from The Maastricht Study, an observational population-based cohort 
study. The rationale and methodology have been described previously.32 In brief, the 
study focuses on the aetiology, pathophysiology, complications and comorbidities 
of diabetes mellitus type 2 (T2D) and is characterized by an extensive phenotyping 
approach. Eligible for participation were all individuals aged between 40 and 75 years and 
living in the southern part of the Netherlands. Participants were recruited through mass 
media campaigns, the municipal registries and the regional Diabetes Patient Registry via 
mailings. Recruitment was stratified according to known T2D status, with an oversampling 
of individuals with T2D for reasons of efficiency. The present report includes cross-sectional 
data from 3,451 participants who completed the baseline survey between November 
2010 and September 2013. The examinations of each participant were performed within 
a time window of three months. The study has been approved by the institutional medical 
ethical committee (NL31329.068.10) and the Minister of Health, Welfare, and Sports of the 
Netherlands (Permit 131088-105234-PG). All participants gave written informed consent. 
Data are available from The Maastricht Study for any researcher who meets the criteria for 
access to confidential data, and the corresponding author may be contacted to request 
data.
Blood pressure measurements and determination of blood pressure variability
A detailed description of the office, 24-hour ambulatory and 7-day home blood pressure 
measurements and determination of BPV has been reported previously.33 Briefly, within-
visit BPV was calculated as the standard deviation (SD) of three consecutive office blood 
pressure measurements, with a 1-minute interval, after ten minutes of rest. 24-hour BPV 
was calculated as the average real variability of blood pressure readings taken every 15 
minutes between 08:00 A.M. and 11:00 P.M., and every 30 minutes between 11:00 P.M. – 
08.00 A.M.. 7-day BPV was calculated as the SD of home blood pressure measurements 
taken twice, with a 1-minute interval, each morning and evening, for 7 consecutive days. 
Microvascular dysfunction measures
For all MVD measures, participants were asked to refrain from smoking and drinking 
caffeine-containing beverages three hours before the measurement.34 A light meal was 
allowed until ≥90 minutes prior to the examination.  For retinal measurements, pupils 
were dilated with 0.5% tropicamide and 2.5% phenylephrine ≥15 minutes before the 
start of the examination. Skin blood flow measurements were performed in a climate-
controlled room at 24 °C.35 
Features of cerebral small vessel disease
Brain MRI measurements were implemented from December 2013 onwards and were 
available in 2,313 of the 3,451 participants (67%). Brain MRI was performed on a 3T 
MRI scanner (Siemens Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany). We 
evaluated four MRI CSVD features, i.e. total brain parenchyma volume, white matter 
hyperintensity volume, lacunar infarcts and cerebral microbleeds. A detailed description 
of the MRI protocol is provided in Item S1 (Supplementary Material). Briefly, the MRI 
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protocol consisted of a 3D T1-weighted sequence, T2-weighted fluid-attenuated inversion 
recovery (FLAIR), and a gradient recalled echo (GRE) pulse sequence with susceptibility-
weighted imaging (SWI).36 T1-weighted images and FLAIR images were analyzed by use 
of an automated method.37, 38 T1-weighted images were segmented into grey matter, 
white matter and cerebrospinal fluid volumes.37 Intracranial volume was calculated as 
the sum of grey matter, white matter (including white matter hyperintensity volume) and 
cerebrospinal fluid volumes. Total brain parenchyma volume was calculated as the sum 
of grey and white matter volumes. T1-weighted and FLAIR images were used to identify 
white matter hyperintensities.38 White matter hyperintensity volume was summed to 
assess total white matter hyperintensity burden. Lacunar infarcts were defined as focal 
brain parenchyma defects of ≥3 mm and <15mm in size with a similar signal intensity as 
cerebrospinal fluid on all sequences and a hyperintense rim on FLAIR images.6 Cerebral 
microbleeds were rated on three-dimensional T2* GRE imaging with SWI by use of the 
Microbleed Anatomical Rating Scale,39 and were defined as focal lesions of ≥2 mm and 
≤10mm in size with a hypointense signal.6 The presence of lacunar infarcts and cerebral 
microbleeds was rated manually by three neuroradiologists. The intraclass correlation 
coefficients for the three raters based on 50 randomly selected scans were 0.84 (95% 
confidence interval [95%CI] 0.74-0.91) and 0.83 (0.72-0.90) for the presence of lacunar 
infarcts and cerebral microbleeds, respectively.
Flicker light-induced retinal arteriolar and venular dilation response
We measured retinal arteriolar and venular dilation to flicker light exposure by the Dynamic 
Vessel Analyzer (Imedos, Jena, Germany), as previously described.7, 40 Briefly, a baseline 
recording of 50 seconds was followed by 40-second flicker light exposure followed by 
a 60-second recovery period. We calculated baseline diameters (in measurement units) 
as the average diameter during the 20-50 seconds recording. For both the arteriolar and 
venular dilation, percentage dilation over baseline was calculated using the average 
dilation achieved at time points 10 and 40 seconds during the flicker stimulation period. 
Urinary albumin excretion 
To assess UAE, participants were requested to collect two 24-hour urine samples. Urinary 
albumin concentration was measured with a standard immunoturbidimetric assay by an 
automatic analyzer (due to a change of supplier, by the Beckman Synchron LX20 and the 
Roche Cobas 6000) and multiplied by collection volume to obtain 24-hour UAE. A urinary 
albumin concentration below the detection limit of the assay was set at 1.5 mg/L (2 mg/L 
for the Beckman Synchron LX20 and 3 mg/L for the Roche Cobas 6000) before multiplying 
by collection volume. Only urine collections with a collection time between 20 and 28 
hours were considered valid. If needed, UAE was extrapolated to 24-hour excretion. 
For this study, UAE was preferably based on the average of two (available in 91.3% of 
participants) 24-hour urine collections.
Heat-induced skin hyperaemia
We measured heat-induced skin hyperaemia by laser Doppler flowmetry (Perimed, 
Järfälla, Sweden), as previously described.7 Briefly, skin blood flow at the wrist, expressed 
in arbitrary perfusion units (PU), was recorded unheated for two minutes to serve as a 
baseline. After two minutes, the temperature of the laser Doppler probe was rapidly 
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and locally increased to 44°C and was kept constant until the end of the registration. 
Skin hyperaemia was expressed as the percentage increase in average PU during the 23 
minutes heating phase over the two minutes average baseline PU. 
Plasma biomarkers of microvascular dysfunction
We measured four plasma biomarkers of MVD: sICAM-1, sVCAM-1, sE-selectin and 
vWF.41 sICAM-1, sVCAM-1 and sE-selectin were measured in EDTA plasma samples with 
commercially available 4-plex sandwich immunoassay kits with different standards 
and antibodies (Meso Scale Discovery, Rockville, Maryland, United States of America). 
For this technique in this study, the intra- and inter-assay coefficients of variation were 
10.3 and 8.4% for sICAM-1, 5.0 and 4.7% for sVCAM-1, and 2.9 and 7.4% for sE-selectin, 
respectively. Von Willebrand Factor (vWF) was quantified in citrate plasma using ELISA 
(Dako, Glostrup, Denmark). The intra- and inter-assay coefficients of variation were 3.0 and 
4.3%, respectively. 
Covariates
We determined glucose metabolism status according to the World Health Organization 
2006 criteria as normal glucose metabolism, prediabetes or T2D.42 Education level was 
classified into three groups: low (none, primary or lower vocational education only), 
intermediate (intermediate general secondary, intermediate vocational or higher general 
secondary education) and high (higher vocational education or university level of 
education). We determined alcohol consumption (none, low [women ≤7, men ≤14 units/
week], high [women >7, men >14 units/week]), smoking status (never, former, current), 
medication use, body mass index, total/high density lipoprotein (HDL) cholesterol ratio and 
prior cardiovascular disease as described previously.7, 8, 32 Estimated glomerular filtration 
rate (eGFR) was computed with the CKD-EPI (Chronic Kidney Disease Epidemiology 
collaboration) formula using serum creatinine and cystatin C.43 Plasma biomarkers 
of low-grade inflammation (i.e. high-sensitive C-reactive protein, serum amyloid A, 
interleukin-6, interleukin-8 and tumor necrosis factor alpha) were determined as described 
previously.32, 44 Carotid-femoral pulse wave velocity, a measure of aortic stiffness,44 was 
measured according to international guidelines45 with the use of applanation tonometry 
(Sphygmocor, Atcor Medical, Sydney Australia) at the right common carotid and right 
common femoral arteries. As described previously, we used questionnaires to assess the 
Mediterranean diet score (“diet score”),46 moderate-to-vigorous physical activity32 and 
socio-economic status (income level and occupation status).47 
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Statistical analysis
We inversed (multiplying by -1) total brain parenchyma volume, retinal arteriolar 
and venular dilation response and skin hyperaemia so that higher values indicated 
worse microvascular function. White matter hyperintensity volume and UAE were log-
transformed (base 2) to normalize their skewed distribution. 
We summarized the three BPV measures (i.e. within-visit, 24-hour and 7-day BPV) into a 
systolic and diastolic BPV composite score, as done previously.48 We hypothesized that 
each BPV measure is associated with MVD according to similar underlying mechanisms. 
Furthermore, a composite score reduces the influence of the biological variability of its 
components,49 and it reduces the chance of a type 1 error. The BPV composite scores were 
calculated when at least data on two of the three BPV measures were available. The scores 
were calculated by summation and averaging of the z-scores of the three systolic and 
diastolic BPV measures, respectively. 
We also calculated separate composite scores for the CSVD features, for the retinal arteriolar 
and venular dilation response and for the plasma biomarkers of MVD, respectively. The 
CSVD composite score was calculated as described previously;50 one point per CSVD 
feature was assigned based on the following cut-offs: for lower total brain parenchyma 
volume quartile 1 vs. quartiles 2 to 4; for higher white matter hyperintensity volume 
quartile 4 vs. quartiles 1 to 3; and for lacunar infarcts and cerebral microbleeds presence 
vs. absence. The points for each feature were combined to compute the CSVD composite 
score (range 0-4). The composite scores for retinal arteriolar and venular dilation and 
plasma biomarkers of MVD were calculated by summation and averaging of the z-scores 
of the retinal arteriolar and venular dilation responses and the four plasma biomarkers of 
MVD, respectively. 
We used linear regression to investigate the association between the systolic and diastolic 
BPV composite scores and the CSVD composite score, the retinal arteriolar and venular 
dilation composite score, UAE, skin hyperaemia and the plasma biomarkers of MVD 
composite score. All analyses were adjusted for age and sex (model 1), and additionally for 
glucose metabolism status (model 2), mean 24-hour systolic or diastolic blood pressure 
(where appropriate) (model 3), and education level, body mass index, smoking status, 
alcohol consumption, total/HDL cholesterol ratio, lipid-modifying medication, and the 
individual classes of antihypertensive medication (i.e. beta blockers, diuretics, calcium 
channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor 
blockers) (model 4). For analyses with log-transformed UAE as the outcome, regression 
coefficients were back-transformed and expressed as higher ratio per SD higher systolic 
and diastolic BPV.
We tested interaction terms with age,51 sex52 and glucose metabolism status53 to evaluate 
whether the association between the BPV composite scores and the MVD measures 
differed according to these factors. 
206   |   Chapter 6
Several sensitivity analyses were performed. First, we repeated the analysis with the 
individual BPV measures as the determinant, i.e. within-visit, 24-hour and 7-day systolic and 
diastolic BPV. Second, we repeated the analysis using as the outcome the individual CSVD 
features, the individual retinal arteriolar and venular dilation response and the individual 
plasma biomarkers of MVD, respectively. Third, we repeated the analysis with additional 
adjustment for eGFR, prior cardiovascular disease, plasma biomarkers of low-grade 
inflammation, and carotid-femoral pulse wave velocity. These covariates were entered 
into a separate model because of the risk of overadjustment bias: these factors may be 
confounders, but may also mediate any association between BPV and MVD. Fourth, we 
repeated the analysis additionally adjusting for the diet score, and moderate-to-vigorous 
physical activity, and for income level and occupation status (instead of education level). 
Adjustment for these potential confounders was not included in the main analysis, 
because data were missing in a relatively large number of participants (n=1,133 missed 
data on one or more of these variables). Fifth, we used micro-albuminuria defined as ≥30 
mg/24h vs. <30 mg/24h as the outcome instead of UAE per mg/24h.54 Sixth, we repeated 
the analysis with eGFR (continuously and categorically [≥60 vs. <60 ml/min/1.73m2]) as 
the outcome. 
All statistical analyses were performed with Statistical Package for Social Sciences (v22.0; 
IBM, Chicago, Illinois). A P value of <.05 was considered statistically significant. 
Results
Study population 
Figure 1 shows the derivation of the study population. In total, 2,773 participants had 
data available on the BPV composite scores, all potential confounders and at least one 
MVD measure, and were included in the analysis. CSVD features were available in 1,837 
participants, retinal arteriolar and venular dilation response in 1,844, UAE in 2,748, skin 
hyperaemia in 1,320, and plasma biomarkers of MVD in 2,726. These subpopulations were 
comparable with regard to age, sex and cardiovascular risk profile (Supplemental Table 
S1). Participants excluded due to missing data had greater BPV and higher body mass 
index and more often had prior cardiovascular disease compared with those without 
missing data (Supplemental Table S1). 
Table 1 and Supplemental Table S2 show the general characteristics for the total study 
population and according to tertiles of the systolic BPV composite score. Supplemental 
Table S3 shows the characteristics according to tertiles of the diastolic BPV composite 
score. The mean age was 59.9 years, 51.9% were men and 26.9% had T2D. In general, 
participants with the highest compared with the lowest tertile of the systolic BPV 
composite score were older, less often male, had a worse cardiovascular risk profile and 
more often used lipid-modifying and antihypertensive medication.
Blood pressure variability and microvascular dysfunction
Higher systolic and diastolic BPV composite scores were associated with higher UAE (1.04 
[95%CI 1.00-1.08] and 1.07 [1.03-1.11] higher ratio per 1 SD higher systolic and diastolic 
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BPV composite score, respectively), after adjustment for all potential confounders 
(Table 2, model 4). Systolic and diastolic BPV composite scores were not associated with 
the other MVD measures: the CSVD composite score, the retinal arteriolar and venular 
dilation response composite score, skin hyperaemia, and the plasma biomarkers of MVD 
composite score, after full adjustment (Table 2, model 4).
We did not observe consistent interactions with age, sex or glucose metabolism status 
for the associations between systolic and diastolic BPV and any of the MVD measures 
(Supplemental Table S4).
Sensitivity analyses
Of the individual systolic and diastolic BPV measures, 24-hour diastolic BPV was associated 
with a higher CSVD composite score, retinal arteriolar and venular dilation response 
composite score and UAE; 7-day systolic BPV was associated with a higher CSVD composite 
score and plasma biomarkers of MVD composite score; and 7-day diastolic BPV with higher 
UAE and a higher plasma biomarkers of MVD composite score (Supplemental Table S5). 
When we repeated the analysis using each individual MVD measure as the outcome, the 
systolic and diastolic BPV composite scores were associated with higher levels of sVCAM-1 
and the systolic BPV composite score with higher levels of vWF (Supplemental Table S6). 
Results were similar when we additionally adjusted for eGFR, prior cardiovascular disease, 
plasma biomarkers of low-grade inflammation, carotid-femoral pulse wave velocity, the 
diet score, moderate-to-vigorous physical activity, or income level and occupation status 
(Supplemental Tables S7-S14). Each SD higher BPV composite score was associated with 
higher odds of UAE ≥30 mg/24h; odds ratios were 1.19 (95%CI 1.02 – 1.38) for systolic BPV 
and 1.19 (95%CI 1.02 – 1.37) for diastolic BPV (Figure 2 and Supplemental Table S15). The 
systolic and diastolic BPV composite scores were not associated with eGFR (Supplemental 
Table S16). 
Discussion 
We found that greater very short- to mid-term systolic and diastolic BPV are associated 
with higher UAE, but not with other measures of MVD tested, i.e. the CSVD composite 
score, retinal arteriolar and venular dilation response composite score, skin hyperaemia 
and the plasma biomarkers of MVD composite score. The association with higher UAE was 
independent of age, sex, mean 24-hour systolic or diastolic blood pressure, education level, 
and lifestyle and cardiovascular risk factors. The strength of this association corresponds 
to a 1.2 higher odds of UAE ≥30 mg/24h as compared to a UAE of <30 mg/24h per SD 
higher systolic or diastolic BPV composite score.
Our study findings are in agreement with most,16-27 but not all,28-30 previous studies 
that investigated the association between BPV and UAE. Our study adds to the existing 
literature on UAE, because we were able to study this association in the context of various 
other MVD measures, and adjusted for potentially important confounders, including 
dietary habits physical activity. Previous studies on BPV and UAE did not adjust for these 
potential confounders.
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In disagreement with our hypothesis, we did not find an association between greater BPV 
and MVD measured in organs with low microvascular impedance other than the kidneys, 
i.e. the brain and eyes, and with plasma biomarkers of MVD, which at least partly reflect 
MVD in organs with low microvascular impedance. A possible explanation is that the 
kidney microvasculature has a lower impedance than the brain and eye microvasculature, 
e.g. blood flow to the kidneys relative to organ weight (360 ml/min/100 g kidney tissue) 
is higher than to the brain (50 ml/min/100 g brain tissue).55 The kidney microvasculature 
may, therefore, in comparison be most vulnerable to the detrimental effects of BPV. 
Although we found no significant associations between greater BPV and CSVD features, 
retinal arteriolar and venular dilation response and plasma biomarkers of MVD, these 
measures nevertheless reflect MVD in organs with low vascular impedance and may thus 
be vulnerable to an increased pulsatile load,56 albeit to a lesser extent than UAE. Indeed, 
we found positive associations that were quantitatively similar for CSVD features, retinal 
arteriolar and venular dilation response, and plasma biomarkers of MVD. Estimations of 
these associations may have been more inaccurate (i.e. broader confidence intervals), 
because of higher measurement errors in these MVD measures as compared with UAE; 
CSVD features, retinal arteriolar and venular dilation response, and plasma biomarkers of 
MVD were measured only once, whereas UAE was based on two 24-hour urine samples. In 
addition, estimations of the associations may also have been more inaccurate  with CSVD 
features and retinal arteriolar and venular dilation response due to relatively few available 
data (n=1,837 and n=1,844, respectively) as compared with UAE (n=2,748).
As expected, we did not find an association between BPV and skin hyperaemia. The 
skin has relatively high microvascular impedance,4 and, therefore, most of the increased 
pulsatile energy related to greater BPV may be dissipated by arteries and large arterioles 
proximal to the skin capillaries.57
Strengths of this study include the large study population of community-dwelling 
participants, assessment of microvascular function in various vascular beds and the 
extensive adjustment for potential confounders. 
Our study has several limitations. First, our cross-sectional data preclude reaching causal 
conclusions about the study findings. Indeed, the reverse association may hold true as 
well, i.e. higher UAE (as a reflection of worse kidney function) may lead to greater BPV.58 
However, when we additionally adjusted our analyses for estimated glomerular filtration 
rate, results were similar. Second, the association between greater BPV and UAE may be 
the result of residual confounding due to low-grade inflammation,59, 60 arterial stiffening,4, 
61 activation of the renin-angiotensin system,62, 63 unhealthy dietary habits,64, 65 physical 
inactivity66, 67 and lower socio-economic status.68, 69 However, when we adjusted for low-
grade inflammation, carotid-femoral pulse wave velocity, the diet score, moderate-to-
vigorous physical activity and factors related to socio-economic status (i.e. education, 
income level and occupation status), results did not materially change. In this study, no 
data were available on activation of the renin-angiotensin system, however, and this 
issue requires further study. Third, we may have underestimated the association between 
greater BPV and MVD, because individuals excluded for the present analysis due to 
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missing data had greater BPV and a higher prevalence of prior cardiovascular disease than 
those included in the analysis. Fourth, the study population consisted mainly of middle-
aged individuals who were relatively well-educated and whose cardiovascular risk factors 
were relatively well-controlled. This may have led to an underestimation of the association 
between BPV and MVD. Finally, the study population consisted mainly of individuals from 
Caucasian ethnicity and the results may not be generalizable to other ethnicities. 
Perspectives
In conclusion, this large, relatively healthy population-based study showed that greater 
very short- to mid-term systolic and diastolic BPV was associated with higher UAE, but 
not with other measures of MVD tested, i.e. CSVD features, retinal arteriolar and venular 
dilation response, skin hyperaemia and plasma biomarkers of MVD. This may suggest that 
the microvasculature of the kidneys is most vulnerable to the detrimental effects of greater 
BPV. Future longitudinal studies should  be performed to assess the temporality of these 
associations, and, if confirmed, intervention studies should  assess whether lowering BPV 
will prevent albuminuria.
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Figure legend




Excluded due to a diabetes type other than 
type 2: n = 41
At least 2 BPV-indices
n = 3,234
Missing data on:
• Within-visit and 24-hour BPV (n = 1)
• Within-visit and 7-day BPV (n = 2)
• 24-hour and 7-day BPV (n = 173)
Complete data on potential 
confounders
n = 2,773
Missing data on potential confounders:*
• Education level (n = 72)
• Body mass index (n = 3)
• Smoking status (n = 59)
• Alcohol use (n = 65)
• Lipid profile (n = 4)
• Medication use (n = 4)
• Mean 24-hour blood pressure (n = 374)
Complete data on cerebral 
small vessel disease 
features
n = 1,837
Complete data on heat-
induced skin hyperaemia
n = 1,320
Complete data on urinary 
albumin excretion
n = 2,748




Complete data on flicker 
light-induced retinal 
arteriolar and venular 
dilation response
n = 1,844
Figure 1 Flowchart delineating the derivation of the study population.
*not mutually exclusive.
Abbreviations: BPV, blood pressure variability 
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Figure 2. Associations of systolic and diastolic blood pressure variability composite scores with urinary albumin 
excretion dichotomized as ≥30 mg/24h vs. <30 mg/24h. Point estimates represent the odds ratio of urinary 
albumin excretion per standard deviation higher systolic or diastolic BPV composite score. Results are adjusted 
for age, sex, glucose metabolism status, mean 24-hour systolic or diastolic blood pressure (where appropriate), 
education level, body mass index, smoking status, alcohol consumption, total/high density lipoprotein cholesterol 
ratio, lipid-modifying medication, and the individual classes of antihypertensive medication. Abbreviations: BPV, 
blood pressure variability; CI, confidence interval; OR, odds ratio; UAE, urinary albumin excretion.
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Table 2. Associations between systolic and diastolic blood pressure variability composite scores and 
microvascular dysfunction measures
Systolic blood pressure 
variability composite 
score, per SD
Diastolic blood pressure 
variability composite 
score, per SD
Microvascular dysfunction measure Model β (95% CI) β (95% CI)
Cerebral small vessel disease features 
composite score, per point
1 0.047 (0.011 – 0.083) 0.049 (0.013 – 0.088)
2 0.036 (0.000 – 0.073) 0.043 (0.005 – 0.081)
3 0.023 (-0.015 – 0.051) 0.036 (-0.003 – 0.074)
4 0.016 (-0.021 – 0.054) 0.030 (-0.008 – 0.069)
Retinal arteriolar and venular dilation 
composite score, per SD
1 0.033 (-0.014 – 0.081) 0.021 (-0.030 – 0.071)
2 0.021 (-0.027 – 0.069) 0.014 (-0.036 – 0.064)
3 0.030 (-0.020 – 0.081) 0.027 (-0.023 – 0.078)
4 0.031 (-0.019 – 0.082) 0.025 (-0.025 – 0.076)
Urinary albumin excretion, higher 
ratio 
1 1.14 (1.10 - 1.18) 1.13 (1.09 - 1.17)
2 1.11 (1.07 - 1.15) 1.11 (1.09 - 1.15)
3 1.05 (1.01 - 1.09) 1.09 (1.09 - 1.13)
4 1.04 (1.00 - 1.08) 1.07 (1.03 - 1.11)
Skin hyperaemia, per SD 1 0.027 (-0.029 – 0.083) 0.007 (-0.050 – 0.064)
2 0.006 (-0.051 – 0.063) -0.009 (-0.066 – 0.048)
3 -0.001 (-0.060 – 0.058) -0.006 (-0.064 – 0.052)
4 0.005 (-0.054 – 0.065) -0.003 (-0.061 – 0.055)
Plasma biomarkers of microvascular 
dysfunction composite score, per SD
1 0.089 (0.052 – 0.126) 0.082 (0.043 – 0.120)
2 0.052 (0.015 – 0.088) 0.054 (0.017 – 0.092)
3 0.057 (0.019 – 0.095) 0.056 (0.018 – 0.093)
4 0.035 (-0.001 – 0.072) 0.023 (-0.013 – 0.060)
Model 1: adjusted for age, sex; model 2: model 1 + glucose metabolism status; model 3: model 2 + mean 24-
hour systolic or diastolic blood pressure (where appropriate); model 4: model 3 + education level, body mass 
index, smoking status, alcohol consumption, total/high density lipoprotein cholesterol ratio, lipid-modifying 
medication, and the individual classes of antihypertensive medication (i.e. beta blockers, diuretics, calcium 
channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers). 
Abbreviations: CI: confidence interval; SD: standard deviation.
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Supplemental Material
Item S1 Brain magnetic resonance imaging
Brain magnetic resonance imaging (MRI) was performed on a 3T MRI scanner (Siemens 
Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany) by use of a 64-element 
head/neck coil for parallel imaging. The MRI protocol consisted of a 3D T1-weighted 
magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence (TR/TI/
TE 2300/900/2.98 ms, 176 slices, 256×240 matrix size, 1.00 mm cubic voxel size); a fluid-
attenuated inversion recovery (FLAIR) sequence (TR/TI/TE 5000/1800/394 ms, 176 slices, 
512×512 matrix size, 0.49×0.49×1.00 mm voxel size); a combined proton density (PD) 
and T2-weighted turbo spin echo (TSE) pulse sequence (TR/TE1/TE2 3200/9.4/94 ms, 30 
slices, 640×540 matrix size, 0.36×0.36×4.00 mm voxel size); and a susceptibility-weighted 
imaging (SWI) sequence (TR/TE 28/20 ms, 144 slices, 384×312 matrix size, 0.57×0.57×1.00 
mm voxel size).
Contra-indications for MRI assessments were the presence of a cardiac pacemaker or 
implantable cardioverter-defibrillator, neurostimulator, non-detachable insulin pump, 
metallic vascular clips or stents in the head, cochlear implant, metal-containing intra-
uterine device, metal splinters or shrapnel, dentures with magnetic clip, an inside bracket, 
pregnancy, epilepsy, and claustrophobia. 
T1-weighted images and FLAIR images were analyzed by use of an ISO-13485:2012 
certified, automated method (which included visual inspection).1, 2 T1-weighted images 
were segmented into grey matter, white matter and cerebrospinal fluid volumes (1 voxel 
= 1.00 mm3 = 0.001 ml).1 Intracranial volume was calculated as the sum of grey matter, 
white matter (including white matter hyperintensity volume) and cerebrospinal fluid 
volumes. Total brain parenchyma volume was calculated as the sum of grey and white 
matter volumes. White matter hyperintensities identified were summed to assess total 
white matter hyperintensities burden in milliliter. Lacunar infarcts were defined as focal 
brain parenchyma defects of ≥3 mm and <15 mm in size with a similar signal intensity 
as cerebrospinal fluid on all sequences and a hyperintense rim on T2 and FLAIR images.
3 
Cerebral microbleeds were rated on T2-weighted and SWI images by use of the Microbleed 
Anatomical Rating Scale,4 and were defined as focal lesions of ≥2 mm and ≤10  mm in 
size with a hypointense signal.3 The presence of lacunar infarcts and cerebral microbleeds 
was rated manually by three neuroradiologists. The two-way mixed effects, consistency, 
intraclass correlation coefficients for the three raters based on 50 randomly selected scans 
were 0.84 (95% confidence interval 0.74; 0.91) and 0.83 (0.72; 0.90) for the presence of 
lacunar infarcts and cerebral microbleeds, respectively.
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Supplemental Table S4. P values of interactions with age, sex, and glucose metabolism status
Systolic blood pressure 
variability composite 
score
Diastolic blood pressure 
variability composite score
Interaction with age (<60 vs.  ≥60 years)
Cerebral small vessel disease features 0.465 0.226
Retinal arteriolar and venular dilation 0.916 0.461
Urinary albumin excretion 0.039 * 0.171
Skin hyperaemia 0.579 0.779
Plasma biomarkers of MVD 0.389 0.046 *
Interaction with sex
Cerebral small vessel disease features 0.782 0.955
Retinal arteriolar and venular dilation 0.458 0.788
Urinary albumin excretion <0.001 † <0.001 †
Skin hyperaemia 0.450 0.413
Plasma biomarkers of MVD 0.150 0.013 †
Interaction with glucose metabolism status Prediabetes Type 2 
diabetes
Prediabetes Type 2 
diabetes
Cerebral small vessel disease features 0.803 0.030 ‡ 0.503 0.080
Retinal arteriolar and venular dilation 0.959 0.132 0.473 0.066
Urinary albumin excretion 0.639 0.121 0.628 0.057
Skin hyperaemia 0.681 0.799 0.449 0.816
Plasma biomarkers of MVD 0.050 0.652 0.107 0.011 ‡
*For statistically significant interactions with age, associations appeared stronger in individuals ≥ 60 years. †For 
statistically significant interactions with sex, associations appeared stronger in men. ‡For statistically significant 
interactions with glucose metabolism status, associations with cerebral small vessel disease features appeared 
stronger in individuals with normal glucose metabolism status, whereas associations with plasma biomarkers 
of MVD appeared stronger in individuals with type 2 diabetes. Abbreviations: MVD, microvascular dysfunction.  
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Supplemental Table 6. Associations between systolic and diastolic blood pressure variability and individual 
measures of microvascular dysfunction
Systolic blood pressure 
variability composite 
score, per SD
Diastolic blood pressure 
variability composite
 score, per SD
Microvascular dysfunction Model OR (95% CI) OR (95% CI)
Cerebral small vessel disease features
Total parenchymal brain volume, 1 1.05 (0.93 – 1.19) 1.12 (0.98 – 1.28)
low vs. high 2 1.02 (0.90 – 1.16) 1.11 (0.97 – 1.27)
3 1.05 (0.92 – 1.20) 1.12 (0.98 – 1.29)
4 1.01 (0.88 – 1.16) 1.09 (0.94 – 1.25)
White matter hyperintensity volume, 1 1.13 (1.01 – 1.28) 1.06 (0.93 – 1.20)
high vs. low 2 1.11 (0.98 – 1.25) 1.04 (0.92 – 1.19)
3 1.01 (0.89 – 1.15) 0.97 (0.85 – 1.11)
4 1.00 (0.87 – 1.14) 0.96 (0.84 – 1.11)
Cerebral microbleeds, presence vs. 1 1.12 (0.96 – 1.30) 1.09 (0.92 – 1.28)
absence 2 1.11 (0.96 – 1.29) 1.08 (0.92 – 1.27)
3 1.08 (0.92 – 1.27) 1.07 (0.91 – 1.26)
4 1.09 (0.92 – 1.28) 1.07 (0.91 – 1.27)
Lacunar infarcts, presence vs. 1 1.20 (0.98 – 1.47) 1.25 (1.01 – 1.55)
absence 2 1.17 (0.95 – 1.45) 1.23 (0.99 – 1.53)
3 1.15 (0.93 – 1.44) 1.23 (0.99 – 1.52)
4 1.16 (0.93 – 1.45) 1.22 (0.98 – 1.52)
Flicker light-induced retinal 
arteriolar and venular dilation
Model β (95% CI) β (95% CI)
Flicker light-induced arteriolar 
dilation, per SD
1 -0.028 (-0.076;0.020) -0.013 (-0.064; 0.037)
2 -0.010 (-0.058; 0.038) -0.004 (-0.054; 0.046)
3 -0.021 (-0.071; 0.029) -0.014 (-0.064; 0.037)
4 -0.021 (-0.072; 0.030) -0.014 (-0.066; 0.037)
Flicker light-induced venular dilation, 
per SD
1 -0.015 (-0.063; 0.032) -0.018 (-0.067; 0.032)
2 -0.013 (-0.061; 0.035) -0.016 (-0.066; 0.033)
3 -0.014 (-0.064; 0.036) -0.027 (-0.077; 0.024)
4 -0.016 (-0.066; 0.034) -0.022 (-0.073; 0.028)
Plasma biomarkers of microvascular 
dysfunction
Model β (95% CI) β (95% CI)
Soluble intracellular adhesion 
molecule-1, per SD
1 0.074 (0.035 – 0.112) 0.055 (0.016 – 0.094)
2 0.041 (0.003 – 0.079) 0.032 (-0.007 – 0.070)
3 0.041 (0.002 – 0.081) 0.031 (-0.008 – 0.069)
4 0.022 (-0.016 – 0.060) 0.005 (-0.033 – 0.042)
Soluble vascular adhesion molecule-1, 
per SD
1 0.056 (0.018 – 0.094) 0.067 (0.028 – 0.105)
2 0.038 (0.000 – 0.076) 0.054 (0.016 – 0.093)
3 0.044 (0.005 – 0.084) 0.057 (0.018 – 0.096)
4 0.042 (0.003 – 0.082) 0.045 (0.006 – 0.084)
E-selectin, per SD 1 0.053 (0.014 – 0.092) 0.047 (0.007 – 0.087)
2 0.009 (-0.028 – 0.047) 0.016 (-0.022 – 0.055)
3 0.002 (-0.037 – 0.042) 0.009 (-0.030 – 0.048)
4 -0.019 (-0.057 – 0.019) -0.022 (-0.059 – 0.016)
Von Willebrand Factor, per SD 1 0.058 (0.021 – 0.096) 0.054 (0.015 – 0.093)
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Systolic blood pressure 
variability composite 
score, per SD
Diastolic blood pressure 
variability composite
 score, per SD
Microvascular dysfunction Model OR (95% CI) OR (95% CI)
2 0.045 (0.007 – 0.083) 0.045 (0.006 – 0.083)
3 0.062 (0.023 – 0.102) 0.054 (0.014 – 0.093)
4 0.051 (0.012 – 0.091) 0.036 (-0.003 – 0.075)
Regression coefficients (β) represent difference in markers of microvascular dysfunction for every 1 standard 
deviation increase in blood pressure variability composite score. Model 1: age, sex. Model 2: model 1 + glucose 
metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). 
Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density 
lipoprotein cholesterol ratio, (individual classes of ) antihypertensive medication, lipid-modifying medication. 
Abbreviations: CI, confidence interval; SD, standard deviation; OR, odds ratio. 
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Supplemental Table S7. Associations between systolic and diastolic blood pressure variability and measures of 
microvascular dysfunction, additionally adjusted for estimated glomerular filtration rate
Systolic blood pressure 
variability composite 
score, per SD
Diastolic blood pressure 
variability composite
 score, per SD
Microvascular dysfunction Model β (95% CI) β (95% CI)
Cerebral small vessel disease features, 
per point
1 0.045 (0.009 – 0.082) 0.048 (0.009 – 0.086)
2 0.035 (0.001 – 0.071) 0.041 (0.003 – 0.079)
n=1,822 3 0.021 (-0.017 – 0.059) 0.034 (-0.005 – 0.073)
4 0.014 (-0.023 – 0.052) 0.027 (-0.011 – 0.066)
5 0.014 (-0.024 – 0.052) 0.028 (-0.010 – 0.067)
Flicker light-induced arteriolar and 
venular 
1 0.033 (-0.015 – 0.081) 0.019 (-0.031 – 0.070)
2 0.020 (-0.028 – 0.069) 0.013 (-0.037 – 0.063)
dilation, per SD 3 0.030 (-0.021 – 0.080) 0.026 (-0.024 – 0.077)
n=1,831 4 0.031 (-0.020 – 0.082) 0.025 (-0.026 – 0.076)
5 0.031 (-0.020 – 0.082) 0.025 (-0.026 – 0.076)
Urinary albumin excretion, ratio 
increase
n=2,724
1 1.14 (1.10 - 1.18) 1.13 (1.09 - 1.17)
2 1.10 (1.07 - 1.14) 1.10 (1.07 - 1.15)
3 1.05 (1.01 - 1.09) 1.09 (1.05 - 1.13)
4 1.04 (1.00 - 1.08) 1.07 (1.03 - 1.11)
5 1.04 (1.00 - 1.08) 1.07 (1.03 - 1.11)
Skin hyperaemia, per SD 1 0.028 (-0.028 – 0.085) 0.006 (-0.051 – 0.064)
n=1,309 2 0.007 (-0.050 – 0.064) -0.009 (-0.067 – 0.048)
3 -0.000 (-0.060 – 0.059) -0.007 (-0.065 – 0.051)
4 0.007 (-0.053 – 0.066) -0.003 (-0.061 – 0.055)
5 0.007 (-0.053 – 0.066) -0.003 (-0.061 – 0.055)
Plasma biomarkers of microvascular 1 0.090 (0.053 – 0.127) 0.083 (0.044 – 0.121)
2 0.053 (0.016 – 0.089) 0.055 (0.018 – 0.092)
dysfunction, per SD 3 0.057 (0.019 – 0.095) 0.056 (0.019 – 0.094)
n=2,720 4 0.036 (-0.001 – 0.072) 0.024 (-0.013 – 0.060)
5 0.037 (0.001 – 0.073) 0.025 (-0.010 – 0.061)
Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, 
for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel 
disease features, β’s are expressed per point; for urinary albumin excretion, β’s are expressed as ratio increase. 
Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or 
diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol 
use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of ) antihypertensive 
medication, lipid-modifying medication. Model 5: model 4 + estimated glomerular filtration rate. Abbreviations: 
CI, confidence interval; SD, standard deviation. 
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Supplemental Table S8. Associations between systolic and diastolic blood pressure variability and measures of 
microvascular dysfunction, additionally adjusted for prior cardiovascular disease
Systolic blood pressure 
variability composite 
score, per SD
Diastolic blood pressure 
variability composite
 score, per SD
Microvascular dysfunction Model β (95% CI) β (95% CI)
Cerebral small vessel disease 
features, per point
n=1,817
1 0.044 (0.008 – 0.080) 0.049 (0.011 – 0.088)
2 0.034 (-0.002 – 0.070) 0.043 (0.005 – 0.081)
3 0.020 (-0.018 – 0.058) 0.036 (-0.003 – 0.074)
4 0.013 (-0.025 – 0.051) 0.030 (-0.009 – 0.069)
5 0.012 (-0.026 – 0.050) 0.028 (-0.011 – 0.066)
Flicker light-induced arteriolar 
and venular 
1 0.032 (-0.015 – 0.080) 0.019 (-0.032 – 0.069)
2 0.020 (-0.028 – 0.068) 0.012 (-0.038 – 0.062)
dilation, per SD 3 0.031 (-0.019 – 0.081) 0.026 (-0.025 – 0.076)
n=1,824 4 0.030 (-0.020 – 0.081) 0.023 (-0.027 – 0.074)
5 0.029 (-0.021 – 0.080) 0.023 (-0.028 – 0.074)
Urinary albumin excretion, ratio 
increase
n=2,714
1 1.14 (1.07 - 1.15) 1.13 (1.06 - 1.14)
2 1.11 (1.01 - 1.09) 1.10 (1.05 - 1.12)
3 1.05 (1.00 - 1.08) 1.08 (1.03 - 1.10)
4 1.04 (1.00 - 1.08) 1.07 (1.03 - 1.10)
5 1.04 (1.09 - 1.17) 1.07 (1.03 - 1.10)
Skin hyperaemia, per SD 1 0.022 (-0.034 – 0.079) 0.008 (-0.050 – 0.065)
n=1,306 2 0.002 (-0.055 – 0.059) -0.008 (-0.065 – 0.050)
3 -0.004 (-0.064 – 0.056) -0.004 (-0.062 – 0.054)
4 0.002 (-0.057 – 0.062) 0.000 (-0.059 – 0.058)
5 0.002 (-0.057 – 0.062) 0.000 (-0.059 – 0.058)
Plasma biomarkers of 
microvascular 
1 0.092 (0.055 – 0.129) 0.081 (0.042 – 0.120)
2 0.056 (0.019 – 0.092) 0.054 (0.016 – 0.092)
dysfunction, per SD 3 0.061 (0.023 – 0.099) 0.056 (0.017 – 0.093)
n=2,691 4 0.040 (0.003 – 0.077) 0.023 (-0.014 – 0.059)
5 0.038 (0.001 – 0.075) 0.020 (-0.017 – 0.056)
Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, 
for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel 
disease features, β’s are expressed per point; for urinary albumin excretion, β’s are expressed as ratio increase. 
Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or 
diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol 
use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of ) antihypertensive 
medication, lipid-modifying medication. Model 5: model 4 + prior cardiovascular disease. Abbreviations: CI, 
confidence interval; SD, standard deviation.
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Supplemental Table S9. Associations between systolic and diastolic blood pressure variability and measures of 
microvascular dysfunction, additionally adjusted for plasma biomarkers of low-grade inflammation
Systolic blood pressure 
variability composite 
score, per SD
Diastolic blood pressure 
variability composite
 score, per SD
Microvascular dysfunction Model β (95% CI) β (95% CI)
Cerebral small vessel disease 
features, per point
1 0.046 (0.010 – 0.083) 0.051 (0.012 – 0.090)
2 0.036 (-0.001 – 0.072) 0.045 (0.007 – 0.083)
n=1,820 3 0.021 (-0.017 – 0.059) 0.037 (-0.002 – 0.076)
4 0.015 (-0.023 – 0.053) 0.031 (-0.008 – 0.070)
5 0.015 (-0.023 – 0.053) 0.031 (-0.007 – 0.070)
Flicker light-induced arteriolar 
and venular 
1 0.035 (-0.013 – 0.083) 0.019 (-0.031 – 0.069)
2 0.023 (-0.026 – 0.071) 0.013 (-0.038 – 0.063)
dilation, per SD 3 0.032 (-0.018 – 0.083) 0.026 (-0.025 – 0.077)
n=1,828 4 0.034 (-0.017 – 0.085) 0.024 (-0.027 – 0.075)
5 0.033 (-0.018 – 0.083) 0.025 (-0.026 – 0.076)
Urinary albumin excretion, 
ratio increase
n=2,721
1 1.14 (1.10 - 1.18) 1.13 (1.09 - 1.17)
2 1.10 (1.07 - 1.14) 1.10 (1.07 - 1.15)
3 1.05 (1.01 - 1.09) 1.09 (1.05 - 1.13)
4 1.04 (1.00 - 1.08) 1.07 (1.03 - 1.11)
5 1.04 (1.00 - 1.08) 1.07 (1.03 - 1.11)
Skin hyperaemia, per SD 1 0.025 (-0.031 – 0.082) 0.005 (-0.052 – 0.063)
n=1,307 2 0.005 (-0.052 – 0.062) -0.010 (-0.068 – 0.047)
3 -0.002 (-0.061 – 0.058) -0.007 (-0.066 – 0.051)
4 0.005 (-0.054 – 0.065) -0.004 (-0.062 – 0.054)
5 0.002 (-0.054 – 0.065) -0.004 (-0.062 – 0.054)
Plasma biomarkers of 
microvascular 
1 0.089 (0.052 – 0.126) 0.082 (0.043 – 0.120)
2 0.056 (0.015 – 0.088) 0.054 (0.017 – 0.092)
dysfunction, per SD 3 0.057 (0.019 – 0.095) 0.056 (0.018 – 0.093)
n=2,726 4 0.035 (-0.001 – 0.072) 0.023 (-0.013 – 0.060)
5 0.033 (-0.002 – 0.069) 0.026 (-0.009 – 0.061)
Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, 
for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel 
disease features, β’s are expressed per point; for urinary albumin excretion, β’s are expressed as ratio increase. 
Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or 
diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol 
use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of ) antihypertensive 
medication, lipid-modifying medication. Model 5: model 4 + composite score of plasma biomarkers of low-
grade inflammation. Abbreviations: CI, confidence interval; SD, standard deviation; OR, odds ratio.
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Supplemental Table S10. Associations between systolic and diastolic blood pressure variability and measures 
of microvascular dysfunction, additionally adjusted for carotid-femoral pulse wave velocity
Systolic blood pressure 
variability composite score, 
per SD
Diastolic blood pressure 
variability composite score, 
per SD
Microvascular dysfunction Model β (95% CI) β (95% CI)
Cerebral small vessel disease 
features, per point
n=1552
1 0.053 (0.013; 0.092) 0.048 (0.006; 0.089)
2 0.043 (0.004; 0.082) 0.041 (0.001; 0.082)
3 0.032 (-0.009; 0.072) 0.031 (-0.010; 0.073)
4 0.021 (-0.020; 0.061) 0.022 (-0.020; 0.063)
5 0.018 (-0.023; 0.059) 0.022 (-0.020; 0.063)
Flicker light-induced retinal 
arteriolar and venular dilation, 
per SD n=1,519
1 0.013 (-0.039; 0.065) 0.020 (-0.035; 0.074)
2 0.002 (-0.05; 0.055) 0.013 (-0.041; 0.068)
3 0.015 (-0.040; 0.070) 0.027 (-0.028; 0.082)
4 0.013 (-0.042; 0.069) 0.023 (-0.032; 0.079)
5 0.013 (-0.042; 0.069) 0.024 (-0.031; 0.079)
Urinary albumin excretion, 
ratio increase n=2,335
1 1.13 (1.09 - 1.17) 1.12 (1.08 - 1.16)
2 1.10 (1.06 - 1.14) 1.10 (1.06 - 1.14)
3 1.05 (1.01 - 1.09) 1.08 (1.04 - 1.13)
4 1.04 (1.00 - 1.08) 1.07 (1.03 - 1.11)
5 1.04 (1.00 - 1.08) 1.07 (1.03 - 1.11)
Skin hyperaemia, per SD 
n=1,142
1 0.047 (-0.014; 0.109) 0.024 (-0.037; 0.086)
2 0.025 (-0.037; 0.087) 0.007 (-0.054; 0.069)
3 0.019 (-0.046; 0.084) 0.011 (-0.052; 0.073)
4 0.030 (-0.036; 0.095) 0.017 (-0.046; 0.080)
5 0.030 (-0.035; 0.095) 0.017 (-0.046; 0.080)
Plasma biomarkers of 
microvascular dysfunction, per 
SD n=2,313
1 0.072 (0.032; 0.112) 0.083 (0.043; 0.124)
2 0.038 (-0.001; 0.077) 0.059 (0.020; 0.098)
3 0.045 (0.005; 0.086) 0.060 (0.021; 0.100)
4 0.029 (-0.010; 0.068) 0.031 (-0.007; 0.069)
5 0.028 (-0.011; 0.067) 0.031 (-0.007; 0.069)
Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, 
for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel 
disease features, β’s are expressed per point; for urinary albumin excretion, β’s are expressed as ratio increase. 
Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or 
diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol 
use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of ) antihypertensive 
medication, lipid-modifying medication. Model 5: model 4 + carotid-femoral pulse wave velocity. Abbreviations: 
BPV, blood pressure variability; CI, confidence interval; SD, standard deviation; OR, odds ratio.
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Supplemental Table S11. Associations between systolic and diastolic blood pressure variability and measures 
of microvascular dysfunction, additionally adjusted for diet score
Systolic blood pressure 
variability composite score, 
per SD
Diastolic blood pressure 
variability composite score, 
per SD
Microvascular dysfunction Model β (95% CI) β (95% CI)
Cerebral small vessel disease 
features, per point
n=1,748
1 0.050 (0.013; 0.087) 0.048 (0.009; 0.088)
2 0.040 (0.003; 0.076) 0.042 (0.003; 0.081)
3 0.026 (-0.013; 0.064) 0.034 (-0.006; 0.074)
4 0.021 (-0.017; 0.060) 0.030 (-0.009; 0.069)
5 0.021 (-0.017; 0.060) 0.030 (-0.009; 0.069)
Flicker light-induced retinal 
arteriolar and venular dilation, 
per SD n=1,758
1 0.033 (-0.017; 0.082) 0.014 (-0.038; 0.065)
2 0.021 (-0.029; 0.070) 0.008 (-0.044; 0.059)
3 0.029 (-0.022; 0.081) 0.021 (-0.031; 0.073)
4 0.032 (-0.021; 0.084) 0.021 (-0.032; 0.073)
5 0.032 (-0.021; 0.084) 0.021 (-0.032; 0.073)
Urinary albumin excretion, ratio 
increase n=2,602
1 1.14 (1.09 - 1.18) 1.12 (1.08 - 1.17)
2 1.10 (1.07 - 1.15) 1.10 (1.06 - 1.14)
3 1.05 (1.01 - 1.09) 1.08 (1.04 - 1.12)
4 1.04 (1.00 - 1.08) 1.06 (1.03 - 1.10)
5 1.04 (1.00 - 1.08) 1.06 (1.03 - 1.10)
Skin hyperaemia, per SD 
n=1,249
1 0.040 (-0.018; 0.098) 0.019 (-0.039; 0.078)
2 0.019 (-0.039; 0.078) 0.004 (-0.054; 0.063)
3 0.014 (-0.047; 0.075) 0.008 (-0.051; 0.067)
4 0.018 (-0.043; 0.079) 0.009 (-0.050; 0.068)
5 0.018 (-0.043; 0.08) 0.010 (-0.050; 0.069)
Plasma biomarkers of 
microvascular dysfunction, per 
SD n=2,575
1 0.090 (0.051; 0.128) 0.081 (0.041; 0.121)
2 0.052 (0.014; 0.089) 0.055 (0.016; 0.094)
3 0.057 (0.018; 0.097) 0.057 (0.018; 0.096)
4 0.036 (-0.002; 0.074) 0.025 (-0.013; 0.062)
5 0.036 (-0.002; 0.074) 0.025 (-0.013; 0.063)
Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, 
for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel 
disease features, β’s are expressed per point; for urinary albumin excretion, β’s are expressed as ratio increase. 
Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or 
diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol 
use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of ) antihypertensive 
medication, lipid-modifying medication. Model 5: model 4 + diet score. Abbreviations: CI, confidence interval; 
SD, standard deviation .
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Supplemental Table S12. Associations between systolic and diastolic blood pressure variability and measures 
of microvascular dysfunction, additionally adjusted for physical activity
Systolic blood pressure 
variability composite score, 
per SD
Diastolic blood pressure 
variability composite score, 
per SD
Microvascular dysfunction Model β (95% CI) β (95% CI)
Cerebral small vessel disease 
features, per point
n=1,651
1 0.048 (0.010; 0.086) 0.042 (0.000; 0.083)
2 0.039 (0.001; 0.077) 0.036 (-0.005; 0.076)
3 0.023 (-0.016; 0.063) 0.027 (-0.015; 0.068)
4 0.017 (-0.023; 0.056) 0.021 (-0.020; 0.062)
5 0.016 (-0.023; 0.056) 0.021 (-0.020; 0.062)
Flicker light-induced retinal 
arteriolar and venular dilation, 
per SD n=1,657
1 0.029 (-0.021; 0.079) 0.014 (-0.040; 0.068)
2 0.017 (-0.034; 0.067) 0.006 (-0.048; 0.060)
3 0.025 (-0.028; 0.077) 0.020 (-0.035; 0.074)
4 0.023 (-0.030; 0.076) 0.017 (-0.038; 0.072)
5 0.023 (-0.030; 0.076) 0.017 (-0.038; 0.072)
Urinary albumin excretion, 
ratio increase n=2,437
1 1.14 (1.10 - 1.19) 1.13 (1.08 - 1.17)
2 1.11 (1.07 - 1.16) 1.10 (1.06 - 1.15)
3 1.05 (1.01 - 1.10) 1.08 (1.04 - 1.12)
4 1.04 (1.00 - 1.08) 1.06 (1.02 - 1.11)
5 1.04 (1.00 - 1.08) 1.06 (1.02 - 1.11)
Skin hyperaemia, per SD 
n=1,180
1 0.036 (-0.024; 0.097) 0.014 (-0.048; 0.076)
2 0.017 (-0.044; 0.078) -0.001 (-0.063; 0.061)
3 0.011 (-0.053; 0.075) 0.004 (-0.059; 0.067)
4 0.020 (-0.044; 0.084) 0.006 (-0.057; 0.070)
5 0.019 (-0.045; 0.083) 0.006 (-0.058; 0.069)




1 0.089 (0.050; 0.128) 0.073 (0.032; 0.115)
2 0.055 (0.016; 0.093) 0.048 (0.008; 0.088)
3 0.056 (0.016; 0.096) 0.046 (0.006; 0.087)
4 0.036 (-0.002; 0.075) 0.016 (-0.023; 0.055)
5 0.037 (-0.002; 0.076) 0.017 (-0.022; 0.057)
Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, 
for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel 
disease features, β’s are expressed per point; for urinary albumin excretion, β’s are expressed as ratio increase. 
Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or 
diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol 
use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of ) antihypertensive 
medication, lipid-modifying medication. Model 5: model 4 + physical activity. Abbreviations: CI, confidence 
interval; SD, standard deviation.
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Supplemental table S13. Associations between systolic and diastolic blood pressure variability and measures 
of microvascular dysfunction, additionally adjusted for income level
Systolic blood pressure 
variability composite score, 
per SD
Diastolic blood pressure 
variability composite 
score, per SD
Microvascular dysfunction Model β (95% CI) β (95% CI)
Cerebral small vessel disease 
features, per point
n=1,445
1 0.054 (0.014; 0.095) 0.048 (0.005; 0.091)
2 0.042 (0.003; 0.082) 0.038 (-0.004; 0.081)
3 0.026 (-0.015; 0.068) 0.031 (-0.011; 0.074)
4 0.026 (-0.016; 0.068) 0.031 (-0.012; 0.074)
Flicker light-induced retinal 
arteriolar and venular dilation, 
per SD n=1,439
1 0.017 (-0.037; 0.071) 0.006 (-0.052; 0.065)
2 0.005 (-0.049; 0.060) -0.002 (-0.061; 0.056)
3 0.011 (-0.045; 0.068) 0.010 (-0.05; 0.069)
4 0.017 (-0.040; 0.075) 0.010 (-0.05; 0.07)
Urinary albumin excretion, 
ratio increase n=2,121
1 1.14 (1.10 - 1.19) 1.13 (1.08 - 1.17)
2 1.11 (1.06 - 1.15) 1.10 (1.05 - 1.14)
3 1.05 (1.01 - 1.10) 1.08 (1.03 - 1.12)
4 1.05 (1.01 - 1.09) 1.06 (1.02 - 1.11)
Skin hyperaemia, per SD 
n=1,017
1 0.031 (-0.030; 0.092) 0.027 (-0.037; 0.091)
2 0.014 (-0.048; 0.077) 0.012 (-0.052; 0.077)
3 0.006 (-0.059; 0.071) 0.015 (-0.050; 0.080)
4 0.011 (-0.054; 0.077) 0.021 (-0.045; 0.087)
Plasma biomarkers of 
microvascular dysfunction, per 
SD n=2,097
1 0.094 (0.052; 0.137) 0.087 (0.042; 0.131)
2 0.058 (0.016; 0.099) 0.057 (0.014; 0.100)
3 0.067 (0.023; 0.110) 0.058 (0.014; 0.102)
4 0.048 (0.006; 0.090) 0.025 (-0.018; 0.067)
Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, 
for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel 
disease features, β’s are expressed per point; for urinary albumin excretion, β’s are expressed as ratio increase. 
Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or 
diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol 
use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of ) antihypertensive 
medication, lipid-modifying medication. Model 5: model 4 + income level.  Abbreviations: CI, confidence interval; 
SD, standard deviation. 
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Supplemental table S14. Associations between systolic and diastolic blood pressure variability and measures 
of microvascular dysfunction, additionally adjusted for occupation status
Systolic blood pressure 
variability composite score, 
per SD
Diastolic blood pressure 
variability composite score, 
per SD
Microvascular dysfunction Model β (95% CI) β (95% CI)
Cerebral small vessel disease 
features, per point
n=1,568
1 0.037 (-0.002; 0.077) 0.050 (0.008; 0.091)
2 0.025 (-0.014; 0.064) 0.040 (-0.001; 0.081)
3 0.012 (-0.030; 0.053) 0.034 (-0.007; 0.075)
4 0.007 (-0.035; 0.048) 0.029 (-0.013; 0.070)
Flicker light-induced retinal 
arteriolar and venular dilation, 
per SD n=1,552
1 0.038 (-0.016; 0.091) 0.025 (-0.031; 0.080)
2 0.024 (-0.029; 0.078) 0.017 (-0.038; 0.073)
3 0.031 (-0.026; 0.087) 0.030 (-0.026; 0.086)
4 0.033 (-0.024; 0.090) 0.030 (-0.027; 0.086)
Urinary albumin excretion, 
ratio increase
n=2,302
1 1.15 (1.11 - 1.20) 1.14 (1.09 - 1.18)
2 1.12 (1.07 - 1.16) 1.11 (1.07 - 1.16)
3 1.06 (1.02 - 1.10) 1.09 (1.05 - 1.14)
4 1.06 (1.01 - 1.10) 1.08 (1.04 - 1.12)
Skin hyperaemia, per SD 
n=1,113
1 0.068 (0.007; 0.128) 0.048 (-0.013; 0.110)
2 0.046 (-0.016; 0.107) 0.031 (-0.031; 0.093)
3 0.041 (-0.023; 0.105) 0.032 (-0.031; 0.094)
4 0.044 (-0.021; 0.108) 0.028 (-0.035; 0.091)
Plasma biomarkers of 
microvascular dysfunction, per 
SD n=2,284
1 0.099 (0.058; 0.141) 0.087 (0.043; 0.130)
2 0.058 (0.017; 0.098) 0.057 (0.015; 0.098)
3 0.064 (0.022; 0.107) 0.057 (0.015; 0.099)
4 0.042 (0.001; 0.083) 0.028 (-0.014; 0.069)
Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, 
for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel 
disease features, β’s are expressed per point; for urinary albumin excretion, β’s are expressed as ratio increase. 
Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or 
diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol 
use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of ) antihypertensive 
medication, lipid-modifying medication. Model 5: model 4 + occupation status. Abbreviations: CI, confidence 
interval; SD, standard deviation.
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Supplemental Table S15. Associations between systolic and diastolic blood pressure variability and urinary 
albumin excretion as a categorical variable
Systolic blood pressure 
variability composite score, 
per SD
Diastolic blood pressure 
variability composite 
score, per SD
Microvascular dysfunction Model OR (95% CI) OR (95% CI)
Urinary albumin excretion, ≥30 
mg/24h vs. <30 mg/24h
n=2,748
1 1.39 (1.22 – 1.59) 1.32 (1.16 – 1.50)
2 1.30 (1.14 – 1.49) 1.25 (1.10 – 1.43)
3 1.19 (1.03 – 1.38) 1.20 (1.05 – 1.38)
4 1.19 (1.02 – 1.38) 1.19 (1.02 – 1.37)
Regression coefficients (β) represent odds ratio of ≥30 mg/24h urinary albumin excretion per 1 SD increase in 
blood pressure variability composite score. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. 
Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + 
body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol 
ratio, (individual classes of ) antihypertensive medication, lipid-modifying medication. Abbreviations: BPV, blood 
pressure variability; CI, confidence interval; OR, odds ratio.
Supplemental Table S16. Associations between systolic and diastolic blood pressure variability and estimated 
glomerular filtration rate
Systolic blood pressure 
variability composite score, 
per SD
Diastolic blood pressure 
variability composite 
score, per SD
Estimated glomerular filtration rate Model β (95% CI) β (95% CI)
Lower estimated glomerular filtration 
rate, per SD
n=2,748
1 0.007 (-0.026 - 0.041) 0.026 (-0.008 - 0.060)
2 0.002 (-0.032 - 0.035) 0.022 (-0.012 - 0.057)
3 0.017 (-0.018 - 0.053) 0.026 (-0.008 - 0.061)
4 -0.004 (-0.038 - 0.030) -0.006 (-0.040 - 0.028)
Model OR (95%CI) OR (95%CI)
Estimated glomerular filtration rate, 
≥60 vs. <60 ml/min/1.73m2, odds 
ratio
n=2,748
1 1.135 (0.947 - 1.36) 1.173 (0.984 - 1.397)
2 1.055 (0.874 - 1.274) 1.103 (0.923 - 1.318)
3 1.098 (0.906 - 1.332) 1.142 (0.957 - 1.363)
4 1.042 (0.842 - 1.29) 1.021 (0.842 - 1.239)
Regression coefficients (β) represent standard deviation lower estimated glomerular filtration rate, and odds 
ratio for ≥60 vs. <60 ml/min/1.73m2 estimated glomerular filtration rate, for every 1 SD increase in blood 
pressure variability composite score. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 
3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body 
mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, 
(individual classes of ) antihypertensive medication, lipid-modifying medication. Abbreviations: CI, confidence 
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General discussion
The microvasculature (i.e., the vascular meshwork comprised of arterioles, capillaries and 
venules) provides local blood perfusion, blood-tissue diffusion and haemostatic balance1 
needed for nutrient distribution and waste product collection in tissues. Deterioration of 
the microvasculature (i.e., microvascular dysfunction) is emerging as a possible factor in 
adverse cerebral outcome, such as dementia, late-life depression and stroke.2-6 With the 
ageing of the population7 and the increasing amount of individuals with a high burden of 
cardiovascular risk factors,8 the identification of possible contributors to the development 
of adverse cerebral outcomes is needed.5 Several possible risk factors for microvascular 
dysfunction have thus far been identified, such as arterial stiffening,9 type 2 diabetes,10, 
11 hypertension, ageing and obesity.4 However, other determinants of microvascular 
dysfunction may be present, and the mechanisms by which microvascular dysfunction 
may lead to adverse cerebral outcome remains poorly understood.
In this thesis, we evaluated the causes of microvascular dysfunction and investigated 
whether microvascular dysfunction is associated with adverse cerebral outcomes 
(i.e., dementia, late-life depression and stroke). In addition, we evaluated whether 
microvascular dysfunction mediates the pathways between cardiovascular risk factors 
and adverse cerebral outcome. In this thesis, we had several key findings, which we will 
discuss in this chapter. The key findings are:
1. Microvascular dysfunction is associated with dementia, late-life depression, stroke 
and all-cause mortality.
2. Cerebral small vessel disease features additively increase stroke risk.
3. Microvascular dysfunction is implicated in the pathway between arterial stiffness 
and type 2 diabetes, and adverse cerebral outcome.
4. Greater blood pressure variability is associated with albuminuria.
5. In addition, we will propose a pathophysiological model that links these findings, 
and we will discuss several methodological considerations that apply to the findings 
of this thesis. Finally, we will discuss the clinical implications of the findings in this 
thesis and propose recommendations for future studies.
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Key findings
Microvascular dysfunction is associated with dementia, late-life depression, stroke 
and all-cause mortality
In chapter two of this thesis, we tested the hypothesis that cerebral microvascular 
dysfunction is associated with incident adverse cerebral outcome.1, 2, 5 For this, we 
conducted a systematic review and meta-analysis on the association between cerebral 
small vessel disease and incident dementia, late-life depression and stroke, and all-cause 
mortality. We found a strong and consistent association between various cerebral small 
vessel disease features and these adverse cerebral outcomes during follow-up. Presence 
of cerebral small vessel disease increases the risk of adverse outcome with a degree similar 
to that of presence of type 2 diabetes12-15 or hypertension.16-20 These findings imply that 
the cerebral microvasculature is important for optimal organ function, at least in cerebral 
tissue. The longitudinal design of the analysis sheds light on the temporality of the 
associations; if these associations are causal, cerebral small vessel disease is implicated in 
the pathophysiological processes that later lead to adverse cerebral outcome. 
In addition, it has been hypothesised that measures of generalised microvascular 
dysfunction also reflect microvascular dysfunction in cerebral tissue and that this is 
associated with adverse cerebral outcome. In accordance, previous studies have shown 
that measures of generalised microvascular dysfunction (i.e., albuminuria21 and plasma 
biomarkers of microvascular dysfunction)22-25 are associated with worse cognitive 
performance. To further test this hypothesis, we investigated, in chapter four, whether a 
composite score of microvascular dysfunction measures (i.e., cerebral small vessel disease 
features, flicker light-induced retinal arteriolar and venular dilation response, albuminuria, 
plasma biomarkers of microvascular dysfunction and heat-induced skin hyperaemia) 
was associated with worse cognitive performance. We found that this composite score 
was indeed associated with worse cognitive performance, even after excluding cerebral 
microvascular dysfunction (i.e., cerebral small vessel disease) from this score. These 
findings contribute to the hypothesis that generalised microvascular dysfunction reflects 
cerebral microvascular disease and is implicated in the pathophysiological process of 
adverse cerebral outcome.
Cerebral small vessel disease features additively increase stroke risk
In chapter two, we showed that the combination of two cerebral small vessel disease 
features was more strongly associated with incident stroke than individual features. The 
existence of additive effects among cerebral small vessel disease features implies that 
a dose-response relationship may be present between cerebral small vessel disease 
severity and adverse cerebral outcome. From a clinical point of view, this finding may be 
important, because it may help better predict disease course and identify patients at risk 
for adverse cerebral outcome. This suggests that imaging scales that integrate multiple 
cerebral small vessel disease features26 are most suitable to assess cerebral small vessel 
disease and most likely to enable improved risk prediction of clinical outcomes beyond 
established risk factors. 
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Microvascular dysfunction is implicated in the pathway between arterial stiffness 
and type 2 diabetes, and adverse cerebral outcome
Several cardiovascular risk factors are associated with adverse cerebral outcome, and this 
association may be mediated by microvascular dysfunction.11, 27-29 In chapter three and five, 
we therefore investigated whether microvascular dysfunction mediates the associations 
between arterial stiffness and type 2 diabetes, and adverse cerebral outcome. 
Greater arterial stiffness leads to excessive pressure and flow pulsatility, which may 
transmit distally and damage the microcirculation.27, 28 Previous studies9 30-43 have shown an 
association between greater arterial stiffness and measures of adverse cerebral outcomes 
(i.e., cognitive decline and incident dementia). In chapter five, we investigated the 
associations between arterial stiffness (measured as aortic stiffness and carotid stiffness) 
and worse cognitive performance, and whether any such associations were mediated by 
a composite score of various microvascular dysfunction measures. Aortic stiffness, but not 
carotid stiffness, was associated with worse cognitive performance, and this association 
was mediated, in part, by a composite score of microvascular dysfunction. Although 
aortic stiffness (i.e., higher carotid-femoral pulse wave velocity) and carotid stiffness (i.e., 
higher carotid distensibility coefficient) reflect, at least partly, a similar process of arterial 
stiffenning,44 aortic stiffness may be a more precise reflection.44, 45 Accordingly, aortic 
stiffness may be more strongly associated with microvascular dysfunction and worse 
cognitive performance.
Type 2 diabetes is associated with hyperglycaemia, impaired insulin-dependent arteriolar 
dilation, advanced glycation, excessive oxidative stress and epigenetic changes, which 
may damage the microcirculation.11, 29, 46 In addition, type 2 diabetes is associated with a 
higher incidence of depressive symptoms.47 However, no previous study has investigated 
whether the association between type 2 diabetes and depressive symptoms is mediated by 
microvascular dysfunction. In chapter 3, we showed, in a longitudinal study, that baseline 
type 2 diabetes is associated with greater change in depressive symptoms over time, and 
that this association was, in part, mediated by cerebral microvascular dysfunction (i.e., 
cerebral small vessel disease features). 
From a clinical point of view, the finding that microvascular dysfunction mediates, in part, 
the association between classical cardiovascular risk factors and adverse cerebral outcome 
is important, as it identifies microvascular dysfunction as potential target for prevention 
of brain diseases in patients with cardiovascular risk factors. However, a significant portion 
of the associations between arterial stiffness and type 2 diabetes, and adverse cerebral 
outcome, was not mediated by microvascular dysfunction. This remaining association 
may be due to microvascular dysfunction that is not directly captured in our measures 
of microvascular dysfunction. For example, cerebral microvascular dysfunction measures 
such as microinfarctions, loss of white matter integrity and lower cerebral blood flow 
reactivity may contain additional information but were not available in this thesis. In 
addition, it is possible that only a subset of individuals with arterial stiffness or type 2 
diabetes develop adverse cerebral outcome that are related to microvascular dysfunction. 
Worse cognitive performance in arterial stiffness may be related to macrovascular disease 
or Aβ deposition.48 Additionally, depressive symptoms in type 2 diabetes may be related 
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to other mediators such as psychosocial factors,47 diabetes-related comorbidities47 and 
glucose neurotoxicity.49
Greater blood pressure variability is associated with albuminuria
It has been hypothesised that greater blood pressure variability (i.e., greater fluctuations 
of blood pressure) is associated with microvascular dysfunction.50, 51 This association 
may be implicated in the pathway between arterial stiffness and type 2 diabetes, and 
microvascular dysfunction.52, 53 However, the association between blood pressure 
variability and microvascular dysfunction remains incompletely understood. In chapter 
six, we therefore investigated whether blood pressure variability (i.e., within-visit, 24-
hour and 7-day blood pressure variability) is associated with microvascular dysfunction 
measures including brain (i.e., cerebral small vessel disease features), eye (i.e., flicker 
light-induced retinal arteriolar and venular dilation response), kidney (i.e., albuminuria), 
plasma biomarkers of microvascular dysfunction and skin measures (i.e., heat-induced 
skin hyperaemia). We hypothesised that the effect of greater blood pressure variability 
on microvascular dysfunction is stronger in organs with a low vascular impedance (i.e., 
brain, eyes and kidneys) and weaker in organs with a high vascular impedance (e.g., 
skin). In partial disagreement with this hypothesis, we found that greater very short- to 
mid-term blood pressure variability was associated with higher albuminuria but not 
with other measures of microvascular dysfunction tested. Kidney microvasculature has a 
lower impedance than the brain and eye microvasculature; e.g., blood flow to the kidneys 
relative to organ weight (360 ml/min/100 g) is higher than to the brain (50 ml/min/100 g 
brain).54 Therefore, the kidney microvasculature may be comparatively more vulnerable to 
the detrimental effects of blood pressure variability. 
Microvascular dysfunction and brain diseases: mechanisms
The findings of this thesis may be summarized into the following pathophysiological 
model (see Figure 7.1). Microvascular dysfunction is associated with a marked increase in 
adverse cerebral outcome, irrespective of whether microvascular dysfunction is located 
in brain tissue or in other organs; these measures appear to reflect overlapping changes 
that hamper brain tissue function. In addition, type 2 diabetes and arterial stiffness are 
associated with adverse cerebral outcome, and microvascular dysfunction is at least 
partly implicated in this pathway. Blood pressure variability may, at least in the kidney, 
lead to microvascular dysfunction. Microvascular dysfunction may lead to adverse 
cerebral outcome through multiple pathways, including impaired cerebral perfusion, 
impaired neurogenesis, impaired neurovascular coupling, impaired blood-brain barrier 
permeability, impaired haemostatic regulation and impaired cerebral autoregulation, 
which eventually causes ischaemia and neuronal dysfunction.55 
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Figure 7.1. Potential pathways for causes and consequences of microvascular dysfunction.
Methodological considerations
There are several methodological aspects of this thesis that need to be taken into 
consideration when interpreting the results. First, this thesis includes a collection of 
observational cohort studies, and data in these studies are subject to biases such as 
confounding bias, overadjustment bias and reverse causation. Second, in this thesis, 
composite scores are often used to summarize measures of the same (patho)physiological 
construct. The construction of composite scores is based on certain assumptions, and 
these need to be taken into consideration when interpreting the results.
Confounding bias
Confounding bias arises when an observed association between an exposure variable and 
an outcome variable is erroneously assumed to be direct, although in reality, they are 
both separately associated with another variable (i.e., a ‘confounder factor’).56 Changes 
(or variation) in a confounding factor are reflected in both the exposure variable and the 
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outcome variable, which creates statistical dependence between the two (illustrated in 
Figure 7.2). Alternatively, the exposure variable may influence the confounding factor 
(and thus the outcome variable) via a mechanism that is unrelated to the causal pathway 
of interest. 
Due to the non-randomized nature of observational studies, confounder bias has an 
important influence on the validity of the results. However, all analysis with observational 
studies in this thesis are adjusted for a large set of possible confounding factors, which 
helps reduce this bias. Nevertheless, residual confounding remains possible due to or an 
unknown or unmeasured factor or due to complex factor interaction. 
 
Figure 7.2. A confounding factor is associated with both the exposure variable and the outcome variable 
(solid lines). An erroneous direct association between the exposure variable and the outcome variable may be 
assumed (dashed line).
Overadjustment bias
Adjustment for a large set of variables may, on the one hand, help reduce confounding 
bias, but may, on the other hand, induce overadjustment bias. Overadjustment bias 
occurs when the adjustment variable mediates the causal pathway of interest between 
the exposure variable and the outcome variable (illustrated in Figure 7.3). Some of the 
potential confounding factors that were adjusted for in this thesis may also, in part, 
mediate the association between the exposure variables and the outcome variables. For 
example, the association between microvascular dysfunction and cognitive function may 
be confounded by type 2 diabetes but also be mediated.3, 11, 57 In general, adjustment for 
these factors will (partly) mask the observed association between the exposure variable 
and the outcome variable.58 
In addition to overadjustment by a mediating factor, overadjustment bias may occur 
when the adjusted factor is a proxy of the exposure variable or outcome variable, and 
is measured with greater precision (illustrated in Figure 7.3). Because this proxy variable 
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reflects one of the variable, it may account for part of the covariation that is attributable 
to the exposure variable and the outcome variable.58 
The effect of overadjustment bias needs to be taken into consideration when interpreting 
the results of this thesis. The possible adjustment for mediating factors may have led 
to an underestimation of the strength of the associations in this thesis. However, when 
overadjustment bias risk was present, these variables were often added to separate 
models, and its results were interpreted with caution.
 
Figure 7.3. A mediating factor is associated with the exposure variable, and subsequently influences the 
outcome variable (solid lines). A proxy variable reflects the exposure variable or the outcome variable with 
higher precision. Adjustment for the mediating factor or proxy variable will mask the observed association 
between the exposure variable and outcome variable (dashed line).
Reverse causation
Most of the analyses in this thesis are based on cross-sectional data, making it difficult 
to ascertain the temporality of the relationship between the exposure variable and the 
outcome variable.59 In other words, for causal inference, it is important to know which 
of the variables changes before the other. With cross-sectional measurements, it is not 
possible to discern the temporal relationship from the data, and any interpretation 
regarding causation should thus be done carefully. However, in chapter two and three, 
we established longitudinal relationships between cerebral small vessel disease and 
dementia, late-life depression, stroke and all-cause mortality. From this, the argument can 
be made that the associations found in chapter four and five follow the same temporal 
relation. Nevertheless, even when temporality has been established, it is not possible to 
discern correlation from causation in observational studies.60 To discern correlation from 
causation, interventional studies are needed.
Composite scores
A composite score is used to organize multiple correlated variables into more meaningful, 
conceptual information. By grouping together multiple measures of the same construct, 
the influence of the biological variability of its components is reduced. Furthermore, 
when a single composite score is used instead of all its components separately, it reduces 
the chance of a type 1 error. Substantial conceptual or statistical overlap among the 
components of the composite score must be present.61 In this thesis, we often constructed 
composite scores for microvascular dysfunction and for cognitive function, based on 
prior evidence that all measures used for the composite scores reflect microvascular 
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dysfunction1-3, 5, 10, 57, 62, 63 or cognitive function.64-67 Nevertheless, these components may 
vary in relationship strength with the outside variables (e.g., outcome variables) and 
may reflect slightly varying underlying pathophysiological processes, which influences 
statistical power and interpretability of the composite scores. Therefore, these factors 
should be taken into consideration when interpreting the results. In this thesis, robustness 
of composite scores that were not yet established in literature was tested by individually 
excluding components of the composite scores.
Clinical implications and recommendations for future studies
The present thesis contributes to increasing evidence that microvascular dysfunction 
contributes to adverse cerebral outcome. In addition, this thesis shows that individuals 
with cerebral microvascular dysfunction (i.e., the presence of cerebral small vessel 
disease features) are at high risk of developing dementia, late-life depression, stroke and 
mortality; a risk similar to that of individuals with type 2 diabetes12-15 or hypertension.16-20 
The presence of microvascular dysfunction should be recognized as a prognostic factor 
for adverse cerebral outcome and should prompt work-up and treatment of relevant risk 
factors, including type 2 diabetes, hypertension and hypercholesterolaemia. Additionally, 
hospital-admitted patients with microvascular dysfunction may be at a higher risk of 
low tissue oxygenation in the presence of dehydration and poor saturation and may 
correspondingly benefit from fluid supplementation and oxygen therapy.1 
Provided that the associations described in this thesis are causal, microvascular dysfunction 
might be an important target for prevention strategies of adverse cerebral outcome. 
However, effective evidence for treatment of microvascular dysfunction is presently 
lacking. Trials are therefore needed that target suspected mechanisms of microvascular 
dysfunction, including capillary rarefaction, glycocalyx degeneration, impaired capillary 
flow regulation, impaired arteriolar and venular dilation response, blood-brain barrier 
dysfunction, increased inflammatory response and procoagulant activation.1, 3, 55 Recent 
research suggests that lifestyle modifications, such as weight loss and exercise, may, at 
least in part, favorably influence microvascular function.11 In addition, drugs such as renin-
angiotensin-aldosterone system inhibitors, antihyperglycemic agents (i.e., metformin 
and glucagon-like peptide 1 receptor [GLP-1R] agonists) and statins may improve 
microvascular function,11, 68, 69 possibly beyond their blood pressure- or glucose-lowering 
effects.11, 68 However, only one previous study70, 71 found that inhibiting the progression 
of microvascular dysfunction correlated with reduced occurrence of cognitive decline 
and stroke, whereas others72, 73 did not. Future longitudinal studies are needed to further 
evaluate the association between microvascular dysfunction and adverse cerebral 
outcome, and the effect of microvascular dysfunction treatment.
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Ouderdomsgerelateerde hersensziekten zoals dementie en beroertes, maar ook depressie, 
maken de laatste jaren een sterke opmars als veroorzakers van sterfte en ziektelast. Eén 
van de veroorzakers van deze ziekten kan  schade aan de kleinste bloedvaatjes van 
het lichaam, de haarvaatjes, zijn. De haarvaatjes, ook wel de microcirculatie genoemd, 
vervullen een belangrijke rol in het gezond houden van het lichaam, door een veelvoud 
aan taken zoals het leveren van voedingsstoffen aan, en het weghalen van afvalstoffen uit 
de organen. Daarbij vervullen ze (onder andere) een belangrijke rol in het reguleren van 
de bloeddruk. Schade aan de haarvaten (microvasculaire dysfunctie), kan ertoe leiden dat 
deze processen verstoord raken. Dit is vooral het geval in organen die sterk afhankelijk 
zijn van een goede bloedvoorziening, zoals de hersenen. Daarom wordt microvasculaire 
dysfunctie genoemd als een mogelijke oorzaak van hersenproblematiek zoals dementie, 
depressie en beroertes. Nu de bevolking steeds ouder wordt, zijn er steeds meer mensen 
die lijden onder een ongunstig vasculair risicoprofiel met ‘klassieke’ cardiometabole 
risicofactoren zoals overgewicht, hoge bloeddruk (hypertensie) en suikerziekte (type 
2 diabetes). Het is belangrijk om te onderzoeken hoe deze risicofactoren bijdragen 
aan microvasculaire dysfunctie en daardoor hersenproblematiek. Er zijn al meerdere 
risicofactoren voor microvasculaire dysfunctie geïdentificeerd, zoals stijfheid van de 
grote slagaderen (arteriën) van het lichaam (vaatstijfheid), type 2 diabetes, hypertensie, 
leeftijd en overgewicht. We weten momenteel niet welke andere factoren ook bijdragen 
aan microvasculaire dysfunctie, en het mechanisme waardoor deze risicofactoren en 
microvasculaire dysfunctie leiden tot hersenproblematiek is nog onduidelijk.
Dit proefschrift richt zich op het evalueren van de oorzaken van microvasculaire dysfunctie 
en de effecten ervan op hersenproblematiek (i.e. dementie, depressie en beroertes). 
Daarbovenop onderzoekt dit proefschrift of microvasculaire dysfunctie een spil is in de 
reeds bekende associatie tussen cardiometabole risicofactoren en hersenproblematiek. 
De hoofdbevindingen in deze thesis zijn:
1. Microvasculaire dysfunctie is geassocieerd met dementie, depressie, beroerte en 
mortaliteit;
2. Hoe meer verschillende vormen van microvasculaire dysfunctie in de hersenen 
aanwezig zijn, des te hoger het risico op een beroerte;
3. Microvasculaire dysfunctie kan de relatie tussen vaatstijfheid en hersenproblematiek, 
en type 2 diabetes en hersenproblematiek deels verklaren;
4. Grotere fluctuaties in bloeddruk zijn geassocieerd met albuminurie, een maat van 
microvasculaire dysfunctie.
Aan het eind van deze samenvatting wordt er een pathofysiologisch model beschreven 
dat de relatie tussen bovenstaande bevindingen beschrijft. Tot slot worden de gevolgen 
van deze bevindingen voor de dagelijkse praktijk besproken, alsmede de aard van de 
studies die verricht dienen te worden om de kennis verder uit te breiden.
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Hoofdbevindingen
Microvasculaire dysfunctie is geassocieerd met dementie, depressie, beroerte en 
mortaliteit
In het tweede hoofdstuk van deze thesis hebben we de hypothese getest dat microvasculaire 
dysfunctie in de hersenen gerelateerd is aan het krijgen van hersenproblematiek. Om dit 
uit te zoeken, hebben wij een grote literatuurstudie uitgevoerd, waarin we systematisch 
alle artikelen over dit onderwerp hebben bekeken. Vervolgens hebben wij de vergelijkbare 
data ervan hebben samengevat middels een test, waarmee op statistische wijze wordt 
vastgesteld of deze associatie bestaat. Hiertoe hebben we gekeken naar alle studies 
die een relatie hebben onderzocht tussen bepaalde kenmerken van microvasculaire 
dysfunctie in de hersenen, cerebral small vessel disease genoemd, en het krijgen van 
dementie, depressie, en beroerte, of het optreden van sterfte. We vonden een sterke en 
ook consistente associatie tussen verschillende van deze kenmerken van cerebral small 
vessel disease, en het optreden van bovenstaande uitkomsten. Om een idee te geven 
van de relevantie van cerebral small vessel disease; als er cerebral small vessel disease 
aantoonbaar is, dan is iemands risico op het krijgen van dementie, depressie, en beroerte 
hetzelfde als bij aanwezigheid van type 2 diabetes1-4 of hypertensie.5-9 Hieruit kunnen we 
opmaken dat de microcirculatie in de hersenen belangrijk is voor optimale hersenfunctie. 
Als de gemeten microvasculaire functie in de hersenen een weerspiegeling is van de 
rest van het lichaam, betekent dit dat de microcirculatie belangrijk is voor optimale 
orgaanfunctie. Een belangrijk gegeven voor de interpretatie van deze data is dat de 
geïncludeerde onderzoeken in deze literatuurstudie van longitudinale aard zijn, dat wil 
zeggen, iedere deelnemer is voor een lange periode gevolgd nadat cerebral small vessel 
disease is gemeten. Hierdoor weet je vrij zeker dat er éérst microvasculaire dysfunctie in 
de hersenen moet optreden, voordat de klinische uitkomstmaten meetbaar zijn, in plaats 
van andersom.
Microvasculaire dysfunctie in andere organen dan de hersenen zouden de mate van 
cerebral small vessel disease kunnen weerspiegelen, en daarom dus ook geassocieerd 
kunnen zijn met hersenproblematiek. Andere studies hebben al aangetoond dat 
bepaalde tekenen van microvasculaire dysfunctie, zoals albumineverlies via de urine,10 
en verhoogde bloed biomarkers van microvasculaire dysfunctie, aanwezig zijn bij 
mensen met verslechterde geheugenfunctie. Om dit principe verder te onderzoeken, 
hebben we in hoofdstuk vier gekeken of een composietscore, een soort optelsom 
van verschillende maten van microvasculaire dysfunctie, weerspiegelt of iemand 
een slechtere geheugenfunctie heeft. Hiervoor hebben we verschillende maten voor 
microvasculaire dysfunctie samengevat in een score, namelijk: maten van cerebral small 
vessel disease, vaatreactiviteit van netvliesvaten op lichtflitsen, albumineverlies in de 
urine, bloed biomarkers van microvasculaire dysfunctie en vaatreactiviteit van de huid op 
warmtestimulatie. We concludeerden dat deze composietscore inderdaad verhoogd (i.e. 
ongunstiger) is bij mensen met een slechtere geheugenfunctie, en dat deze associatie 
aanwezig bleef wanneer we cerebral small vessel disease uit de score haalden. Dit betekent 
dat ook microvasculaire dysfunctie in andere organen dan de hersenen geassocieerd 
is met een slechtere geheugenfunctie. Deze studie is dus een onderbouwing voor de 
hypothese dat microvasculaire dysfunctie in het hele lichaam de (dys)functie van de 
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microcirculatie in de hersenen weerspiegelt, en dus ook een rol zou kunnen spelen bij het 
pathofysiologische proces dat leidt tot hersenproblematiek. 
Hoe meer verschillende vormen van microvasculaire dysfunctie in de hersenen 
aanwezig zijn, des te hoger het risico op een beroerte
In hoofdstuk twee toonden we aan dat de aanwezigheid van twee maten van cerebral 
small vessel disease sterker geassocieerd is met het optreden van een beroerte dan alleen 
enkelvoudig aanwezige maten. Deze bevinding impliceert dat er een dosis-respons 
relatie zou kunnen zijn tussen de mate van cerebral small vessel disease en de mate van 
hersenproblematiek die daarbij optreedt. Dit is een relevante bevinding voor clinici, 
omdat het kan leiden tot een betere voorspelling voor patiënten die een risico lopen op 
bijvoorbeeld dementie of beroerte.  Een speciale schaal om de mate van cerebral small 
vessel disease te scoren zou dan nog een risicopredictie kunnen geven bovenop reeds 
bekende risicofactoren.
Microvasculaire dysfunctie kan de relatie tussen vaatstijfheid en type 2 diabetes, 
en hersenproblematiek (deels) verklaren
Zoals boven al aangegeven, zijn meerdere cardiovasculaire risicofactoren geassocieerd 
met hersenproblematiek, en zou deze associatie veroorzaakt (ook wel gemedieerd 
genoemd) kunnen worden door microvasculaire dysfunctie.11-14 Het doel van hoofdstuk 
drie en vijf was om te onderzoeken of microvasculaire dysfunctie inderdaad een 
mediërende rol heeft in de associatie tussen zowel vaatstijfheid en hersenproblematiek, 
als type 2 diabetes en hersenproblematiek.
De aanvoerende slagaderen in het lichaam, de arteriën, werken als een buffer voor 
de bloeddrukgolven vanuit het hart, door middel van hun meeverende elastische 
wand. Stijvere arteriën, bijvoorbeeld door aderverkalking, leiden tot een ongunstig 
bloeddrukpatroon, waardoor schade kan ontstaan.11, 12  Voorgaande studies15 16-29 
toonden al aan dat er een associatie bestaat tussen arteriële stijfheid en de aanwezigheid 
van dementie, of het optreden van cognitieve achteruitgang. In hoofdstuk vijf hebben 
we deze associatie opnieuw onderzocht, door te kijken of twee verschillende maten 
van vaatstijfheid, namelijk buikslagaderstijfheid (aortastijfheid) en halsslagaderstijfheid 
(carotisstijfheid), een associatie vertonen met een slechtere geheugenfunctie. Het bleek 
dat aortastijfheid geassocieerd is met een slechtere geheugenfunctie. Vervolgens hebben 
we met een statistische analyse aangetoond dat deze associatie deel verklaard kon 
worden door microvasculaire dysfunctie. We vonden in onze studie geen associatie tussen 
carotisstijfheid en geheugenfunctie, dit kan komen doordat de meting voor aortastijfheid 
betrouwbaarder is dan de meting voor carotisstijfheid,30, 31 waardoor eventuele associaties 
eerder kunnen worden aangetoond met aortastijfheid dan met carotisstijfheid.
Type 2 diabetes kan, net als vaatstijfheid, leiden tot microvasculaire dysfunctie. Het wordt 
verondersteld dat in patiënten met type 2 diabetes, het hebben van o.a. hoge bloedsuikers, 
verminderde insulineafhankelijke vaatfunctie, aantasting van eiwitten en cellen door 
reactie met glucose (glycolysering) en zuurstofradicalen (oxidatieve stress), kan leiden 
tot deze schade aan de microcirculatie.13, 14, 32 De aanwezigheid van type 2 diabetes 
bleek eerder al  geassocieerd met het optreden van depressieve klachten, hetgeen dus 
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mogelijk veroorzaakt wordt door microvasculaire dysfunctie. In hoofdstuk drie hebben 
we bevestigd dat type 2 diabetes geassocieerd is met een toename van depressieve 
klachten over de tijd. Tevens hebben we aangetoond dat deze associatie deels verklaard 
wordt door microvasculaire dysfunctie in de hersenen. 
De bevinding dat microvasculaire dysfunctie de associatie tussen ‘klassieke’ cardiovasculaire 
risicofactoren en hersenproblematiek medieert is belangrijk, omdat microvasculaire 
dysfunctie daarmee een doel kan worden voor het behandelen en voorkomen van 
hersenziekten bij mensen met deze cardiovasculaire risicofactoren. Het is echter wel 
belangrijk vast te stellen dat een aanzienlijk deel van de gevonden associaties tussen 
cardiovasculaire risicofactoren en hersenproblematiek niet (statistisch) gemedieerd werd 
door microvasculaire dysfunctie in onze studies. Dit ‘niet-verklaarde deel’ kan bestaan 
uit een effect van microvasculaire dysfunctie dat niet goed geobjectiveerd kan worden 
met onze gemeten maten van microvasculaire dysfunctie. Wij hebben bijvoorbeeld geen 
onderzoek gedaan naar functionele uitkomstmaten voor microvasculaire dysfunctie, 
zoals het adaptatievermogen van de microcirculatie in de hersenen op bepaalde stimuli 
(cerebrale autoregulatie genoemd). Dit adaptievermogen kan echter wel een belangrijke 
weerspiegeling zijn van microvasculaire dysfunctie, en eerder afwijkingen vertonen 
dan structurele metingen van de hersenen, zoals het geval is bij cerebral small vessel 
disease.33 Het is ook mogelijk dat slechts een deel van de mensen met vaatstijfheid of 
type 2 diabetes hersenproblematiek krijgt die direct gerelateerd is aan microvasculaire 
dysfunctie. Zo kan slechtere cognitie bij vaatstijfheid of type 2 diabetes ook een gevolg zijn 
van macrovasculaire schade, of de ziekte van Alzheimer.34 Daarnaast kunnen depressieve 
symptomen in type 2 diabetes ook veroorzaakt worden door aan diabetes gerelateerde 
risicofactoren, zoals psychosociale factoren,35 comorbiditeit35 en directe zenuwschade 
door hoge bloedsuikers.36 
Grotere fluctuaties in bloeddruk zijn geassocieerd met albuminurie, een maat van 
microvasculaire dysfunctie
Naast ‘klassieke’ risicofactoren voor microvasculaire dysfunctie, worden er ook nieuwe 
risicofactoren beschreven. Een mogelijke risicofactor voor microvasculaire dysfunctie is 
het hebben van fluctuaties in de bloeddruk. Fluctuaties in de bloeddruk zijn normaal, 
maar wanneer dit te veel wordt (wanneer het lichaam het verschil in bloeddrukken 
minder goed kan opvangen), kan het leiden tot microvasculaire dysfunctie.37, 38 Om 
deze hypothese te testen, hebben we in hoofdstuk 6 bekeken of grote fluctuaties in de 
bloeddruk leiden tot microvasculaire dysfunctie. We hadden hierbij de verwachting dat 
organen die bloeddruk(fluctuaties) makkelijk doorlaten, namelijk de nieren en hersenen, 
meer schade zouden ondervinden dan andere organen. We vonden dat een grotere 
bloeddrukvariabiliteit alleen was geassocieerd met microvasculaire dysfunctie in de 
nieren, maar niet in de hersenen of andere organen. Mogelijk komt dit omdat de nieren 
van alle organen de grootste bloedtoevoer hebben, waardoor zij meer blootgesteld 
worden aan bloeddrukfluctuaties dan  andere organen.39
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Conclusie
Dit proefschrift laat zien dat microvasculaire dysfunctie een centrale rol speelt in de 
relatie tussen cardiometabole risicofactoren en het krijgen van hersenproblematiek, 
zoals dementie, depressie en beroertes. In onderstaande figuur zijn de belangrijkste 
bevindingen van dit proefschrift schematisch weergegeven. Wij hopen dat deze 
thesis aanknopingspunten geeft voor vervolgonderzoek dat kan helpen het risico op 





















Figuur. Potentiele mechanismen voor de oorzaken en gevolgen van microvasculaire dysfunctie 
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Valorisation addendum
The goal of scientific research is to establish new facts and to reach new conclusions, but 
without any impact to society, these new conclusions would have little consequences. 
The goal of this chapter is to discuss the impact on society of the conclusions reached in 
this thesis, and to discuss any recommendations for further research on this topic in order 
to maximize this impact.
Relevance of this research
In the Netherlands and most other parts of the world, life expectancy has been increasing 
for the last couple of decades and will continue to do so for some more decades to come. 
With the increasing age of the population, the amount of individuals with a high burden of 
cardiovascular risk factors increases. More importantly, so does the number of individuals 
with age-related brain diseases such as dementia, late-life depression and stroke. The 
findings in this thesis suggest that deterioration of the microvasculature, i.e. the vascular 
meshwork comprised of arterioles, capillaries and venules, is an important contributor 
to the development of these age-related brain diseases. In addition, this thesis suggests 
that microvascular deterioration, also called microvascular dysfunction, mediates the 
association between cardiovascular risk factors and age-related brain diseases. 
The conclusions in this thesis provide an important contribution to our current 
understanding of the pathophysiology of age-related brain diseases and indicate that 
prevention and/or treatment of microvascular dysfunction may be an important clinical 
goal. In practice, to prevent or slow down progression of age-related brain diseases in 
individuals with microvascular dysfunction, early and adequate cardiometabolic health 
must be pursued. Moreover, interventions aiming to favourably influence microvascular 
function on top of cardiometabolic management may provide additional prevention of 
age-related brain diseases. 
Future research
Before studies on prevention of and intervention for microvascular dysfunction can be 
conducted, further longitudinal observational studies are needed to confirm the causal 
relationship between cardiovascular risk factors, microvascular dysfunction, and age-
related brain diseases. Although the results in this thesis are consistent across all chapters, 
only chapter 2 and chapter 3 describe longitudinal relationships from which temporal 
associations, and thus causality, may be implied. Furthermore, in the present thesis, 
microvascular dysfunction was defined as a higher composite score of several measures 
of microvascular dysfunction, and sometimes specifically by measures of cerebral small 
vessel disease, instead of clinically relevant microvascular disease. There is currently no 
scale to define clinically relevant microvascular dysfunction based on the measures of 
microvascular dysfunction used in this thesis. Future studies are therefore needed to 
evaluate at what point microvascular dysfunction becomes clinically relevant, and whether 
the observed associations with microvascular dysfunction and age-related brain diseases 
are also present at this point. This thesis already demonstrated that the combination of 
two cerebral small vessel disease features is most strongly associated with incident stroke. 
This suggests that scales that incorporate the effect of multiple measures of microvascular 
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function are most suitable to assess microvascular dysfunction, and most likely to enable 
improved risk prediction of clinical outcomes beyond established risk factors. 
In addition to observational studies, randomized controlled trials are needed to evaluate 
the possible effectiveness of interventions for microvascular dysfunction. Currently, 
evidence for improved outcome with treatment programs aimed at strict cardiovascular 
risk management in patients with microvascular dysfunction is lacking. It has been 
suggested however, that statins, ACE inhibitors and aspirin improve microvascular 
function by mechanisms beyond  their respective lipid-lowering, blood pressure-lowering 
and anticoagulant effects; the so-called pleiotropic effect.
Clinical recommendations
As stated above, there are currently no comprehensive guidelines available for the 
diagnosis and treatment of microvascular disease. In 2013, the STRIVE neuroimaging 
standards to aid in the standardized assessment of microvascular disease in the brain were 
published. However, it is not advisable for a clinician to actively screen for microvascular 
dysfunction using neuroimaging or other techniques, given the current lack of guidelines 
for intervention. However, features of microvascular dysfunction are often found as 
incidental findings on scans with other primary indications. A clinician should, upon 
diagnosing a patient with microvascular dysfunction, be prompted to perform adequate 
cardiovascular risk assessment. The risk factors that are associated to macrovascular 
disease appear to be similarly associated with microvascular dysfunction; e.g. smoking, 
type 2 diabetes, obesity, hypertension and hyperlipidaemia. As such, treatment aimed at 
cardiovascular risk factor management, including lifestyle counselling regarding smoking 
cessation, nutrition and physical activity is warranted.
Conclusion
The findings in this thesis suggest that identification and treatment of microvascular 
dysfunction can be helpful in prevention of age-related brain disease.
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